0001367920-19-000057.txt : 20191107 0001367920-19-000057.hdr.sgml : 20191107 20191107070631 ACCESSION NUMBER: 0001367920-19-000057 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 70 CONFORMED PERIOD OF REPORT: 20190930 FILED AS OF DATE: 20191107 DATE AS OF CHANGE: 20191107 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CONCERT PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001367920 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-36310 FILM NUMBER: 191198101 BUSINESS ADDRESS: STREET 1: 65 HAYDEN AVENUE STREET 2: SUITE 3000N CITY: LEXINGTON STATE: MA ZIP: 02421 BUSINESS PHONE: 781-860-0045 MAIL ADDRESS: STREET 1: 65 HAYDEN AVENUE STREET 2: SUITE 3000N CITY: LEXINGTON STATE: MA ZIP: 02421 FORMER COMPANY: FORMER CONFORMED NAME: CONCERT PHARMACEUTICALS INC DATE OF NAME CHANGE: 20060628 10-Q 1 q3201910-q.htm 10-Q Document
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_____________________
FORM 10-Q
_____________________ 
(Mark One)
ý
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2019
or
¨
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from                      to                     
Commission File Number 001-36310
_____________________ 
CONCERT PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
_____________________
 
Delaware
20-4839882
(State or other jurisdiction of
incorporation or organization)
(I.R.S. Employer
Identification No.)
 
 
65 Hayden Avenue, Suite 3000N
Lexington, Massachusetts
(Address of principal executive offices)
02421
(Zip Code)
(781) 860-0045
(Registrant’s telephone number, including area code) 
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.001 per share
CNCE
Nasdaq Global Market
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  ý    No  ¨
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes  ý    No  ¨
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer
¨
Accelerated filer
x
 
 
 
 
Non-accelerated filer
¨ 
Smaller reporting company
x

 
 
 
 
Emerging growth company
x
 
 


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ý
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes  ¨    No  ý
The number of shares outstanding of the registrant’s common stock as of November 4, 2019: 23,841,155


TABLE OF CONTENTS
 
 
 
Page No.
 
 
 
 
 
 
Item 1.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Item 2.
 
 
 
Item 3.
 
 
 
Item 4.
 
 
 
 
 
 
Item 1A.
 
 
 
Item 6.
 
 
 
 


3

PART I. FINANCIAL INFORMATION
 
Item 1.
Financial Statements.
CONCERT PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)
(Amounts in thousands, except share and per share data)
 
September 30,
 
December 31,
 
2019
 
2018
Assets
 
 
 
Current assets:
 
 
 
Cash and cash equivalents
$
33,384

 
$
17,770

Investments, available for sale
88,165

 
135,544

Marketable equity securities
5,435

 
7,525

Interest receivable
291

 
556

Accounts receivable
11

 
15

Contract asset (Note 8)
—

 
16,000

Prepaid expenses and other current assets
3,830

 
2,739

Total current assets
131,116

 
180,149

Property and equipment, net
7,993

 
8,919

Restricted cash
1,157

 
1,157

Other assets
16

 
—

Income taxes receivable
2,358

 
2,322

Operating lease right-of-use assets, long-term (Note 11)
9,317

 
—

Total assets
$
151,957

 
$
192,547

Liabilities and stockholders’ equity
 
 
 
Current liabilities:
 
 
 
Accounts payable
$
1,302

 
$
1,277

Accrued expenses and other liabilities
4,434

 
5,669

Income taxes payable
—

 
390

Deferred revenue, current portion
7,783

 
1,413

Lease liability, current portion (Note 11)
235

 
—

Total current liabilities
13,754

 
8,749

Deferred revenue, net of current portion
2,750

 
9,120

Deferred lease incentive, net of current portion
—

 
4,088

Deferred rent, net of current portion
—

 
2,850

Lease liability, net of current portion (Note 11)
16,190

 
—

Total liabilities
32,694

 
24,807

Commitments (Note 11)

 

Stockholders’ equity:
 
 
 
Preferred stock, $0.001 par value per share; 5,000,000 shares authorized; no shares issued and outstanding in 2019 and 2018, respectively
—

 
—

Common stock, $0.001 par value per share; 100,000,000 shares authorized; 24,030,711 and 23,518,690 shares issued and 23,841,155 and 23,437,587 outstanding in 2019 and 2018, respectively
23

 
23

Additional paid-in capital
293,469

 
284,369

Accumulated other comprehensive loss
(35
)
 
(137
)
Accumulated deficit
(174,194
)
 
(116,515
)
Total stockholders’ equity
119,263

 
167,740

Total liabilities and stockholders’ equity
$
151,957

 
$
192,547

See accompanying notes.

4

CONCERT PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(UNAUDITED)
(Amounts in thousands, except per share data)
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2019
 
2018
 
2019
 
2018
Revenue:
 
 
 
 
 
 
 
License and research and development revenue
$
10

 
$
11

 
$
1,064

 
$
10,492

Operating expenses:
 
 
 
 
 
 
 
Research and development
13,511

 
11,031

 
43,797

 
28,549

General and administrative
4,742

 
6,320

 
15,329

 
17,464

Total operating expenses
18,253

 
17,351

 
59,126

 
46,013

Loss from operations
(18,243
)
 
(17,340
)
 
(58,062
)
 
(35,521
)
Investment income
724

 
703

 
2,474

 
2,003

Unrealized gain (loss) on marketable equity securities
334

 
(732
)
 
(2,091
)
 
(1,359
)
Loss before tax provision
(17,185
)
 
(17,369
)
 
(57,679
)
 
(34,877
)
Provision for income taxes
—

 
18

 
—

 
298

Net Loss
$
(17,185
)
 
$
(17,387
)
 
$
(57,679
)
 
$
(35,175
)
Other comprehensive income:
 
 
 
 
 
 
 
Unrealized (loss) gain on investments, available for sale
(39
)
 
87

 
102

 
166

Comprehensive loss
$
(17,224
)
 
$
(17,300
)
 
$
(57,577
)
 
$
(35,009
)
 
 
 
 
 
 
 
 
Net loss per share applicable to common stockholders - basic and diluted
$
(0.72
)
 
$
(0.74
)
 
$
(2.43
)
 
$
(1.51
)
 
 
 
 
 
 
 
 
Weighted-average number of common shares used in net loss per share applicable to common stockholders - basic and diluted
23,807

 
23,421

 
23,703

 
23,349

See accompanying notes.

5

CONCERT PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (UNAUDITED)
 
 
Nine Months Ended September 30, 2019
 
 
Common Stock
 
Additional paid-in capital
 
Accumulated other comprehensive income
 
Accumulated deficit
 
Total stockholders’ equity
 
 
Issued
 
In Treasury
 
Amount
 
 
 
(in thousands)
Balance at December 31, 2018
 
23,519

 
81

 
$
23

 
$
284,369

 
$
(137
)
 
$
(116,515
)
 
$
167,740

Exercise of stock options
 
154

 
47

 
—

 
805

 
—

 
—

 
805

Release of restricted stock units
 
202

 
61

 
—

 
(741
)
 
—

 
—

 
(741
)
Unrealized gain on short-term investments
 
—

 
—

 
—

 
—

 
97

 
—

 
97

Stock-based compensation expense
 
—

 
—

 
—

 
2,929

 
—

 
—

 
2,929

Exercise of stock warrants
 
71

 
—

 
—

 
1,000

 
—

 
—

 
1,000

Offering expenses incurred
 
—

 
—

 
—

 
(206
)
 
—

 
—

 
(206
)
Net loss
 
—

 
—

 
—

 
—

 
—

 
(21,826
)
 
(21,826
)
Balance at March 31, 2019
 
23,946

 
189

 
$
23

 
$
288,156

 
$
(40
)
 
$
(138,341
)
 
$
149,798

Exercise of stock options
 
40

 
—

 
—

 
165

 
—

 
—

 
165

Unrealized gain on short-term investments
 
—

 
—

 
—

 
—

 
44

 
—

 
44

Stock-based compensation expense
 
—

 
—

 
—

 
2,362

 
—

 
—

 
2,362

Net loss
 
—

 
—

 
—

 
—

 
—

 
(18,668
)
 
(18,668
)
Balance at June 30, 2019
 
23,986

 
189

 
$
23

 
$
290,683

 
$
4

 
$
(157,009
)
 
$
133,701

Exercise of stock options
 
9

 
—

 
—

 
36

 
—

 
—

 
36

Unrealized loss on short-term investments
 
—

 
—

 
—

 
—

 
(39
)
 
—

 
(39
)
Stock-based compensation expense
 
—

 
—

 
—

 
2,420

 
—

 
—

 
2,420

Proceeds from at-the-market offering
 
36

 
—

 
—

 
330

 
—

 
—

 
330

Net loss
 
—

 
—

 
—

 
—

 
—

 
(17,185
)
 
(17,185
)
Balance at September 30, 2019
 
24,031

 
189

 
$
23

 
$
293,469

 
$
(35
)
 
$
(174,194
)
 
$
119,263



6

 
 
Nine Months Ended September 30, 2018
 
 
Common Stock
 
Additional paid-in capital
 
Accumulated other comprehensive income
 
Accumulated deficit
 
Total stockholders’ equity
 
 
Issued
 
In Treasury
 
Amount
 
 
 
(in thousands)
Balance at December 31, 2017
 
23,148

 
8

 
$
23

 
$
273,059

 
$
(407
)
 
$
(76,243
)
 
$
196,432

Exercise of stock options
 
145

 
17

 
—

 
658

 
—

 
—

 
658

Release of restricted stock units
 
174

 
53

 
—

 
(1,206
)
 
—

 
—

 
(1,206
)
Unrealized loss on short-term investments
 
—

 
—

 
—

 
—

 
(75
)
 
—

 
(75
)
Stock-based compensation expense
 
—

 
—

 
—

 
3,299

 
—

 
—

 
3,299

Adoption of ASC 606 as of January 1, 2018
 
—

 
—

 
—

 
—

 
—

 
15,752

 
15,752

Net loss
 
—

 
—

 
—

 
—

 
—

 
(4,463
)
 
(4,463
)
Balance at March 31, 2018
 
23,467

 
78

 
$
23

 
$
275,810

 
$
(482
)
 
$
(64,954
)
 
$
210,397

Exercise of stock options
 
25

 
—

 
—

 
253

 
—

 
—

 
253

Unrealized gain on short-term investments
 
—

 
—

 
—

 
—

 
154

 
—

 
154

Stock-based compensation expense
 
—

 
—

 
—

 
2,804

 
—

 
—

 
2,804

Net loss
 
—

 
—

 
—

 
—

 
—

 
(13,325
)
 
(13,325
)
Balance at June 30, 2018
 
23,492

 
78

 
$
23

 
$
278,867

 
$
(328
)
 
$
(78,279
)
 
$
200,283

Exercise of stock options
 
17

 
3

 
—

 
38

 
—

 
—

 
38

Unrealized gain on short-term investments, net of tax $47
 
—

 
—

 
—

 
—

 
87

 
—

 
87

Stock-based compensation expense
 
—

 
—

 
—

 
2,731

 
—

 
—

 
2,731

Net loss
 
—

 
—

 
—

 
—

 
—

 
(17,387
)
 
(17,387
)
Balance at September 30, 2018
 
23,509

 
81

 
$
23

 
$
281,636

 
$
(241
)
 
$
(95,666
)
 
$
185,752


See accompanying notes.

7

CONCERT PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)
(Amounts in thousands)
 
Nine Months Ended 
 September 30,
 
2019
 
2018
Operating activities
 
 
 
Net loss
$
(57,679
)
 
$
(35,175
)
Adjustments to reconcile net loss to net cash used in operating activities:
 
 
 
Depreciation and amortization
1,256

 
875

Stock-based compensation expense
7,711

 
8,834

Accretion of premiums and discounts on investments
(899
)
 
(234
)
Amortization of deferred lease incentive
—

 
(589
)
Non-cash license consideration (Note 8)
—

 
(10,452
)
Other noncash items
—

 
(46
)
Unrealized loss on marketable equity securities
2,090

 
1,359

Loss on disposal of asset
4

 
52

Non-cash lease expense (Note 11)
161

 
—

Changes in operating assets and liabilities:
 
 
 
Accounts receivable
4

 
155

Interest receivable
265

 
115

Prepaid expenses and other current assets
(1,091
)
 
(4
)
Contract asset
16,000

 
—

Other assets
(16
)
 
26

Accounts payable
207

 
457

Accrued expenses and other liabilities
(827
)
 
(100
)
Income taxes receivable
(36
)
 
(77
)
Income taxes payable
(390
)
 
372

Deferred rent
—

 
2,033

Deferred revenue
—

 
(16
)
Operating lease liability (Note 11)
(445
)
 
—

Net cash used in operating activities
(33,685
)
 
(32,415
)
Investing activities
 
 
 
Purchases of property and equipment
(520
)
 
(2,405
)
Purchases of investments
(93,326
)
 
(46,120
)
Maturities of investments
141,706

 
93,144

Net cash provided by investing activities
47,860

 
44,619

Financing activities
 
 
 
Proceeds from exercises of stock options
1,006

 
934

Proceeds from exercise of warrants
1,000

 
—

Repurchase of common stock pursuant to share surrender
(741
)
 
(1,206
)
Proceeds from at-the-market offering, net of issuance costs
174

 
—

Net cash provided by (used in) financing activities
1,439

 
(272
)
Net increase in cash and cash equivalents and restricted cash
15,614

 
11,932

Cash, cash equivalents and restricted cash at beginning of period
18,927

 
29,222

Cash, cash equivalents and restricted cash at end of period
$
34,541

 
$
41,154

Supplemental cash flow information:
 
 
 
Cash paid for income taxes
$
453

 
$
50

Purchases of property and equipment unpaid at period end
$
—

 
$
99

Public offering costs unpaid at period end
$
50

 
$
—

Cash paid included in measurement of lease liabilities
$
2,082

 
$
—

Tenant improvements paid by landlord
$
—

 
$
4,996


See accompanying notes.

8
CONCERT PHARMACEUTICALS, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)



1. Nature of Business

Concert Pharmaceuticals, Inc., or Concert or the Company, was incorporated on April 12, 2006 as a Delaware corporation with operations based in Lexington, Massachusetts. The Company is a clinical stage biopharmaceutical company that applies its extensive knowledge of deuterium chemistry to discover and develop novel small molecule drugs. The Company’s approach starts with previously studied compounds, including approved drugs, that the Company believes can be improved with deuterium substitution to provide better pharmacokinetic or metabolic properties, enhancing clinical safety, tolerability or efficacy. The Company believes this approach may enable drug discovery and clinical development that is more efficient and less expensive than conventional small molecule drug research and development. The Company’s pipeline includes multiple clinical stage candidates and a number of preclinical compounds that it is currently assessing.
The Company had cash and cash equivalents and investments of $121.5 million at September 30, 2019. The Company believes that its cash and cash equivalents and investments at September 30, 2019 will be sufficient to allow the Company to fund its current operating plan for at least the next twelve months. The Company may pursue additional cash resources through public or private financings, by establishing collaborations with or licensing its technology to other companies and through other arrangements.
Since its inception, the Company has generated an accumulated deficit of $174.2 million through September 30, 2019. The Company's operating results may fluctuate significantly from year to year, depending on the timing and magnitude of clinical trial and other development activities under its current development programs. Substantially all the Company's net losses have resulted from costs incurred in connection with its research and development programs and from general and administrative costs associated with its operations. The Company expects to continue to incur significant expenses and increasing operating losses for at least the next several years.

The Company is subject to risks common to companies in the biotechnology industry, including, but not limited to, risks of failure or unsatisfactory results of nonclinical studies and clinical trials, the need to obtain additional financing to fund the future development of its pipeline, the need to obtain marketing approval for its product candidates, the need to successfully commercialize and gain market acceptance of its product candidates, dependence on key personnel, protection of proprietary technology, compliance with government regulations, development by competitors of technological innovations and ability to transition from pilot-scale manufacturing to large-scale production of products.

Unless otherwise indicated, all amounts in the following tables are in thousands except share and per share amounts.

2. Basis of Presentation and Significant Accounting Policies
Basis of Presentation
The accompanying condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments, consisting of normal recurring accruals and revisions of estimates, considered necessary for a fair presentation of the condensed consolidated financial statements have been included. Interim results for the three and nine months ended September 30, 2019 are not necessarily indicative of the results that may be expected for the fiscal year ending December 31, 2019 or any other future period.
The accompanying condensed consolidated financial statements reflect the accounts of Concert and its subsidiaries. All intercompany transactions between the Company and its subsidiaries have been eliminated. Management has determined that the Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the Company’s consolidated financial statements and the accompanying notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018 filed with the Securities and Exchange Commission, or SEC, on February 28, 2019.
Use of Estimates and Summary of Significant Accounting Policies

The preparation of the consolidated financial statements in conformity with U.S. generally accepted accounting principles, or GAAP, requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenue, expenses and the disclosure of contingent assets and liabilities and the Company's ability to continue as a going concern. In preparing the consolidated financial statements, management used estimates in the following areas, among others: revenue recognition; lease accounting; income tax expense; stock-based compensation expense; accrued expenses; and the

9
CONCERT PHARMACEUTICALS, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)


evaluation of the existence of conditions and events that raise substantial doubt regarding the Company’s ability to continue as a going concern. Actual results could differ from those estimates.
With the exception of the adoption of Accounting Standards Update, or ASU, 2016-02 during the nine months ended September 30, 2019 discussed in Note 11, there have been no material changes to the significant accounting policies previously disclosed in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2018.
Recently Adopted Accounting Pronouncements

In February 2016, the Financial Accounting Standards Board, or FASB, issued ASU 2016-02, Leases, or Topic 842. ASU 2016-02 requires lessees to recognize assets and liabilities on the balance sheet for the rights and obligations created by leases. On January 1, 2019, the Company adopted ASU 2016-02 and all related amendments. For discussion regarding the impact of this accounting pronouncement, refer to Note 11 appearing elsewhere in this Quarterly Report on Form 10-Q.

In June 2018, the FASB issued ASU 2018-07, Improvements to Nonemployee Share-Based Payment Accounting, that expands the scope of Topic 718, Compensation - Stock Compensation, to include share-based payment transactions for acquiring goods and services from nonemployees. ASU 2018-07 provides that an entity should apply the requirements of Topic 718 to nonemployee awards except for certain exemptions specified in the amendment. The Company adopted this new standard effective January 1, 2019, and it did not have a material effect on the consolidated financial statements and related disclosures.

In August 2018, the SEC issued Release No. 33-10532 that amends and clarifies certain financial reporting requirements. The principal change to the Company’s financial reporting is the inclusion of the annual disclosure requirement of changes in stockholders’ equity in Rule 3-04 of Regulation S-X to interim periods. The Company adopted this new rule beginning with its first Quarterly Report on Form 10-Q for the quarter ended March 31, 2019.
Pending Accounting Pronouncements

In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses. The new standard requires entities to measure all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions and reasonable and supportable forecasts. ASU 2016-13 will become effective for the Company for fiscal years beginning after December 15, 2019, with early adoption permitted. The Company is currently evaluating the impact ASU 2016-13 will have on its financial statements and related disclosures.

In August 2018, the FASB issued ASU 2018-15, Intangible-Goodwill and Other Internal-Use Software (Subtopic 350-40): Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement that is a Service Contract. The standard aligns the requirements for capitalizing implementation costs in a cloud computing arrangement service contract with the requirements for capitalizing implementation costs incurred for internal-use software. The new guidance also prescribes the balance sheet, income statement and cash flow classification of the capitalized implementation costs and related amortization expense, and requires additional quantitative and qualitative disclosures. ASU 2018-15 is effective for fiscal years beginning after December 15, 2019 and early adoption is permitted. The Company is currently evaluating the impact ASU 2018-15 will have on its financial statements and related disclosures.

3. Fair Value Measurements

The Company has certain financial assets and liabilities that are recorded at fair value which have been classified as Level 1, 2 or 3 within the fair value hierarchy as described in the accounting standards for fair value measurements:

•
Level 1—quoted prices for identical instruments in active markets;
•
Level 2—quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, and model-derived valuations in which all significant inputs and significant value drivers are observable in active markets; and
•
Level 3—valuations derived from valuation techniques in which one or more significant value drivers are unobservable.

The tables below present information about the Company’s financial assets and liabilities that are measured and carried at fair value as of September 30, 2019 and December 31, 2018 (in thousands) and indicate the level within the fair value hierarchy where each measurement is classified.

10
CONCERT PHARMACEUTICALS, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)


 
Level 1
 
Level 2
 
Level 3
 
Total
September 30, 2019
 
 
 
Cash equivalents:
 
 
 
Money market funds
$
21,253

 
$
—

 
$
—

 
$
21,253

U.S. Treasury obligations
4,238

 
—

 
—

 
4,238

Investments, available for sale:
 
 

U.S. Treasury obligations
38,689

 
—

 
—

 
38,689

Government agency securities
26,873

 
22,603

 
—

 
49,476

Marketable equity securities:
 
 
 
 
 
 
 
Corporate equity securities (Note 8)
5,435

 
—

 
—

 
5,435

Total
$
96,488

 
$
22,603

 
$
—

 
$
119,091


 
Level 1
 
Level 2
 
Level 3
 
Total
December 31, 2018
 
 
 
Cash equivalents:
 
 
 
Money market funds
$
7,643

 
$
—

 
$
—

 
$
7,643

U.S. Treasury obligations
1,748

 
—

 
—

 
1,748

Investments, available for sale:
 
 
 
U.S. Treasury obligations
34,103

 
746

 
—

 
34,849

Government agency securities
64,733

 
35,962

 
—

 
100,695

Marketable equity securities:
 
 
 
 
 
 
 
Corporate equity securities (Note 8)
7,525

 
—

 
—

 
7,525

Total
$
115,752

 
$
36,708

 
$
—

 
$
152,460



4. Cash, Cash Equivalents, Investments and Marketable Equity Securities
Cash equivalents include all highly liquid investments maturing within 90 days from the date of purchase. Investments consist of securities with original maturities greater than 90 days when purchased. The Company classifies these investments as available-for-sale and records them at fair value in the accompanying consolidated balance sheets. In accordance with ASU 2016-01, unrealized gains or losses from equity securities are included in net income. Unrealized gains or losses from other investments, including debt securities, are included in accumulated other comprehensive income (loss). Premiums or discounts from par value are amortized to investment income over the life of the underlying investment.

11
CONCERT PHARMACEUTICALS, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)


Cash, cash equivalents, available for sale investments, and marketable equity securities included the following at September 30, 2019 and December 31, 2018:
 
 
Average maturity
 
Amortized cost
 
Unrealized gains
 
Unrealized losses
 
Fair value
September 30, 2019
 
 
 
 
 
 
 
 
 
 
Cash
 
 
 
$
7,893

 
$
—

 
$
—

 
$
7,893

Money market funds
 
 
 
21,253

 
—

 
—

 
21,253

U.S. Treasury obligations
 
52 days
 
4,238

 
—

 
—

 
4,238

Cash and cash equivalents
 
 
 
$
33,384

 
$
—

 
$
—

 
$
33,384

 
 
 
 
 
 
 
 
 
 
 
U.S. Treasury obligations
 
169 days
 
38,683

 
14

 
(8
)
 
38,689

Government agency securities
 
88 days
 
49,443

 
34

 
(1
)
 
49,476

Investments, available for sale
 
 
 
$
88,126

 
$
48

 
$
(9
)
 
$
88,165

 
 
 
 
 
 
 
 
 
 
 
September 30, 2019
 
 
 
Acquisition value
 
Unrealized gains
 
Unrealized losses
 
Fair value
Marketable equity securities (Note 8)
 
 
 
$
10,451

 
$
—

 
$
(5,016
)
 
$
5,435


 
 
Average maturity
 
Amortized cost
 
Unrealized gains
 
Unrealized losses
 
Fair value
December 31, 2018
 
 
 
 
 
 
 
 
 
 
Cash
 
 
 
$
8,379

 
$
—

 
$
—

 
$
8,379

Money market funds
 
 
 
7,643

 
—

 
—

 
7,643

U.S. Treasury obligations
 
31 days
 
1,748

 
—

 
—

 
1,748

Cash and cash equivalents
 
 
 
$
17,770

 
$
—

 
$
—

 
$
17,770

 
 
 
 
 
 
 
 
 
 
 
U.S. Treasury obligations
 
151 days
 
$
34,856

 
$
2

 
$
(9
)
 
$
34,849

Government agency securities
 
153 days
 
100,748

 
7

 
(60
)
 
100,695

Investments, available for sale
 
 
 
$
135,604

 
$
9

 
$
(69
)
 
$
135,544

 
 
 
 
 
 
 
 
 
 
 
December 31, 2018
 
 
 
Acquisition value
 
Unrealized gains
 
Unrealized losses
 
Fair value
Marketable equity securities (Note 8)
 
 
 
$
10,451

 
$
—

 
$
(2,926
)
 
$
7,525

Although available to be sold to meet operating needs or otherwise (and therefore classified as current assets), securities are generally held through maturity. The cost of securities sold is determined based on the specific identification method for purposes of recording realized gains and losses. During 2019 and 2018, there were no realized gains or losses on sales of investments, and no investments were adjusted other than for temporary declines in fair value.

5. Restricted Cash
Restricted cash as of September 30, 2019 and 2018 is held as collateral for stand-by letters of credit issued by the Company to its landlords in connection with the current and previous leases of the Company's Lexington, Massachusetts facilities.


12
CONCERT PHARMACEUTICALS, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)


Cash, cash equivalents and restricted cash consisted of the following:

 
September 30,
2019
 
September 30,
2018
Cash and cash equivalents
$
33,384

 
$
39,597

Restricted cash
1,157

 
1,557

Total cash, cash equivalents and restricted cash shown in the statements of cash flows
$
34,541

 
$
41,154


6. Accrued Expenses and Other Liabilities
Accrued expenses and other liabilities consisted of the following:
 
September 30,
2019
 
December 31,
2018
Accrued professional fees and other
$
502

 
$
672

Employee compensation and benefits
2,245

 
3,067

Research and development expenses
1,687

 
1,476

Deferred lease incentive, current portion
—

 
454

 
$
4,434

 
$
5,669



7. Income Taxes

Deferred tax assets and deferred tax liabilities are recognized based on temporary differences between the financial reporting and tax basis of assets and liabilities using statutory rates. A valuation allowance is recorded against deferred tax assets if it is more likely than not that some or all of the deferred tax assets will not be realized.

The Company’s ability to use its operating loss carryforwards and tax credits to offset future taxable income is subject to restrictions under Sections 382 and 383 of the United States Internal Revenue Code, or the Internal Revenue Code. Net operating loss and tax credit carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant stockholders over a three-year period in excess of 50 percent, as defined under Sections 382 and 383 of the Internal Revenue Code. Such changes would limit the Company’s use of its operating loss carryforwards and tax credits. In such a situation, the Company may be required to pay income taxes, even though significant operating loss carryforwards and tax credits exist.

The Company records a provision or benefit for income taxes on ordinary pre-tax income or loss based on its estimated effective tax rate for the year. As of September 30, 2019, the Company forecasts an ordinary pre-tax loss for the year ended December 31, 2019 and, since it maintains a full valuation allowance on its deferred tax assets, the Company did not record an income tax benefit for the three or nine months ended September 30, 2019.

8. Revenue

The Company's revenue is generated through collaborative licensing agreements, patent assignments, and sales of intellectual property. The Company generates its revenue through one segment and the revenue recognized under each of the Company's arrangements during the current and prior period is described below.

On January 1, 2018, the Company adopted ASU 2014-19, Revenue from Contracts with Customers, or ASC 606. The Company adopted ASC 606 using the modified retrospective approach. For detailed information regarding the adoption of ASC 606, the impact on its consolidated financial statements and its collaboration arrangements, see Note 2 and Note 12 to the accompanying consolidated financial statements appearing in the Company's Annual Report on Form 10-K filed with the SEC on February 28, 2019.
Contract Assets
The Company did not have a contract asset as of September 30, 2019 as compared to $16.0 million as of December 31, 2018. The decrease in the contract asset balance is the result of the receipt of the $16.0 million that had initially been held in escrow

13
CONCERT PHARMACEUTICALS, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)


for indemnification purposes related to the asset purchase by Vertex Pharmaceuticals, Inc., or Vertex, and was released to the Company in February 2019.
Contract Liabilities
As of September 30, 2019 and December 31, 2018, the Company had $10.5 million in contract liabilities related to unsatisfied performance obligations as well as variable consideration paid in advance but currently constrained from recognition.
The contract liabilities consist of the following deferred revenue:
 
•
$7.8 million related to the Company's collaboration with Celgene Corporation, or Celgene, $1.4 million of which is attributable to the CTP-730 program and is currently expected to be recognized as revenue in the next twelve months as the Company satisfies its remaining research and development activities pursuant to mutually agreed upon development plans, and $6.4 million of which is attributable to two additional license programs that the Company will not recognize as revenue unless Celgene exercises its rights with respect to those programs, or in the second quarter of 2020 at such time that Celgene's rights lapse; and
•
$2.8 million related to a payment received from GlaxoSmithKline, or GSK, that the Company will not recognize as revenue until all repayment obligations lapse.
Revenue Arrangements
Vertex

On March 3, 2017, the Company and Vertex entered into an Asset Purchase Agreement, or the Vertex Agreement, pursuant to which, subject to the satisfaction or waiver of the conditions therein, the Company sold and assigned to Vertex, CTP-656, a deuterated analog of ivacaftor, now known as VX-561, and other cystic fibrosis assets of the Company. On July 25, 2017, or the Vertex Closing Date, the transaction contemplated by the Vertex Agreement closed and Vertex paid the Company $160 million in cash consideration. In addition, Vertex has agreed to pay the Company an aggregate of up to $90 million upon the achievement of certain milestone events. In February 2019, the $16.0 million initially held in escrow was released to the Company.

As of December 31, 2018, the Vertex indemnification variable consideration represented a contract asset to be released from escrow 18 months following the Vertex Closing Date and was classified as a current asset in the accompanying consolidated balance sheet. In February 2019, the $16.0 million initially held in escrow was released to the Company. Additionally, the variable consideration related to the regulatory milestone payments are fully constrained due to the uncertainty associated with the achievement of the respective milestones. Accordingly, no contract asset was recorded as of September 30, 2019.

Processa

On October 4, 2017, the Company entered into a License and Option Agreement, or the Option, with Promet Therapeutics, LLC, or Promet, pursuant to which the Company granted Promet an option to obtain an exclusive license to CTP-499, a deuterated analog of 1-(S)-5-hydroxyhexyl-3,7-dimethylxanthine, or HDX, an active metabolite of pentoxifylline, provided certain conditions were met. On October 5, 2017, Promet closed an asset purchase agreement with Heatwurx, Inc., a public company, creating Processa Pharmaceuticals, Inc., or Processa.

On March 21, 2018, the Company entered into an Amendment to the Option, or the Amendment, and a Securities Purchase Agreement, both with Promet and Processa. Pursuant to the Amendment, the Company granted Promet, who then assigned to Processa, an exclusive, worldwide, royalty-bearing license to develop, manufacture and commercialize CTP-499, now known as PCS-499. Upon transfer of the license and as consideration for the license, the Company received 2,090,301 shares of common stock of Processa.

The Company is also eligible to receive royalties on worldwide net sales.

The Amendment contained one performance obligation: an exclusive, worldwide, royalty-bearing license to develop, commercialize and sublicense CTP-499. The Company determined that the transaction price was $10.5 million, which was based on the fair value of the non-cash consideration received on March 19, 2018, which consisted of 2,090,301 shares of publicly traded common stock of Processa. The transaction price of $10.5 million was allocated to the single performance obligation. The performance obligation was considered satisfied at contract inception as the exclusive license transferred

14
CONCERT PHARMACEUTICALS, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)


control to the customer at this point in time. Accordingly, revenue of $10.5 million was recognized during the first quarter of 2018.

Subsequent changes to the fair value of the underlying securities are recognized as unrealized gains or losses on marketable equity securities within the condensed consolidated statement of operations and comprehensive loss.
The Amendment contains consideration that is variable based on royalties upon the customer's commercial success with the licensed product. The consideration related to royalty payments is considered variable consideration that is fully constrained in accordance with the royalty recognition constraint. The variable consideration related to royalties will be recognized in the period the products are sold by Processa and the Company has a present right to payment.

For the three and nine months ended September 30, 2019, the Company recognized $2 thousand and $24 thousand in revenue, respectively, related to intellectual property cost reimbursements. For the three months and nine months ended September 30, 2018, the Company recognized $10.5 million in revenue related to the transfer of the license.

Cipla

The Company entered into a License Agreement, or the Cipla Agreement, on January 16, 2019, or the Cipla Closing Date, with Cipla Technologies LLC, or Cipla, pursuant to which the Company granted Cipla an exclusive, worldwide, royalty-bearing license to develop, manufacture and commercialize CTP-354, a novel GABAA receptor subtype-selective modulator. As consideration for the license, the Company received an upfront payment of $1.0 million.
The Cipla Agreement also provides Cipla the option to purchase the Company’s existing inventory of CTP-354 held as of the Effective Date, valued in aggregate at $0.3 million. Additionally, upon the achievement of certain milestone events, Cipla has agreed to pay the Company an aggregate of up to $57.0 million. The first milestone payment the Company may be entitled to receive is $3.0 million when the first IND for the first CTP-354 product goes into effect.
Furthermore, the Company is eligible to receive royalties on worldwide net sales of future product sales at defined percentages ranging from the mid-single to high-single digits.
The Cipla Agreement contained one performance obligation: an exclusive, worldwide, royalty-bearing license to develop, manufacture, commercialize and sublicense CTP-354, referred to as the Transfer of License Performance Obligation. The Company concluded the option to purchase existing inventory did not provide Cipla a material right, and as such, was treated as a separate contract. The transaction price was determined to be $1.0 million based on the upfront consideration received as of the Cipla Closing Date.
As of the Cipla Closing Date, the Transfer of License Performance Obligation was satisfied as the control of CTP-354 transferred to Cipla, the customer. As a result, the full transaction price was recognized as revenue on the Cipla Closing Date. The sale of existing inventory is recognized as goods are transferred to the customer.
The arrangement with Cipla contains consideration that is variable based on the customer’s achievement of certain development and regulatory milestones in addition to royalties upon the customer’s commercial success with the licensed product. The next milestone payment the Company may be entitled to receive of $3.0 million related to the first IND for the first CTP-354 product going into effect is considered variable consideration that is fully constrained due to the uncertainty associated with the achievement of the development milestone. The consideration related to royalties is also variable consideration that is fully constrained in accordance with the royalty recognition constraint. The variable consideration related to royalties will be recognized in the period the products are sold by Cipla and the Company has a present right to payment.
The Company did not recognize revenue for the three months ended September 30, 2019. The Company recognized $1.0 million in revenue associated with the sale of existing inventory and the Transfer of License Performance Obligation for the nine months ended September 30, 2019.


9. Stock-Based Compensation
The Company’s equity incentive plans provide for the issuance of a variety of stock-based awards, including incentive stock options, nonstatutory stock options and awards of stock, to directors, officers and employees of the Company, as well as consultants and advisors to the Company. As of September 30, 2019, the Company has granted awards in the form of stock options and restricted stock units, or RSUs. The stock options generally have been granted with an exercise price equal to the

15
CONCERT PHARMACEUTICALS, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)


fair value of the underlying common stock on the date of grant, a vesting period of three or four years, and an expiration date no later than ten years from the date of grant.
Effective January 1, 2019, an additional 937,503 shares were added to the Company’s 2014 Stock Incentive Plan, or the 2014 Plan, for future issuance pursuant to the terms of the 2014 Plan. As of September 30, 2019, there were 1,192,083 shares of common stock available for future award grants under the 2014 Plan.
Total stock-based compensation expense related to all stock-based options and awards recognized in the condensed consolidated statements of operations and comprehensive loss consisted of:

 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2019
 
2018
 
2019
 
2018
Research and development
$
1,190

 
$
1,211

 
$
3,728

 
$
4,012

General and administrative
1,230

 
1,520

 
3,983

 
4,822

Total stock-based compensation expense
$
2,420

 
$
2,731

 
$
7,711

 
$
8,834


Stock Options

Stock options are valued using the Black-Scholes-Merton option valuation model, and compensation cost is recognized based on such fair value over the period of vesting. The weighted average fair value of options granted in the three and nine months ended September 30, 2019 and 2018 reflect the following weighted-average assumptions:
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2019
 
2018
 
2019
 
2018
Expected volatility
74.37
%
 
77.72
%
 
76.86
%
 
77.19
%
Expected term
6.0 years

 
6.0 years

 
6.0 years

 
6.0 years

Risk-free interest rate
1.59
%
 
2.98
%
 
2.16
%
 
2.65
%
Expected dividend yield
—
%
 
—
%
 
—
%
 
—
%
For the three and nine months ended September 30, 2019 and 2018, expected volatility was estimated using a weighted-average of the Company's historical volatility of its common stock and the historical volatility of the common stock of a group of similar companies that were publicly traded. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available.

The following table provides certain information related to the Company's outstanding stock options:
 
 
Three Months Ended
September 30,
 
Nine Months Ended
September 30,
 
 
2019
 
2018
 
2019
 
2018
 
 
(in thousands, except per share data)
Weighted average fair value of options granted, per option
 
$
6.46

 
$
10.42

 
$
8.95

 
$
17.92

Aggregate grant date fair value of options vested during the period
 
$
2,234

 
$
2,110

 
$
7,070

 
$
5,839

Total cash received from exercises of stock options
 
$
36

 
$
23

 
$
1,006

 
$
934

Total intrinsic value of stock options exercised
 
$
59

 
$
187

 
$
1,167

 
$
2,539


16
CONCERT PHARMACEUTICALS, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)


The following is a summary of stock option activity for the nine months ended September 30, 2019:
 
Number of
Option Shares
 
Weighted
Average
Exercise
Price per
Share
 
Weighted
Average
Remaining
Contractual
Term
 
Aggregate
Intrinsic
Value
 
 
 
 
 
(In years)
 
(In thousands)
Outstanding at December 31, 2018
3,557,406

 
$
15.26

 
 
 
 
      Granted
1,032,250

 
$
13.25

 
 
 
 
      Exercised
(202,508
)
 
$
8.33

 
 
 
 
      Forfeited or expired
(184,474
)
 
$
18.44

 
 
 
 
Outstanding at September 30, 2019
4,202,674

 
$
14.96

 
6.99
 
$
390

Exercisable at September 30, 2019
2,429,295

 
$
13.70

 
6.03
 
$
390

Vested and expected to vest at September 30, 2019(1)
4,049,442

 
$
14.90

 
6.93
 
$
390


(1) 
This represents the number of vested stock option shares as of September 30, 2019, plus the number of unvested stock option shares that the Company estimated as of September 30, 2019 would vest, based on the unvested stock option shares at September 30, 2019 and an estimated forfeiture rate of 7%.

As of September 30, 2019, there was $17.4 million of unrecognized compensation cost related to stock options that are expected to vest. The stock option costs are expected to be recognized over a weighted average remaining vesting period of 2.5 years.

Restricted Stock Units

On July 6, 2017, the Company granted 0.5 million RSUs, or the 2017 RSU grant, to executives and employees. The awards granted to non-executive employees were service-based, whereas the awards granted to executives were a blend of service-based and performance-based. Assuming all service and performance conditions were achieved, fifty percent of the RSUs would vest on March 31, 2018, and the remaining fifty percent of the RSUs would vest on March 31, 2019. Certain executive awards were subject to the achievement of defined performance criteria prior to March 31, 2018, including the closing of the asset purchase contemplated by the Vertex Agreement and the institution by the Patent Trial and Appeal Board, or PTAB, of the Post Grant Review, or PGR, petition filed by the Company against Incyte Corporation. In January 2018, the PTAB decided not to institute the PGR petition and, as a result, the corresponding performance-based awards did not vest on March 31, 2018.

The Company used the accelerated attribution method to recognize expense over the required service period based on its estimate of the number of performance-based awards that vested. For any change in the estimate of the number of performance-based awards that were probable of vesting, the Company cumulatively adjusted compensation expense in the period that the change in estimate was made.

On August 15, 2019, or the 2019 RSU grant date, the Company granted 0.4 million RSUs, or the 2019 RSU grant, to certain executives and employees. All awards are service-based and vest ratably over two years. On the first anniversary of the 2019 RSU grant date, thirty-five percent of the RSUs will vest. The remainder of the RSUs will vest on the second anniversary of the 2019 RSU grant date.

RSUs are not included in issued and outstanding common stock until the shares are vested and settled. As of September 30, 2019, all achieved RSUs from the 2017 RSU grant had vested, and no RSUs from the 2019 RSU grant had vested. The fair value of an RSU is measured based on the market price of the underlying common stock as of the date of grant.

17
CONCERT PHARMACEUTICALS, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)


The following is a summary of RSU activity, including both service-based and performance-based RSUs for the nine months ended September 30, 2019:

 
Number of
RSU Shares
 
Weighted
Average
Grant Date Fair Value
 
 
 
 
Outstanding at December 31, 2018
228,150

 
$
13.87

      Granted
412,220

 
$
10.27

      Released
(202,550
)
 
$
13.87

      Forfeited
(25,600
)
 
$
13.87

Outstanding at September 30, 2019
412,220

 
$
10.27


As of September 30, 2019, there was $4.0 million of unrecognized compensation cost related to RSUs that are expected to vest. The RSU costs are expected to be recognized over a weighted average remaining vesting period of 1.9 years.

10. Loss Per Share
Basic net loss per common share is calculated by dividing net loss allocable to common stockholders by the weighted-average common shares outstanding during the period, without consideration of common stock equivalents. For purposes of the diluted net loss per share calculation, common stock equivalents are excluded from the calculation if their effect would be anti-dilutive. As such, basic and diluted net loss per share applicable to common stockholders are the same for periods with a net loss.
The following table illustrates the determination of loss per share for each period presented.
 
Three Months Ended
September 30,
 
Nine Months Ended
September 30,
 
2019
 
2018
 
2019
 
2018
 
(in thousands, except per share amounts)
Numerator:
 
 
 
 
 
 
 
Net loss applicable to common stockholders - basic and diluted
$
(17,185
)
 
$
(17,387
)
 
$
(57,679
)
 
$
(35,175
)
 
 
 
 
 
 
 
 
Denominator:
 
 
 
 
 
 
 
Weighted average shares outstanding - basic and diluted
23,807

 
23,421

 
23,703

 
23,349

 
 
 
 
 
 
 
 
Net loss per share applicable to common stockholders - basic and diluted
$
(0.72
)
 
$
(0.74
)
 
$
(2.43
)
 
$
(1.51
)
 
 
 
 
 
 
 
 
Anti-dilutive potential common stock equivalents excluded from the calculation of net loss per share:
 
 
 
 
 
 
 
Stock options
214

 
515

 
290

 
758

Restricted stock units
410

 
133

 
72

 
214

Warrants
61

 
132

 
72

 
132



11. Lease

The FASB issued ASU 2016-02, or the leasing standard or ASC 842, in February 2016. ASU 2016-02 requires lessees to recognize assets and liabilities on the balance sheet for the rights and obligations created by all leases with terms of more than 12 months. ASU 2016-02 also requires certain qualitative and quantitative disclosures designed to give financial statement users information on the amount, timing and uncertainty of cash flows arising from leases.

18
CONCERT PHARMACEUTICALS, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)


The Company adopted ASU 2016-02 effective January 1, 2019. The Company has elected to employ the transitionary relief recently offered by the FASB under ASU 2018-11, and implement the new standard without the restatement of comparative periods’ financial information. ASU 2018-11 also provides for recognizing the effects of applying ASU 2016-02 as a cumulative-effect adjustment to retained earnings as of January 1, 2019; however, no such adjustment was required as of January 1, 2019.
The Company has elected to employ the package of practical expedients offered under ASC 842, which allow the Company to not reassess the following:
•
the presence of a lease in any expired or existing contracts;
•
the lease classification for any expired or existing leases; and
•
the initial direct costs for any existing leases.

The Company currently leases 55,522 square feet of office and laboratory space, or the Lease, located at 65 Hayden Avenue, Lexington, Massachusetts, or the Premises, which was classified as an operating lease under ASC 840. The Lease is also classified as an operating lease under ASC 842 in accordance with the Company’s election of the practical expedient under ASC 842. Pursuant to the package of practical expedients, the Company will also not reassess initial direct costs for the Premises. Additionally, the Company has made the policy election to adopt the practical expedient to not separate lease components from nonlease components for the right-to-use asset class of office and laboratory space. This policy election results in the Company accounting for the lease component, the use of the Premises and the non-lease components, which include the use of the parking garage, building elevators and HVAC, as a single lease component.
The Company occupied the Premises in the third quarter of 2018; however, the Company gained access to the space on January 1, 2018 in order to start making certain tenant improvements. Accordingly, for accounting purposes the lease commencement date was determined to be January 1, 2018 under the prior guidance of ASC 840, and therefore the Company had begun recognizing lease expense as of that date. The Lease term extends ten years following January 1, 2019. The Company is entitled to two five-year options to extend the Lease; however, these options were not included in the calculation of the Lease asset or liability. The Company has elected to employ the provision under ASC 842 to use hindsight with respect to determining the lease term (i.e., consideration of the actual outcome of lease renewals, termination options and purchase options) and in assessing any impairment of right-of-use assets for existing leases. The Company notes no events such as renewals or termination options have occurred with respect to the Lease for the Premises. Therefore, the hindsight practical expedient under ASC 842 has no impact on the accounting term as previously determined under ASC 840. As of September 30, 2019, the remaining lease term for the Premises is 9 years and 3 months.
The Lease provides for annual base rent of approximately $2.8 million in the first year following the Base Rent Commencement Date of January 1, 2019, which increases on a yearly basis by 3.0% (subject to an abatement of base rent of approximately $0.5 million at the beginning of the second year of the Lease term if the Company is not in default under the Lease). There are no variable payments, exercise purchase options, penalties, fees or residual value guarantees under the Lease. The Company is also obligated to pay the Landlord for certain costs, taxes and operating expenses related to the Premises, subject to certain exclusions; however, the Company has concluded that these payments are not in-substance fixed payments and therefore are not included in the calculation of the related lease liability and asset under ASC 842.
The Company recorded the liability associated with the Lease for the Premises at the present value of the lease payments not yet paid, discounted using the discount rate for the Lease established at the commencement date. As the Lease does not provide an implicit rate, the Company had to estimate the incremental borrowing rate, or IBR, as of the commencement date. The IBR is defined under ASC 842 as the rate of interest that the Company would have to pay to borrow on a collateralized basis over a similar term for an amount equal to the lease payments in a similar economic environment.
The IBR for the Lease was determined by establishing a credit rating of the Company using the Rank Order Model. Based on the established credit rating, the Company determined a borrowing rate using the Recovery Rate method, adjusted for the risk-free rate, which resulted in an IBR of approximately 13%. The Company used this IBR of 13% to discount the remaining lease payments over the remaining lease term and recorded a lease liability of $16.9 million on January 1, 2019. This lease liability will be amortized over the remaining lease term in an amount equal to the difference between the cash rent paid and the monthly interest calculated on the remaining lease liability. As of September 30, 2019, the Company had a current lease liability of $0.2 million and a non-current lease liability of $16.2 million recorded in its condensed consolidated balance sheets.
The Company received an improvement allowance from the Landlord of approximately $5.0 million for certain permitted costs related to the design of Company improvements to the Premises, consisting of normal tenant improvements. The Company is deemed to be the owner of these tenant improvements during the lease term.

19
CONCERT PHARMACEUTICALS, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)


These $5.0 million of improvements are included in the Company’s property, plant and equipment balances in its condensed consolidated balance sheets as of September 30, 2019 and are depreciated over the shorter of their useful life or the related lease term.
On January 1, 2019, the Company recorded a right-of-use asset in the amount $9.5 million, which represents the lease liability of $16.9 million, adjusted for previously accrued rent of $2.9 million and previously recorded unamortized lease incentives (the improvement allowance) in the amount of $4.5 million. The right-of-use asset will be amortized over the remaining lease term in an amount equal to the difference between the calculated straight-line expense of the total lease payments less the monthly interest calculated on the remaining lease liability. As of September 30, 2019, the Company had a long-term lease asset of $9.3 million recorded in its condensed consolidated balance sheets.
The Company will recognize lease expense, calculated as the remaining cost of the lease allocated over the remaining lease term, on a straight-line basis. Lease expense will be presented as part of continuing operations in the condensed consolidated statement of operations and comprehensive loss. For the nine months ended September 30, 2019, the Company recognized $1.8 million in lease expense.
For the nine months ended September 30, 2019, the Company paid $2.1 million in rent relating to the Lease. As a payment arising from an operating lease, the $2.1 million will be classified within operating activities in the Condensed Consolidated Statements of Cash Flows.
Supplemental cash flow information:
For the nine months ended September 30,
(in thousands)
2019
Cash paid for amounts included in the measurement of lease liabilities
Operating cash flows from operating leases
$
2,082

Supplemental balance sheet information:
For the nine months ended September 30,
(in thousands)
2019
2018
 
 
 
Operating lease right-of-use assets
$
9,317

$
—

Operating lease liability
16,425

—

 
 
 
Weighted average remaining lease term
9.25

10.25

Weighted average discount rate
13.08
%
—
%
Maturities of lease liabilities:
For the twelve months ended December 31,
 
(in thousands)
 
 
2019
$
696

*
2020
2,406

 
2021
2,969

 
2022
3,058

 
2023
3,150

 
Thereafter
17,223

 
Total lease payments
29,502

 
Less imputed interest
(13,077
)
*
Total
$
16,425

 
* Excludes the nine months ended September 30, 2019
 
 



20
CONCERT PHARMACEUTICALS, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)


12. Open Market Sale Agreement

On March 1, 2019, the Company entered into an Open Market Sale Agreement, or the ATM Agreement, with Jefferies LLC, or Jefferies, with respect to an at-the-market offering program under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock, par value $0.001 per share, having an aggregate offering price of up to $50 million, referred to as Placement Shares, through Jefferies as its sales agent. The Company will pay Jefferies a commission equal to 3.0% of the gross sales proceeds of any Placement Shares sold through Jefferies under the ATM Agreement, and also has provided Jefferies with customary indemnification and contribution rights. In addition, the Company has agreed to reimburse certain legal expenses and fees by Jefferies in connection with the offering up to a maximum of $50,000, in addition to certain ongoing disbursements of Jefferies' counsel. As of November 4, 2019, the Company has sold 36,167 shares of its common stock in accordance with the ATM Agreement for net proceeds of $0.4 million, after payment of cash commissions of 3.0 percent of the gross proceeds to its sales agent. Additionally, the Company incurred approximately $0.3 million related to legal, accounting and other fees in connection with the ATM Agreement as of September 30, 2019.


21


Item 2.
Management’s Discussion and Analysis of Financial Condition and Results of Operations.
You should read the following discussion and analysis of our financial condition and results of operations together with our condensed consolidated financial statements and the related notes appearing elsewhere in this Quarterly Report on Form 10-Q. Statements contained or incorporated by reference in this Quarterly Report on Form 10-Q that are not based on historical fact are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements regarding future events and our future results are based on current expectations, estimates, projections, intentions, goals, strategies, plans, prospects and the beliefs and assumptions of our management including, without limitation, our expectations regarding results of operations, general and administrative expenses, research and development expenses, current and future development and manufacturing efforts, regulatory filings, nonclinical and clinical trial results, and the sufficiency of our cash for future operations. You should read the “Risk Factors” section in Part II—Item 1A. of this report for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.


OVERVIEW
We are a clinical stage biopharmaceutical company applying our extensive knowledge of deuterium chemistry to discover and develop novel small molecule drugs. Selective incorporation of deuterium into known molecules has the potential, on a case-by-case basis, to provide better pharmacokinetic or metabolic properties, thereby enhancing their clinical safety, tolerability or efficacy. Our approach typically starts with previously studied compounds, including approved drugs, which we believe may be improved with deuterium substitution. Our technology provides the opportunity to develop products that may compete with the non-deuterated drug in existing markets or to leverage its known activity to expand into new indications and may enable compounds not otherwise well-suited for human drug development to be clinically developed. Our deuterated chemical entity platform, or DCE Platform®, has broad potential across numerous therapeutic areas. Our pipeline includes multiple clinical stage candidates and a number of preclinical compounds that we are currently assessing.
pipelineoct2019.jpg
CTP-543
Background on Alopecia Areata
Alopecia areata is a serious, chronic autoimmune disease affecting approximately 650,000 Americans at any given time that results in partial or complete loss of hair on the scalp and/or body. Alopecia areata occurs when the immune system attacks the hair follicles and is characterized as non-scarring hair loss. It presents in a number of patterns including:
•
Patchy: coin-sized or larger patch or patches of hair loss;
•
Totalis: no hair on the head; and

22

•
Universalis: no hair anywhere on the body.
Onset can occur at any age including childhood, and it affects both women and men equally. While the average age of onset is between 25-35 years, the disease does occur in children, and onset in the first two decades is associated with more severe disease. The emotional effect of alopecia areata can be considerable and may result in anxiety and depression or affect personal attributes such as self-esteem and confidence.  Alopecia areata may also be associated with other autoimmune conditions such as thyroid disease, vitiligo, allergic rhinitis, asthma, lupus, rheumatoid arthritis and ulcerative colitis. The most common form of treatment is corticosteroids including intralesional injections or topical application. However, they are typically not well tolerated and often provide limited efficacy. There are currently no treatments approved by the U.S. Food and Drug Administration, or FDA, for alopecia areata.
CTP-543 Opportunity
CTP-543 was discovered by applying our deuterium chemistry technology to modify ruxolitinib, a Janus kinase, or JAK, inhibitor, which is commercially available under the name Jakafi® in the United States for the treatment of certain blood disorders and for graft versus host disease.

In January 2018, we announced that the FDA had granted Fast Track designation to CTP-543 for the treatment of alopecia areata.
Clinical Development of CTP-543
In 2016, we completed single and multiple ascending dose Phase 1 trials with our investigational treatment CTP-543, which enrolled a total of 77 healthy volunteers. The pharmacokinetic measurements showed increased exposure with increasing doses of CTP-543. CTP-543 was well tolerated across all dose groups and there were no serious adverse events reported in subjects who received CTP-543. In the multiple ascending dose Phase 1 trial of CTP-543, pharmacodynamic analyses were performed to assess the inhibition of IL-6- and IFN-gamma-mediated JAK/STAT signaling. Consistent with the expected pharmacological activity of a JAK1/JAK2 inhibitor, CTP-543 demonstrated a dose-related reduction of IL-6-stimulated phosphorylation of STAT3 in an ex-vivo assay. Also, IFN-gamma-mediated STAT1 signaling, which is believed to play a key role in the pathogenesis of alopecia areata, was significantly inhibited in disease-relevant immune cell types at all doses evaluated.

We also conducted a Phase 1 crossover study evaluating the metabolite profiles of CTP-543 and ruxolitinib. In this study, except for the presence of deuterium, no new metabolites were observed with CTP-543.

A Phase 2 double-blind, randomized, sequential dose-ranging trial to evaluate three sequential doses of CTP-543 (4, 8 and 12 mg twice-daily) and a placebo control in 149 patients with moderate-to-severe alopecia areata was completed in the third quarter of 2019. The primary outcome measure utilized the severity of alopecia tool (SALT) after 24 weeks of dosing. In November 2018, we announced interim topline results from the 4 mg and 8 mg twice-daily cohorts, and in September 2019, we announced final topline results for all three dosing cohorts in the trial. A numerically but not statistically greater percentage of patients treated with the 4 mg twice-daily dose of CTP-543 met the primary efficacy endpoint. Patients treated with either 8 mg twice-daily or 12 mg twice-daily of CTP-543 met the primary efficacy endpoint with statistically significant differences (p <0.001) relative to placebo in the percentage of patients achieving a ≥ 50% relative change from baseline at 24 weeks. The 8 mg twice-daily and 12 mg twice-daily groups were also significantly different from placebo in the number of patients achieving ≥ 75% and ≥ 90% relative change in SALT from baseline at 24 weeks. At Week 24, patients treated with 8 mg twice-daily and 12 mg twice-daily compared to placebo also rated significantly greater improvement in their alopecia areata on the Patient Global Impression of Improvement Scale. Treatment with CTP-543 was generally well tolerated. The most common side effects were headache, nasopharyngitis, upper respiratory tract infection, cough, acne and nausea. One serious adverse event of facial cellulitis was reported as possibly related to treatment; however, after a brief interruption, treatment was continued and this patient completed the trial. No thromboembolic events were reported during the trial.


23

Responders: ≥ 50% Change in SALT Relative to Baseline
respondersgreatera01.jpg
Patient SALT Improvement Thresholds
Relative Change in SALT from Baseline to Week 24
patientsaltimprovementv2a01.jpg

In March 2019, we initiated an open label trial to evaluate once-daily compared to twice-daily dosing of CTP-543 in patients with moderate-to-severe alopecia areata in the United States. In June 2019, we completed enrollment of 57 adult patients in the trial. Patients were randomized to receive CTP-543 either 8 mg twice-daily or 16 mg once-daily over a 24 week treatment period. The trial will measure the change in SALT score between Week 24 and baseline. The trial is expected to be completed in the fourth quarter of 2019.

In May 2019, we initiated a second open label trial to evaluate once-daily compared to twice-daily dosing of CTP-543 in patients with moderate-to-severe alopecia areata in the United States and Canada. In September 2019, we completed enrollment of 66 adult patients in the trial. Patients were randomized to receive CTP-543 either 12 mg twice-daily or 24 mg once-daily

24

over a 24 week treatment period. The trial will measure the relative change in SALT score between Week 24 and baseline. The trial is expected to be completed in the first half of 2020.

All patients who complete 24 weeks of treatment in the 12 mg twice-daily cohort of the Phase 2 dose-ranging trial, the two ongoing open label studies and future studies, are eligible to enroll into an open label extension study of CTP-543. The open label extension study began enrolling patients in April 2019.
CTP-692
Background on Schizophrenia
Schizophrenia is a chronic and devastating neuropsychiatric disorder that is a leading cause of disability worldwide. The disease is believed to afflict nearly 1% of the world’s population, affecting both men and women equally, and striking all ethnic and socioeconomic groups with a similar level of prevalence. The illness is characterized by multiple symptoms that are categorized into three clusters known as positive symptoms (hallucinations and delusional behaviors), negative symptoms (anhedonia, social withdrawal and apathy), and cognitive dysfunction (diminished capacity for learning, memory and executive function). The theory underlying current antipsychotic therapies is that excessive dopaminergic neurotransmission and dysfunctional D2 receptor signaling plays a key pathophysiological role in the disease, and consequently all typical and atypical antipsychotics in clinical practice possess some level of D2 antagonist or partial agonist activity. Currently available antipsychotic drugs often exhibit efficacy for positive symptoms, but have been limited in their capacity to treat negative symptoms and cognitive deficits.

There is an extensive body of evidence supporting N-methyl-D-aspartate, or NMDA, receptor hypofunction as a key underlying mechanism of schizophrenia. The NMDA receptor comprises two binding domains and, in addition to requiring glutamate binding, activation with a co-agonist such as D-serine or glycine is necessary for NMDA receptor activation. D-serine is believed to be the most important human NMDA synaptic co-agonist. It has been postulated for some time that administration of NMDA co-agonists could benefit patients with schizophrenia since there is evidence that plasma and cerebral spinal fluid, or CSF, levels of endogenous D-serine are reduced in patients with schizophrenia. In addition, evidence of both impaired D-serine synthesis and increased D-serine metabolism have been reported in patients with schizophrenia relative to normal individuals.
CTP-692 Opportunity
CTP-692 is a selective deuterium-modified analog of the endogenous amino acid, D-serine. Based on published nonclinical and clinical effects of D-serine, we believe that CTP-692 has the potential to help restore NMDA receptor activity in key areas of the brain to improve clinical outcomes in patients with schizophrenia. Clinical studies have shown that levels of D-serine measured in the plasma and CSF of patients with schizophrenia are significantly lower than healthy controls. Academic studies have demonstrated that oral dosing of D-serine can result in dose-dependent improvement in positive, negative and cognitive symptoms in patients with schizophrenia when added to D2-modulating antipsychotics. However, nonclinical studies have demonstrated that D-serine can cause nephrotoxicity in rats. In addition, in some patients who received high doses of D-serine, clinical findings suggesting renal impairment were observed. As a result, the clinical development of D-serine has historically been limited.

In nonclinical studies in rats, when administered at doses where D-serine resulted in significantly increased blood levels of serum creatinine and blood urea nitrogen, indicating renal toxicity, CTP-692 did not cause changes in blood levels of those markers, suggesting that CTP-692 could have reduced toxicity and a larger therapeutic window. In these studies, administration of CTP-692 also resulted in greater exposure than similar doses of D-serine. It therefore may be better-suited for development as a human therapeutic agent. CTP-692 will initially be developed as an adjunctive therapy along with standard antipsychotic medicines in patients with schizophrenia.
Clinical Development of CTP-692
The Phase 1 program was designed to assess CTP-692’s safety, tolerability and pharmacokinetics in healthy volunteers. The Phase 1 program included three studies: a crossover comparison of CTP-692 versus D-serine, a single-ascending dose study that also assessed the effect of food on the pharmacokinetics of CTP-692, and a multiple-ascending dose trial assessing CTP-692 dosed orally over seven days.

In the crossover study, a single dose of CTP-692 was found to result in greater plasma exposure than did the same amount of D-serine. In the single- and multiple-ascending dose trials, CTP-692 was evaluated across doses ranging from 0.5 to 4 grams

25

compared to placebo in a total of 72 volunteers. CTP-692 demonstrated a favorable safety, tolerability and pharmacokinetic profile with no serious adverse events reported. Importantly, key blood and urine markers of kidney function did not indicate any signs of renal impairment. 

In the fourth quarter of 2019, we expect to advance CTP-692 into a Phase 2 trial as an adjunctive treatment for schizophrenia.

Preclinical Pipeline

We are currently assessing a number of preclinical assets as potential development candidates.

COLLABORATION PRODUCT CANDIDATES
We have several collaborative arrangements with companies to develop deuterium-modified versions of their marketed products. In each of these collaborations, the deuterium-modified compound was independently discovered by us. Our collaborators are responsible for any future clinical development activities, expenses and disclosures associated with the following programs.

•
AVP-786 is a combination of deudextromethorphan and an ultra-low dose of quinidine being investigated for the treatment of neurologic and psychiatric disorders that is being developed under a collaboration with Avanir Pharmaceuticals, Inc., or Avanir, a subsidiary of Otsuka Pharmaceuticals Co., Ltd., or Otsuka. In November 2015, Avanir announced the initiation of the Phase 3 clinical program to evaluate the safety and efficacy of AVP-786 for the treatment of agitation associated with dementia of the Alzheimer's type. It enrolled 932 patients in two North American Phase 3 double-blind, placebo-controlled trials. The first North American Phase 3 trial completed in February 2019 and the second Phase 3 trial completed in September 2019. The second Phase 3 trial did not meet its primary or key secondary endpoints. In October 2017, Avanir initiated a global Phase 3 trial, which is expected to enroll approximately 400 patients to evaluate the safety and efficacy of AVP-786 for the treatment of agitation associated with dementia of the Alzheimer's type. In February 2019, Avanir initiated a Phase 2/3 trial to evaluate the safety and efficacy of AVP-786 for the treatment of negative symptoms of schizophrenia in approximately 370 patients.
•
CTP-730 is a deuterated analog of apremilast that is being developed under a collaboration with Celgene. In January 2019, Celgene and Bristol-Myers Squibb Company, or BMS, announced that they entered into a definitive merger agreement pursuant to which BMS will acquire Celgene. In June 2019, BMS announced the planned divestiture of OTEZLA® (apremilast) in light of concerns raised by the U.S. Federal Trade Commission, or FTC. In August 2019, BMS announced that Celgene entered into an agreement with Amgen, Inc. to divest OTEZLA®, or the OTEZLA® Divestiture. The closing of the OTEZLA® Divestiture is contingent on BMS and Celgene entering into a consent decree with the FTC in connection with their pending merger, the closing of the pending merger between BMS and Celgene and the satisfaction of other customary closing conditions. The pending merger between BMS and Celgene is expected to close by the end of 2019, subject to the FTC's acceptance of a consent order and the satisfaction of customary closing conditions. Apremilast is a selective phosphodiesterase 4 (PDE4) inhibitor approved in various countries for the treatment of moderate-to-severe plaque psoriasis and psoriatic arthritis, and approved in the United States and Japan for the treatment of oral ulcers associated with Behçet’s Disease. We completed the Phase 1 clinical evaluation of CTP-730. Once-daily dosing of 50 mg of CTP-730 administered for seven days in the Phase 1 clinical trial demonstrated similar steady state exposure to historical data for 30 mg of apremilast twice-daily. Treatment with CTP-730 was generally well tolerated and no serious adverse events were observed. Celgene is responsible for any development of CTP-730 beyond the completed Phase 1 clinical trials. Celgene is assessing the path forward for CTP-730. However, CTP-730 has not advanced into new trials at this time.
•
Jazz Pharmaceuticals is evaluating several formulation and technology options as part of its once nightly oxybate program. Jazz Pharmaceuticals initially evaluated JZP-386, a deuterium containing high sodium analog of Xyrem, which demonstrated favorable deuterium-related effects. However, its current once-nightly development efforts are focused on lower sodium compounds. The collaboration with Jazz Pharmaceuticals provides for the evaluation of deuterium as an option for a once nightly sodium oxybate product (D-SXB).
ASSET PURCHASE AGREEMENT WITH VERTEX PHARMACEUTICALS FOR CTP-656
In July 2017, we completed the sale of worldwide development and commercialization rights to CTP-656, and other assets related to the treatment of cystic fibrosis (CF), to Vertex. CTP-656, now known as VX-561, is an investigational cystic fibrosis transmembrane conductance regulator (CFTR) potentiator that has the potential to be used as part of future once-daily combination regimens of CFTR modulators that treat the underlying cause of cystic fibrosis. We received $160 million in cash

26

upon closing, and if VX-561 is approved as part of a combination regimen to treat cystic fibrosis, we are eligible to receive up to $90 million in additional milestones based on regulatory approval in the United States and agreement for reimbursement in the first of the U.K., Germany or France.

INTELLECTUAL PROPERTY

CTP-543

We hold a U.S. patent covering the composition of matter of deuterated analogs of ruxolitinib and corresponding U.S. patent applications. The patent and the patent applications are expected to expire in 2033. We have corresponding patent applications in Europe and Japan, which if they issue as patents, are expected to expire in 2033. We have retained all of the CTP-543 patent rights.

The PTAB instituted an inter partes review, or IPR, brought against our U.S. Patent No. 9,249,149, or the '149 patent, by Incyte Corporation.  The '149 patent claims deuterated analogs of ruxolitinib including CTP-543.  In April 2019, the PTAB issued a final written decision in connection with the IPR that found that the claims of the '149 patent are not patentable. The '149 patent remains valid and enforceable until appeals have been exhausted. In June 2019, we filed a Notice of Appeal with the Federal Circuit.

The PTAB decision does not prohibit us from developing CTP-543 for alopecia areata and we remain committed to the development of the program. We are working to obtain additional patents to protect CTP-543 and extend its commercial opportunity.


FINANCIAL OPERATIONS OVERVIEW
Since our inception in 2006, we have devoted substantially all of our resources to our research and development efforts, including activities to develop our DCE Platform, and our core capabilities in deuterium chemistry, identify potential product candidates, undertake nonclinical studies and clinical trials, manufacture clinical trial material in compliance with current good manufacturing practices, provide general and administrative support for these operations and establish our intellectual property. We have generated an accumulated deficit of $174.2 million since inception through September 30, 2019 and will require substantial additional capital to fund our research and development. We do not have any products approved for sale and have not generated any revenue from product sales. We have funded our operations primarily through the public offering and private placement of our equity, debt financing, funding from collaborations and patent assignments, an asset sale and other arrangements.

Our operating results may fluctuate significantly from year to year, depending on the timing and magnitude of cash payments received pursuant to collaboration and licensing arrangements and other agreements and the timing and magnitude of clinical trial and other development activities under our current development programs. Substantially all of our net losses have resulted from costs incurred in connection with our research and development programs and from general and administrative costs associated with our operations.
We expect to continue to incur significant expenses and increasing operating losses for at least the next several years. We expect our expenses will increase substantially in connection with our ongoing activities as we continue research and development efforts and develop and conduct additional nonclinical studies and clinical trials with respect to our product candidates.

We do not expect to generate revenue from product sales unless and until we, or our collaborators, obtain marketing approval for one or more of our product candidates, which we expect will take a number of years and is subject to significant uncertainty. If we obtain, or believe that we are likely to obtain, marketing approval for any product candidates for which we retain commercialization rights, and intend to commercialize a product, we expect to incur significant commercialization expenses related to product sales, marketing, manufacturing and distribution. We expect to seek to fund our operations through a combination of equity offerings, debt financings, additional collaborations and licensing arrangements, and other sources for at least the next several years. However, we may be unable to raise additional funds or enter into such other arrangements when needed on favorable terms or at all. Our failure to raise capital or enter into such other arrangements as and when needed would force us to delay, limit, reduce or terminate our research and development programs and could have a material adverse effect on our financial condition and our ability to develop our products. We will need to generate significant revenues to achieve sustained profitability and we may never do so.

27

Revenue
We have not generated any revenue from the sales of approved products. All of our revenue to date has been generated through collaboration, license and research arrangements with collaborators and nonprofit organizations for the development and commercialization of product candidates, a patent assignment agreement and an asset sale. On January 1, 2018, we adopted ASC 606 using the modified retrospective approach. For detailed information regarding the adoption of ASC 606, the impact on our consolidated financial statements and its collaboration arrangements, see Note 2 and Note 12 to the consolidated financial statements appearing in our Annual Report on Form 10-K filed with the SEC on February 28, 2019.

The terms of these agreements may include one or more of the following types of payments: non-refundable license fees, payments for research and development activities, payments based upon the achievement of specified milestones, payment of license exercise or option fees relating to product candidates and royalties on any net product sales. To date, we have received non-refundable upfront payments, several milestone payments, payments for research and development services provided to our collaborators, a change in control payment pursuant to a patent assignment agreement, and a payment for the sale of an asset. However, we have not yet earned any license exercise or option fees, sales-based milestone payments or royalty revenue as a result of product sales.

In the future, we will seek to generate revenue from a combination of product sales and milestone payments and royalties on product sales in connection with our current collaborations, our asset sale with Vertex or other collaborations we may enter into.
Research and development expenses
Research and development expenses consist primarily of costs incurred for the development of our product candidates, which include:
 
•
employee-related expenses, including salary, benefits, travel and stock-based compensation expense;
•
expenses incurred under agreements with contract research organizations and investigative sites that conduct our clinical trials;
•
the cost of acquiring, developing and manufacturing clinical trial materials;
•
facilities, depreciation and other expenses, which include direct and allocated expenses for rent and maintenance of facilities, insurance and other supplies;
•
platform-related lab expenses, which includes costs related to synthesis, analysis and in vitro and in vivo characterization of deuterated compounds to support the selection and progression of potential product candidates;
•
expenses related to consultants and advisors; and
•
costs associated with nonclinical activities and regulatory operations.
Research and development costs are expensed as incurred. Costs for certain development activities are recognized based on an evaluation of the progress to completion of specific tasks using information and data provided to us by our vendors and our clinical sites.

A significant portion of our research and development costs have been external costs, which we track on a program-by-program basis. These external costs include fees paid to investigators, consultants, central laboratories and contract research organizations in connection with our clinical trials, and costs related to acquiring and manufacturing clinical trial materials. Our internal research and development costs are primarily personnel-related costs, depreciation and other indirect costs. We do not track our internal research and development expenses on a program-by-program basis, as they are deployed across multiple projects under development.

The successful development of any of our product candidates is highly uncertain. As such, at this time, we cannot reasonably predict with certainty the duration and completion costs of the current or future clinical trials of any of our product candidates or if, when, or to what extent we will generate revenues from the commercialization and sale of any of our product candidates that obtain marketing approval. We may never succeed in achieving regulatory approval for any of our product candidates. The duration, costs and timing of clinical trials and development of our product candidates will depend on a variety of factors, including:
 
•
the scope and rate of progress of our ongoing as well as any additional clinical trials and research and development activities;
•
conduct of and results from ongoing as well as any additional clinical trials and research and development activities;
•
significant and changing government regulation;

28

•
the terms and timing and receipt of any regulatory approvals;
•
the performance of our collaborators;
•
our ability to manufacture any of our product candidates that we are developing or may develop in the future; and
•
the expense and success of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights, including potential claims that we infringe other parties' intellectual property.
A change in the outcome of any of these variables with respect to the development of a product candidate could mean a significant change in the cost and timing associated with the development of that product candidate. For example, if the FDA or another regulatory authority were to require us to conduct clinical trials or other research and development activities beyond those that we currently anticipate will be required for the completion of clinical development of a product candidate, or if we experience significant delays in enrollment in any of our clinical trials, we could be required to expend significant additional financial resources and time on the completion of clinical development.

Research and development activities are central to our business model. Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, due to the increased size and duration of later-stage clinical trials and the manufacturing that is typically required for those later-stage clinical trials. We expect research and development costs to increase significantly for the foreseeable future as our product candidate development programs progress, but we do not believe that it is possible at this time to accurately project total program-specific expenses through commercialization. There are numerous factors associated with the successful commercialization of any of our product candidates, including future trial design and various regulatory requirements, many of which cannot be determined with accuracy at this time based on our stage of development. Additionally, future commercial and regulatory factors beyond our control will impact our clinical development programs and plans.
General and administrative expenses
General and administrative expenses consist primarily of salaries and related costs for personnel, including stock-based compensation for our employees in executive, operational, finance, legal, business development and human resource functions. Other general and administrative expenses include facility-related costs, depreciation and other expenses not allocated to research and development expense and professional fees for directors, accounting and legal services and expenses associated with obtaining and maintaining patents. In both 2019 and 2018, we incurred expenses for intellectual property matters related to CTP-543.
We anticipate that our general and administrative expenses will increase in the future as our pipeline grows and matures. Additionally, if and when we believe a regulatory approval of the first product candidate that we intend to commercialize on our own appears likely, we anticipate an increase in payroll and related expenses as a result of our preparation for commercial operations, especially as it relates to the sales, marketing and distribution of our product candidates.
Investment income
Investment income consists of interest income earned on cash equivalents and investments. The amount of investment income earned in any particular period may vary primarily as a result of the amount of cash equivalents and investments held during the period and the types of securities included in our portfolio during the period. Our current investment policy is to maintain a diversified investment portfolio of U.S. government-backed securities and money market mutual funds consisting of U.S. government-backed securities.
Unrealized Gains (Losses) on Marketable Equity Securities
Unrealized gains (losses) on marketable equity securities consists of changes in the fair value of common shares of Processa held by us, discussed further in Note 8 in the accompanying condensed consolidated financial statements appearing elsewhere in this Quarterly Report on Form 10-Q.
Income Taxes
We record a provision or benefit for income taxes on pre-tax income or loss based on our estimated effective tax rate for the year. As of September 30, 2019, we forecast an ordinary pre-tax loss for the year ended December 31, 2019 and, since we maintain a full valuation allowance on our deferred tax assets, we did not record an income tax benefit for the three and nine months ended September 30, 2019.

29

Critical Accounting Policies and Significant Judgments and Estimates
Our critical accounting policies are those policies which require the most significant judgments and estimates in the preparation of our condensed consolidated financial statements.

In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). ASU 2016-02 requires lessees to recognize assets and liabilities on the balance sheet for the rights and obligations created by all leases with terms of more than 12 months. On January 1, 2019, we adopted ASU 2016-02 and all related amendments. For discussion regarding the impact of this accounting pronouncement, refer to Note 11 in the accompanying condensed consolidated financial statements appearing elsewhere in this Quarterly Report on Form 10-Q.

With the exception of the adoption of ASU 2016-02, there were no material changes to our critical accounting policies as detailed in our Annual Report on Form 10-K for the fiscal year ended December 31, 2018, which was filed with the SEC on February 28, 2019.

Pending and Recently Adopted Accounting Pronouncements
For detailed information regarding recently issued accounting pronouncements and the actual and expected impact on our condensed consolidated financial statements, see Note 2 in the accompanying condensed consolidated financial statements appearing elsewhere in this Quarterly Report on Form 10-Q.


RESULTS OF OPERATIONS
Discussion of the three and nine months ended September 30, 2019
The following table summarizes our results of operations for the three and nine months ended September 30, 2019.
 
Three months ended September 30,

Nine months ended September 30,
(in thousands)
2019
 
2019
Revenue:
 
 
 
License and research and development revenue
$
10

 
$
1,064

Operating expenses:
 
 
 
Research and development
13,511

 
43,797

General and administrative
4,742

 
15,329

Total operating expenses
18,253

 
59,126

Loss from operations
(18,243
)
 
(58,062
)
Investment income
724

 
2,474

Unrealized gain (loss) on equity securities
334

 
(2,091
)
Net Loss
$
(17,185
)
 
$
(57,679
)

License and Research and Development Revenue

Total revenue was $10 thousand and $1.1 million for the three and nine months ended September 30, 2019, respectively. The revenue recognized in the 2019 periods was primarily a result of the Cipla Agreement executed in the first quarter of 2019. We recognized $1.0 million in revenue associated with this arrangement for the nine months ended September 30, 2019, and no revenue for the three months ended September 30, 2019. For additional details related to the licensing arrangement with Cipla, see Note 8 in the condensed consolidated financial statements appearing elsewhere in this Quarterly Report on Form 10-Q.

On January 1, 2018, we adopted ASC 606 using the modified retrospective approach. For detailed information regarding the adoption of ASC 606, the impact on our consolidated financial statements and our collaboration arrangements, see Note 2 and Note 12 to the consolidated financial statements appearing in our Annual Report on Form 10-K filed with the SEC on February 28, 2019.

30

Research and development expenses
The following table summarizes our external research and development expenses, by program, for the three and nine months ended September 30, 2019, with our internal research expenses separately classified by category.

 
 
Three Months Ended September 30,

Nine Months Ended September 30,
(in thousands)
 
2019
 
2019
CTP-543 external costs
 
$
4,246

 
$
13,197

CTP-692 external costs
 
2,469

 
9,258

External costs for other programs
 
674

 
2,661

Employee and contractor-related expenses
 
4,766

 
14,527

Facility and other expenses
 
1,356

 
4,154

Total research and development expenses
 
$
13,511

 
$
43,797

Research and development expenses were $13.5 million and $43.8 million for the three and nine months ended September 30, 2019, respectively. CTP-543 expenses primarily relate to clinical development including multiple Phase 2 clinical trials. CTP-692 expenses were attributable to the Phase 1 clinical trials completed in 2019 as well as manufacturing costs to support the continued advancement of the CTP-692 program. Employee-related expenses consisted primarily of cash and non-cash stock-based compensation expenses for the three and nine months ended September 30, 2019. Facility-related expenses consisted primarily of rent and maintenance of our premises. External costs for other programs consisted of a $0.5 million payment to the non-profit organization Fast Forward in the first quarter of 2019 related to an existing CTP-354 agreement, which was triggered by the upfront payment from the Cipla Agreement, and costs incurred to develop our research pipeline.
General and administrative expenses
The following table summarizes our general and administrative expenses for the three and nine months ended September 30, 2019.

 
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
(in thousands)
 
2019
 
2019
Employee salaries and benefits
 
$
2,431

 
$
8,178

External professional service and legal expenses
 
1,273

 
4,081

Facility, technology and other expenses
 
964

 
2,840

Depreciation and amortization
 
74

 
230

Total general and administrative expenses
 
$
4,742

 
$
15,329

Investment income

Investment income was $0.7 million and $2.5 million for the three and nine months ended September 30, 2019, respectively, and consists of interest income earned on cash equivalents and investments.
Unrealized gain (loss) on equity securities
We recorded an unrealized gain on marketable equity securities of $0.3 million during the three months ended September 30, 2019 and an unrealized loss on marketable equity securities of $2.1 million during the nine months ended September 30, 2019. The unrealized gains and losses on marketable equity securities consist of changes in the fair value of common shares of Processa held by us, discussed further in Note 8 of the condensed consolidated financial statements appearing elsewhere in this Quarterly Report on Form 10-Q.
Provision for Income Taxes

There was no income tax expense for the three and nine months ended September 30, 2019.

31

Discussion of the three and nine months ended September 30, 2018
The following table summarizes our results of operations for the three and nine months ended September 30, 2018.
 
Three months ended September 30,
 
Nine months ended September 30,
(in thousands)
2018
 
2018
Revenue:
 
 
 
License and research and development revenue
$
11

 
$
10,492

Operating expenses:
 
 
 
Research and development
11,031

 
28,549

General and administrative
6,320

 
17,464

Total operating expenses
17,351

 
46,013

Loss from operations
(17,340
)
 
(35,521
)
Investment income
703

 
2,003

Unrealized loss on equity securities
(732
)
 
(1,359
)
Loss before tax provision
(17,369
)
 
(34,877
)
Provision for income taxes
18

 
298

Net Loss
$
(17,387
)
 
$
(35,175
)

License and Research and Development Revenue

Total revenue was $11 thousand and $10.5 million for the three and nine months ended September 30, 2018, respectively. The revenue recognized in the 2018 periods was primarily attributable to the licensing arrangement executed with Processa, discussed further in Note 8 in the condensed consolidated financial statements appearing elsewhere in this Quarterly Report on Form 10-Q.
Research and development expenses
The following table summarizes our external research and development expenses, by program, for the three and nine months ended September 30, 2018, with our internal research expenses separately classified by category.
 
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
(in thousands)
 
2018
 
2018
CTP-543 external costs
 
$
1,872

 
$
6,059

CTP-692 external costs
 
2,314

 
3,264

External costs for other programs
 
784

 
1,933

Employee and contractor-related expenses
 
4,554

 
13,198

Facility and other expenses
 
1,507

 
4,095

Total research and development expenses
 
$
11,031

 
$
28,549

Research and development expenses were $11.0 million and $28.5 million for the three and nine months ended September 30, 2018, respectively. CTP-543 expenses primarily related to Phase 2 clinical trial costs. CTP-692 expenses were attributable to preclinical studies and the manufacture of clinical drug product to support the advancement of the program into Phase 1 clinical trials. Employee-related expenses consisted primarily of cash and non-cash stock-based compensation expenses for the three and nine months ended September 30, 2018. Facility-related expenses consisted primarily of rent and maintenance of our premises. External costs for other programs consisted of costs incurred to develop our research pipeline.
General and administrative expenses
The following table summarizes our general and administrative expenses for the three and nine months ended September 30, 2018.


32

 
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
(in thousands)
 
2018
 
2018
Employee salaries and benefits
 
$
2,970

 
$
9,516

External professional service and legal expenses
 
2,070

 
4,555

Facility, technology and other expenses
 
1,156

 
3,231

Depreciation and amortization
 
124

 
162

Total general and administrative expenses
 
$
6,320

 
$
17,464

Investment income

Investment income was $0.7 million and $2.0 million for the three and nine months ended September 30, 2018, respectively, and consists of interest income earned on cash equivalents and investments.
Unrealized loss on equity securities
Unrealized loss on marketable equity securities was $0.7 million and $1.4 million for the three and nine month ended September 30, 2018, respectively, and consists of changes in the fair value of common shares of Processa held by us, discussed further in Note 8 of the condensed consolidated financial statements appearing elsewhere in this Quarterly Report on Form 10-Q.
Provision for Income Taxes

Income tax expense for the three and nine months ended September 30, 2018 was $18 thousand and $0.3 million, respectively. We recorded a provision for income taxes of $0.3 million for interest owed to Federal and State tax authorities due to the deferral of $16 million in income from Vertex for cash held in escrow in 2018, as discussed further in Note 8 in the accompanying condensed consolidated financial statements appearing elsewhere in this Quarterly Report on Form 10-Q.

OFF-BALANCE SHEET ARRANGEMENTS
We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined in the rules and regulations of the SEC.


33

LIQUIDITY AND CAPITAL RESOURCES
We have incurred cumulative losses and negative cash flows from operations since our inception in April 2006, and as of September 30, 2019, we had an accumulated deficit of $174.2 million. We generated net income for fiscal year 2015 due to a one-time payment from Auspex Pharmaceuticals, Inc., or Auspex, under a change of control provision described in the patent assignment agreement and again for fiscal year 2017 from the closing of our sale of CTP-656 to Vertex, but we anticipate that we will continue to incur losses for at least the next several years. We expect that our research and development and general and administrative expenses will continue to increase and, as a result, we will need additional capital to fund our operations, which we may raise through a combination of equity offerings, debt financings, additional collaborations and licensing arrangements, and other sources.
We have financed our operations to date primarily through the public offering and private placement of our equity, debt financing and funding from collaborations, patent assignments and an asset sale. In February 2014, we completed our initial public offering whereby we sold 6,649,690 shares of common stock at a price to the public of $14.00 per share, raising aggregate net proceeds of $83.1 million. In March 2015, we sold 3,300,000 shares of common stock through an underwritten public offering at a price to the public of $15.15 per share, raising aggregate net proceeds of $46.7 million.
In June 2015, we received proceeds of $50.2 million in connection with the change in control payment from Auspex, relating to Teva Pharmaceutical Industries Ltd.’s acquisition of Auspex.
In July 2017, the asset purchase contemplated by the Vertex Agreement was completed, and Vertex paid us $160 million in cash consideration.
As of September 30, 2019, we had cash and cash equivalents and investments of $121.5 million. Cash in excess of immediate requirements is invested in accordance with our investment policy, primarily with a view to liquidity and capital preservation. Currently, our funds are held in U.S. government-backed securities and money market mutual funds consisting of U.S. government-backed securities.
Cash flows
The following table sets forth the primary sources and uses of cash for each of the periods set forth below:
 
Nine months ended September 30,
(in thousands)
2019
 
2018
Net cash provided by (used in):
 
 
 
Operating activities
$
(33,685
)
 
$
(32,415
)
Investing activities
47,860

 
44,619

Financing activities
1,439

 
(272
)
Net increase in cash and cash equivalents and restricted cash
$
15,614

 
$
11,932

Operating activities. The cash used for operating activities generally approximates our net loss adjusted for non-cash items and changes in operating assets and liabilities. During the nine months ended September 30, 2019, we received a $16 million payment from Vertex for an indemnification payment previously held in escrow, discussed further in Note 8 of the condensed consolidated financial statements appearing elsewhere in this Quarterly Report on Form 10-Q.
During the nine months ended September 30, 2019, our operating activities used cash of $33.7 million as compared to cash used by operating activities of $32.4 million during the prior year period. Cash used in operating activities during both 2019 and 2018 was primarily driven by our development activities associated with CTP-543 and CTP-692, our wholly owned development programs.
Investing activities. Net cash provided by investing activities consisted of proceeds from the maturity of investments, purchases of investments and purchases of fixed assets. Net cash provided by maturities of investments for the nine months ended September 30, 2019 and 2018 was $141.7 million and $93.1 million, respectively. Net cash used in purchases of investments for the nine months ended September 30, 2019 and 2018 was $93.3 million and $46.1 million, respectively.  Purchases of fixed assets for the nine months ended September 30, 2019 and 2018 was $0.5 million and $2.4 million, respectively. The decrease in the purchases of fixed assets during the 2019 period is primarily due to new office and laboratory equipment purchased in the

34

2018 period to support our new office and laboratory space, discussed further in Note 11 of the condensed consolidated financial statements appearing elsewhere in this Quarterly Report on Form 10-Q.

Financing activities. During the nine months ended September 30, 2019 and 2018, our financing activities provided cash of $1.4 million and used cash of $0.3 million, respectively. The cash provided by financing activities during the nine months ended September 30, 2019 was primarily attributable to the proceeds from exercises of warrants and stock options during the period. For the nine months ended September 30, 2019, net proceeds from the ATM Agreement were $0.4 million, with $49.6 million in aggregate offering price remaining available for issuance. The cash used in financing activities during the nine months ended September 30, 2018 was primarily attributable to withholding taxes paid in lieu of shares surrendered upon the vesting of restricted stock units.

Operating capital requirements

We do not anticipate commercializing any of our product candidates for several years. Although we generated net income in 2017 and 2015 due to one-time payments from Vertex and Auspex, respectively, we anticipate that we will continue to generate losses for the foreseeable future, and we expect the losses to increase as we continue the development of, and seek regulatory approvals for, our product candidates, and begin to commercialize any approved products for which we retain commercialization rights. We are subject to all of the risks incident in the development of new drug products, and we may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect our business, as well as additional risks stemming from the unproven nature of deuterated drugs.

Based on our current expectations, including with respect to our development plans, we believe our existing cash and cash equivalents and investments as of September 30, 2019 will enable us to fund our operating expenses and capital expenditure requirements through 2020. However, we will require additional capital for the further development of our existing product candidates and may also need to raise additional funds sooner to pursue other development activities related to additional product candidates.

To date, we have not generated any revenue from product sales. We do not expect to generate significant revenue from product sales unless and until we, or our collaborators, obtain marketing approval of and commercialize one of our current or future product candidates. Because our product candidates are in various stages of development and the outcome of these efforts is uncertain, we cannot estimate the actual amounts necessary to successfully complete development and commercialization of our product candidates or whether or when we will achieve profitability. We anticipate that we will continue to generate losses for the foreseeable future, and we expect the losses to increase as we continue the development of, and seek marketing approvals for, our product candidates, and begin to commercialize any approved products for which we retain commercialization rights.

Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through a combination of equity offerings, debt financings and additional collaborations, strategic alliances and licensing arrangements, and other arrangements. Except for any obligations of our collaborators to reimburse us for research and development expenses or to make milestone payments under our agreements with them, we do not have any additional committed external sources of funds. Additional capital may not be available on reasonable terms, if at all. If we are unable to raise additional funds when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves. If we raise additional funds through the issuance of additional debt or equity securities, it could result in dilution to our existing stockholders, increased fixed payment obligations and the issuance of securities with rights senior to those of our common stock. We may become subject to covenants under any future indebtedness that could limit our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends, which could adversely impact our ability to conduct our business.

Our expectation with respect to the period of time through which our financial resources will be adequate to support our operations is a forward-looking statement and involves risks and uncertainties, and actual results could vary as a result of a number of factors, including those discussed in the “Risk Factors” section of this Quarterly Report on Form 10-Q. We have based this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently expect. If we cannot expand our operations or otherwise capitalize on our business opportunities because we lack sufficient capital, our business, financial condition and results of operations could be materially adversely affected.

35

Contractual obligations
As of September 30, 2019, our contractual obligations remain consistent with those disclosed in our Annual Report on Form 10-K for the year ended December 31, 2018.

36

Item 3.
Quantitative and Qualitative Disclosures About Market Risk.

We are exposed to market risk related to changes in interest rates.  Our current investment policy is to maintain a diversified investment portfolio in U.S. government-backed securities and money market mutual funds consisting of U.S. government-backed securities. Our cash is deposited in and invested through highly rated financial institutions in North America. As of September 30, 2019 and December 31, 2018, we had $121.5 million and $153.3 million of cash, cash equivalents and investments, respectively. The fair value of cash equivalents and short-term investments is subject to change as a result of potential changes in market interest rates. Due to the short-term maturities of our cash equivalents and the low risk profile of these investments, an immediate 100 basis point change in interest rates at levels as of September 30, 2019 would not have a material effect on the fair market value of our cash equivalents and short term investments.

We contract with suppliers of raw materials and contract manufacturers internationally. Transactions with these providers are predominantly settled in U.S. dollars and, therefore, we believe that we have only minimal exposure to foreign currency exchange risks. We do not hedge against foreign currency risks.

Inflation generally affects us by increasing our cost of labor and clinical trial costs. We do not believe that inflation had a material effect on our business, financial condition or results of operations during the nine months ended September 30, 2019.

37

Item 4.
Controls and Procedures.

Evaluation of Disclosure Controls and Procedures
The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act, refers to controls and procedures that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. Our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and our management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Our disclosure controls and procedures are designed to provide reasonable assurance of achieving their control objectives.
Our management, with the participation of our Principal Executive Officer and Principal Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures as of September 30, 2019, the end of the period covered by this Quarterly Report on Form 10-Q. Based upon such evaluation, our Principal Executive Officer and Principal Financial Officer have concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of such date.
Changes in Internal Control over Financial Reporting
There were no changes in our internal control over financial reporting that occurred during the period covered by this Quarterly Report on Form 10-Q that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

38

PART II. OTHER INFORMATION
 
Item 1A.
Risk Factors.
Our business is subject to numerous risks. The following important factors, among others, could cause our actual results to differ materially from those expressed in forward-looking statements made by us or on our behalf in this Quarterly Report on Form 10-Q and other filings with the SEC, press releases, communications with investors and oral statements. Actual future results may differ materially from those anticipated in our forward-looking statements. We undertake no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

RISKS RELATED TO OUR FINANCIAL POSITION AND NEED FOR ADDITIONAL CAPITAL

We have incurred significant losses since inception, expect to incur losses for at least the next several years and may never sustain profitability.
As of September 30, 2019, we had an accumulated deficit of $174.2 million. We have not generated any revenues from product sales and have financed our operations to date primarily through the public offering of our common stock, private placements of our preferred stock, debt financings and funding from collaborations or other agreements. We have not completed development of any product candidate and have devoted substantially all of our financial resources and efforts to research and development, including nonclinical studies and our clinical development programs. We expect to continue to incur significant expenses and increasing operating losses for at least the next several years. Our net losses may fluctuate significantly from quarter to quarter and year to year. Net losses and negative cash flows have had, and will continue to have, an adverse effect on our stockholders’ equity and working capital.
We anticipate that our expenses will increase substantially if and as we:
 
•
continue to develop and conduct nonclinical studies and clinical trials with respect to our product candidates;
•
seek to identify additional product candidates;
•
in-license or acquire additional product candidates;
•
seek marketing approvals for our product candidates that successfully complete clinical trials;
•
establish sales, marketing, distribution and other commercial infrastructure in the future to commercialize various products for which we may obtain marketing approval;
•
require the manufacture of larger quantities of product candidates for clinical development and potentially commercialization;
•
maintain, expand and protect our intellectual property portfolio;
•
hire additional personnel;
•
add equipment and physical infrastructure to support our research and development; and
•
continue to implement the infrastructure necessary to support our product development and help us comply with our obligations as a public company.

Our ability to become and remain profitable depends on our ability to generate revenue. We do not expect to generate significant revenue unless and until we are, or one of our collaborators is, able to successfully commercialize one or more of our product candidates. Doing so will require success in a range of challenging activities, including completing clinical trials of our product candidates, obtaining marketing approval for these product candidates, manufacturing, marketing and selling those products for which we, or our collaborators, may obtain marketing approval, satisfying any post-marketing requirements and obtaining reimbursement for our products from private insurance or government payors. We, and our collaborators, may never succeed in these activities and, even if we do, or one of our collaborators does, we may never generate revenues that are large enough for us to achieve profitability. Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would decrease the value of our Company and could impair our ability to raise capital, expand our business, maintain our research and development efforts, diversify our pipeline of product candidates or continue our operations. A decline in the value of our Company could cause our stockholders to lose all or part of their investments in us.
We have a limited operating history and no history of commercializing pharmaceutical products, which may make it difficult to evaluate the prospects for our future viability.
We began operations in April 2006. Our operations to date have been limited to financing and staffing our Company, developing our technology and product candidates and establishing collaborations. We have not yet demonstrated an ability to successfully conduct an international multi-center clinical trial, conduct a large-scale pivotal clinical trial, obtain marketing

39

approvals, manufacture product on a commercial scale or arrange for a third party to do so on our behalf, or conduct sales and marketing activities necessary for successful product commercialization. Consequently, predictions about our future success or viability may not be as accurate as they could be if we had a longer operating history or a history of successfully developing and commercializing pharmaceutical products.
We will need substantial additional funding. If we are unable to raise capital when needed, we could be forced to delay, reduce or eliminate our product development programs or commercialization efforts.

Developing pharmaceutical products, including conducting nonclinical studies and clinical trials, is a very time-consuming, expensive and uncertain process that takes years to complete. We expect our expenses to increase in connection with our ongoing activities, particularly as we initiate new clinical trials of, initiate new research and nonclinical development efforts for and seek marketing approval for, our product candidates, or if we in-license or acquire product candidates. In addition, if we obtain marketing approval for any of our product candidates, we may incur significant commercialization expenses related to product sales, marketing, manufacturing and distribution to the extent that such sales, marketing and distribution are not the responsibility of one of our collaborators. In particular, the costs that we may be required to incur for the manufacture of any product candidate that receives marketing approval may be substantial. Manufacturing a drug at commercial scale may require specialized facilities, processes and materials. Furthermore, we will continue to incur costs associated with operating as a public company. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. If we are unable to raise capital when needed or on attractive terms, we may be forced to delay, reduce or eliminate our research and development programs or any future commercialization efforts.

In any event, our existing cash and cash equivalents and investments will not be sufficient to fund all of the efforts that we plan to undertake or to fund the completion of development of any of our product candidates. Accordingly, we will be required to obtain further funding through public or private equity offerings, debt financings, collaborations and licensing arrangements or other sources. Adequate additional financing may not be available to us on acceptable terms, or at all. Our failure to raise capital when needed would have a negative impact on our financial condition and our ability to pursue our business strategy.
We believe our existing cash and cash equivalents and investments as of September 30, 2019 will enable us to fund our operating expenses and capital expenditure requirements through 2020. Our estimate as to how long we expect our cash and cash equivalents and investments to be able to continue to fund our operations is based on assumptions that may prove to be wrong, and we could use our available capital resources sooner than we currently expect. Changing circumstances could cause us to consume capital significantly faster than we currently anticipate, and we may need to spend more money than currently expected because of circumstances beyond our control. Our future funding requirements, both short-term and long-term, will depend on many factors, including: 

•
the progress, timing, costs and results of clinical trials of, and research and nonclinical development efforts for, our product candidates and potential product candidates, including current and future clinical trials;
•
our current collaboration agreements and achievement of milestones under these agreements;
•
our ability to enter into and the terms and timing of any additional collaborations, licensing, product acquisition or other arrangements that we may establish;
•
the number of product candidates that we pursue and their development requirements;
•
the outcome, timing and costs of seeking regulatory approvals;
•
our headcount growth and associated costs as we expand our research and development and establish a commercial infrastructure;
•
the costs of preparing, filing and prosecuting patent applications, maintaining and protecting our intellectual property rights and defending against intellectual property related claims;
•
potential litigation costs; and
•
the costs of operating as a public company.
Raising additional capital may cause dilution to our stockholders or require us to relinquish rights to our technologies or product candidates.

Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through a combination of public or private equity offerings, debt financings, additional collaborations and licensing arrangements, and other sources. We do not have any committed external source of funds, other than potential milestone payments under the Vertex Agreement, as well as potential milestone payments and royalties under our existing license agreements, each of which is subject to the achievement of development, regulatory and/or sales-based milestones with respect to our product candidates. To the extent that we raise additional capital through the sale of common stock, convertible securities or other equity securities, the ownership interests of our stockholders may be materially diluted, and the terms of these securities could include

40

liquidation or other preferences and anti-dilution protections that could adversely affect the rights of our stockholders. In addition, debt financing, if available, would result in increased fixed payment obligations and may involve agreements that include restrictive covenants that limit our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends, that could adversely impact our ability to conduct our business.

If we raise additional funds through collaborations or marketing, distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams or product candidates, or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.

Any future indebtedness could adversely affect our ability to operate our business.

We could in the future incur indebtedness containing financial obligations and restrictive covenants, which could have significant adverse consequences, including:

•
requiring us to dedicate a portion of our cash resources to the payment of interest and principal, reducing money available to fund working capital, capital expenditures, product development and other general corporate purposes;
•
increasing our vulnerability to adverse changes in general economic, industry and market conditions;
•
subjecting us to restrictive covenants that may reduce our ability to take certain corporate actions or obtain further debt or equity financing;
•
limiting our flexibility in planning for, or reacting to, changes in our business and the industry in which we compete; and
•
placing us at a competitive disadvantage compared to our competitors that have less debt or better debt servicing options.

Any financial obligations or restrictive covenants could negatively impact our ability to conduct our business.
RISKS RELATED TO THE DISCOVERY, DEVELOPMENT AND COMMERCIALIZATION OF OUR PRODUCT CANDIDATES
Clinical drug development involves a lengthy and expensive process with an uncertain outcome.

Clinical testing is expensive, time-consuming and uncertain as to outcome. We cannot guarantee that any clinical trials will be conducted as planned or completed on schedule, if at all. The clinical development of our product candidates is susceptible to the risk of failure inherent at any stage of drug development, including failure to demonstrate efficacy in a clinical trial or across a broad or definable population of patients, the occurrence of severe or medically or commercially unacceptable adverse events, fraudulent conduct by clinical investigators, failure to comply with protocols, applicable regulatory requirements or other determinations made by the FDA or any comparable foreign regulatory authority that a drug product is not approvable. It is possible that even if one or more of our product candidates has a beneficial effect, that effect will not be detected during clinical evaluation as a result of one or more of a variety of factors, including the size, duration, design, measurements, conduct or analysis of our clinical trials. Conversely, as a result of the same factors, our clinical trials may indicate an apparent positive effect of a product candidate that is greater than the actual positive effect, if any. Similarly, in our clinical trials, we may fail to detect toxicity of or intolerability caused by our product candidates, or mistakenly believe that our product candidates are toxic or not well tolerated when that is not in fact the case.

While we believe that our DCE Platform may enable drug discovery and clinical development that is more efficient and less expensive than conventional small molecule drug research and development, we may not be able to realize the advantages that we expect. In addition, while a key element of our drug discovery and development strategy involves utilizing existing information regarding non-deuterated compounds to assist the discovery and development of deuterated analogs of those compounds, not all of the product candidates that we develop are based on drugs or drug candidates that progressed into advanced clinical development. Particularly in these situations, existing information regarding the corresponding non-deuterated compound may not be sufficient to mitigate drug development risks.

In addition to the risk of failure inherent in drug development, certain of the deuterated compounds that we, and our collaborators, are developing and may develop in the future may be particularly susceptible to failure to the extent they are based on compounds that others have previously studied or tested, but did not progress in development due to safety,

41

tolerability or efficacy concerns or otherwise. Deuteration of these compounds may not be sufficient to overcome the problems experienced with the corresponding non-deuterated compound.
We may not be able to continue further clinical development of our wholly owned development programs, including CTP-543 and CTP-692. If we are unable to develop, obtain marketing approval for or commercialize our wholly owned development programs, ourselves or through a collaboration, or experience significant delays in doing so, our business could be materially harmed.
We currently have no products approved for sale. The success of our wholly owned development programs will depend on several factors, including: 

•
in the case of CTP-543, our ability to treat moderate-to-severe alopecia areata with acceptable safety and efficacy;
•
in the case of CTP-692, our ability to treat schizophrenia, in patients concurrently receiving antipsychotic medication, with acceptable safety and efficacy;
•
successful and timely completion of clinical trials;
•
receipt of marketing approvals from applicable regulatory authorities;
•
the performance of our future collaborators, if any, for our programs;
•
the extent of any required post-marketing approval commitments to applicable regulatory authorities;
•
establishment of supply arrangements with third-party raw materials suppliers and manufacturers;
•
our ability to manufacture or arrange for the manufacture of our active pharmaceutical ingredients and drug products
with sufficient quality, quantity and reproducibility to support clinical trials and potential future commercialization;
•
establishment of arrangements with third-party manufacturers to obtain finished drug products that are appropriately packaged for sale;
•
obtaining and maintaining patent, trade secret protection, regulatory exclusivity and freedom to operate, both in the United States and internationally;
•
amount of commercial sales, if and when approved;
•
a continued acceptable safety profile of our programs following any marketing approval; and
•
agreement by third-party payors to reimburse patients for the costs of treatment with our products, and the terms of such reimbursement.

If we are unable to successfully develop, receive marketing approval for, and commercialize our wholly owned development programs, or experience delays as a result of any of these factors or otherwise, our business could be materially harmed.
If clinical trials of our product candidates fail to satisfactorily demonstrate safety and efficacy to the FDA and other regulators, we, or our collaborators, may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of these product candidates.

We, or our collaborators, must complete nonclinical development and then conduct extensive clinical trials to demonstrate the safety and efficacy of our product candidates in humans in order to obtain marketing approval from regulatory authorities for the sale of our product candidates. Clinical testing is expensive, difficult to design and implement, can take many years to complete and is inherently uncertain as to outcome. Further, the outcome of nonclinical studies and early clinical trials may not be predictive of the success of later clinical trials, and interim results of a clinical trial do not necessarily predict final results. Moreover, nonclinical and clinical data are often susceptible to varying interpretations and analyses. Many companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in late-stage clinical trials after achieving positive results in earlier development, and we cannot be certain that we will not face similar setbacks.

Any inability to successfully complete nonclinical and clinical development could result in additional costs to us, or our collaborators, and impair our ability to generate revenues from product sales, regulatory and commercialization milestones and royalties. In addition, if (1) we, or our collaborators, are required to conduct additional or larger clinical trials or other testing of our product candidates beyond the trials and testing that we, or they, contemplate, (2) we, or our collaborators, are unable to successfully complete clinical trials of our product candidates or other testing, (3) the results of these trials or tests are unfavorable, uncertain or are only modestly favorable, or (4) there are unacceptable safety concerns associated with our product candidates, we, or our collaborators, in addition to incurring additional costs, may:
 
•
be delayed in obtaining marketing approval for our product candidates;
•
not obtain marketing approval at all;
•
obtain approval for indications or patient populations that are not as broad as intended or desired;
•
obtain approval with labeling that includes significant use or distribution restrictions or significant safety warnings, including boxed warnings;

42

•
be subject to additional post-marketing testing or other requirements; or
•
be required to remove the product from the market after obtaining marketing approval.

For instance, AVP-786 is being developed under a collaboration with Avanir. In November 2015, Avanir announced the initiation of the Phase 3 clinical program to evaluate the safety and efficacy of AVP-786 for the treatment of agitation associated with dementia of the Alzheimer's type. The first North American Phase 3 trial completed in February 2019 and the second Phase 3 trial completed in September 2019. The second Phase 3 trial did not meet its primary or key secondary endpoints. Avanir is also conducting a global Phase 3 trial to evaluate the safety and efficacy of AVP-786 for the treatment of agitation associated with dementia of the Alzheimer's type and a Phase 2/3 trial to evaluate the safety and efficacy of AVP-786 for the treatment of negative symptoms of schizophrenia. However, based on the negative results of the second Phase 3 trial of AVP-786 for the treatment of agitation associated with dementia of the Alzheimer's type, there is no guarantee that Avanir will continue the trials that are currently ongoing or start any new trials of AVP-786.

Even if we, or our collaborators, believe that the results of clinical trials for our product candidates warrant marketing approval, the FDA or comparable foreign regulatory authorities may disagree and may not grant marketing approval of our product candidates.
If we, or our collaborators, experience any of a number of possible unforeseen events in connection with clinical trials of our product candidates, potential marketing approval or commercialization of our product candidates could be delayed or prevented.
We, or our collaborators, may experience numerous unforeseen events during, or as a result of, clinical trials that could delay or prevent marketing approval of our product candidates, including:
 
•
toxicity or serious adverse effects may be observed in our nonclinical studies causing us to delay or abandon clinical trials;
•
clinical trials of our product candidates may produce unfavorable or inconclusive results;
•
unexpectedly high placebo response rates;
•
rater variability in the assessment of clinical endpoints;
•
we, or our collaborators, may decide, or regulators may require us or them, to conduct additional clinical trials and or develop and or validate new clinical endpoints for our clinical trials, or abandon product development programs;
•
the number of patients required for clinical trials of our product candidates may be larger than we, or our collaborators, anticipate, patient enrollment in these clinical trials may be slower than we, or our collaborators, anticipate or participants may drop out of these clinical trials at a higher rate than we, or our collaborators, anticipate;
•
our third-party contractors, or those of our collaborators, including those manufacturing our product candidates or components or ingredients thereof or conducting clinical trials on our behalf or on behalf of our collaborators, may fail to comply with regulatory requirements or meet their contractual obligations to us or our collaborators in a timely manner or at all;
•
criminal or unauthorized misuse of computer systems may result in disruption to our, or our partners' or vendors', clinical trials, nonclinical activities or manufacturing, or may compromise data from our, or our partners' or vendors', clinical or nonclinical studies;
•
regulators or institutional review boards may not authorize us, our collaborators or our or their investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site;
•
we, or our collaborators, may have delays in reaching or fail to reach agreement on acceptable clinical trial contracts or clinical trial protocols with prospective trial sites;
•
patients that enroll in a clinical trial may misrepresent their eligibility to do so or may otherwise not comply with the clinical trial protocol, resulting in the need to drop the patients or the sites from the clinical trial, increase the needed enrollment size for the clinical trial, extend the clinical trial’s duration or cause spurious results;
•
investigators may provide inaccurate or false data, resulting in spurious clinical results, an inadequate data set or regulators’ unwillingness to approve a product;
•
regulators, institutional review boards or data monitoring committees may require that we, or our collaborators, or our or their investigators suspend or terminate clinical research for various reasons, including noncompliance with regulatory requirements or their standards of conduct, a finding that the participants are being exposed to unacceptable health risks, undesirable side effects or other unexpected characteristics of the product candidate or findings of undesirable effects caused by a chemically or mechanistically similar drug or drug candidate;
•
the FDA or comparable foreign regulatory authorities may disagree with our, or our collaborators’, clinical trial design or our or their interpretation of data from nonclinical studies and clinical trials;
•
the FDA or comparable foreign regulatory authorities may change their requirements for approvability for a given product or for an indication after we have initiated work based on their previous guidance;

43

•
the supply or quality of raw materials or manufactured product candidates or other materials necessary to conduct clinical trials of our product candidates may be insufficient, inadequate or not available at an acceptable cost, or we may experience interruptions in supply;
•
we, or our manufacturing vendors, may not produce, or may not consistently produce material, that meets necessary specifications for commercialization;
•
the FDA or comparable foreign regulatory authorities may determine that our, or our manufacturing vendors, manufacturing or quality control processes fail to meet their specifications or guidelines; and
•
the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient to obtain marketing approval.

Product development costs for us, or our collaborators, will increase if we, or they, experience delays in testing or pursuing marketing approvals and we, or they, may be required to obtain additional funds to complete clinical trials and prepare for possible commercialization of our product candidates. We, and our collaborators, do not know whether any nonclinical tests or clinical trials will begin as planned, will need to be restructured or will be completed on schedule, or at all. Significant nonclinical or clinical trial delays also could shorten any periods during which we, or our collaborators, may have the exclusive right to commercialize our product candidates or allow our competitors, or the competitors of our collaborators, to bring products to market before we, or our collaborators, do and impair our ability, or the ability of our collaborators, to successfully commercialize our product candidates and may harm our business and results of operations. In addition, many of the factors that cause, or lead to, clinical trial delays may ultimately lead to the denial of marketing approval of any of our product candidates.
If we, or our collaborators, experience delays or difficulties in the enrollment of patients in clinical trials, our, or their, receipt of necessary regulatory approvals could be delayed or prevented.

We, or our collaborators, may not be able to initiate or continue clinical trials for any of our product candidates if we, or they, are unable to locate and enroll a sufficient number of eligible patients to participate in clinical trials as required by the FDA or comparable foreign regulatory authorities, such as the European Medicines Agency. Patient enrollment is a significant factor in the timing of clinical trials, and is affected by many factors, including:
 
•
the size and nature of the patient population;
•
the severity of the disease under investigation;
•
the availability or interest of clinical sites to enroll patients into our trials;
•
the proximity of patients to clinical sites;
•
the eligibility criteria for the trial;
•
the design of the clinical trial, including any requirement to halt current therapy in connection with the trial;
•
the potential need to discontinue investigational treatment at the completion of the study;
•
the availability of other effective treatments for the indication we are assessing;
•
access to relevant clinical trial sites;
•
efforts to facilitate timely enrollment;
•
competing clinical trials;
•
support by relevant industry or patient organizations with influence over clinical trial sites; and
•
clinicians’ and patients’ perceptions as to the potential advantages and risks of the drug being studied in relation to other available therapies, including any new drugs that may be approved or used for the indications we are investigating.

Our inability, or the inability of our collaborators, to enroll a sufficient number of patients for our, or their, clinical trials could result in significant delays or may require us or them to abandon one or more clinical trials altogether. Enrollment delays in our, or their, clinical trials may result in increased development costs for our product candidates, delay or halt the development of and approval processes for our product candidates and jeopardize our, or our collaborators’, ability to commence sales of and generate revenues from our product candidates, which could cause the value of our Company to decline and limit our ability to obtain additional financing, if needed.
Fast Track designation by the FDA may not lead to a faster development, regulatory review or approval.

Although CTP-543 has been granted Fast Track designation by the FDA for the treatment of alopecia areata, Fast Track designation does not necessarily lead to a faster development pathway or regulatory review process, and does not increase the likelihood of regulatory approval. The FDA may later withdraw the designation if it believes the designation is no longer supported by the data from our clinical development program.

44

Serious adverse events, undesirable side effects or other unexpected properties of our product candidates, including those that we have licensed to collaborators, may be identified during development that could delay or prevent the product candidate’s marketing approval.

All of our product candidates are in nonclinical and clinical development stages and their risk of failure is high. Serious adverse events or undesirable side effects caused by our product candidates, or competitor products with similar mechanisms of action, could cause us, one of our collaborators, an institutional review board, data monitoring committee or regulatory authorities to interrupt, amend, delay or halt clinical trials of one or more of our product candidates and could result in a more restrictive label or the delay or denial of marketing approval by the FDA or comparable foreign regulatory authorities. A dose of a deuterated compound could, in comparison to an equal dose of the corresponding non-deuterated compound, result in altered exposure levels, distribution and half-life in the body and alter the levels of particular metabolites that are present in the body. These changes may cause serious adverse events or undesirable side effects that we, or our collaborators, did not anticipate, whether based on the characteristics of the corresponding non-deuterated compound or otherwise. If any of our product candidates is associated with serious adverse events or undesirable side effects or have properties that are unexpected, we, or our collaborators, may need to abandon development or limit development of that product candidate to certain uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective. Many compounds that initially showed promise in clinical or earlier stage testing have later been found to cause undesirable or unexpected side effects that prevented further development of the compound. In addition, unexpected adverse clinical effects of a deuterated product candidate, including either those identified by us or deuterated analogs of approved drugs being developed by any third-parties, may create general concerns regarding deuteration technology that could delay the development of our product candidates.

The increasing use of social media platforms presents risks and challenges.

The increasing use of social media platforms presents risks and challenges. Social media increasingly is being used by third-parties to communicate about our product candidates and the diseases they are designed to treat. We believe that members of the alopecia areata community may be more active on social media as compared to other patient populations due to the demographics of this patient population. Social media practices in the pharmaceutical and biotechnology industries are evolving, which creates uncertainty and risk of noncompliance with regulations applicable to our business. For example, patients in clinical trials may use social media platforms to comment on the effectiveness of, or adverse experiences with, a product candidate, which could result in reporting obligations. In addition, there is a risk of inappropriate disclosure of sensitive information or negative or inaccurate posts or comments about us on any social networking website. If any of these events were to occur or we otherwise fail to comply with applicable regulations, we could incur liability, face restrictive regulatory actions or incur other harm to our business.

High placebo rates are common in neuropsychiatric clinical trials.

Placebo responses are common in clinical trials of many neuropsychiatric agents, and the rate of such responses has generally been increasing for decades in the United States and Europe. High placebo response rates can cause even effective agents to fail to achieve statistical significance on key endpoints, resulting in failed clinical trials. Even if our compounds demonstrate efficacy in Phase 2 studies, higher than expected placebo response rates may result in their failure in pivotal studies and our inability to obtain regulatory approval.

Even if one of our product candidates receives marketing approval, it may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success and the market opportunity for the product candidate may be smaller than we estimate.

Even if one of our product candidates, including those licensed to our collaborators, is approved by the appropriate regulatory authorities for marketing and sale, it may nonetheless fail to gain sufficient market acceptance by physicians, patients, third-party payors, formulary decision-makers and others in the medical or patient communities. For example, physicians are often reluctant to switch their patients from existing therapies even when new and potentially more effective or convenient treatments enter the market. Further, patients often acclimate to the therapy that they are currently taking and do not want to switch unless their physicians recommend switching products or they are required to switch therapies due to lack of reimbursement for existing therapies. If any of our product candidates receive negative publicity, patients may choose not to request them even if approved, or may not comply with taking them as prescribed.

Efforts to educate the medical community, formulary decision-makers and third-party payors on the benefits of our product candidates may require significant resources and may not be successful. If any of our product candidates is approved but does not achieve an adequate level of market acceptance, we may not generate significant revenues and we may not become

45

profitable. The degree of market acceptance of our product candidates, including those licensed to our collaborators, if approved for commercial sale, will depend on a number of factors, including:
 
•
the efficacy and safety of the product;
•
the potential advantages of the product compared to alternative treatments;
•
the prevalence and severity of any side effects;
•
the clinical indications for which the product is approved;
•
whether the product is designated under physician treatment guidelines as a first-line therapy or as a second- or third-line therapy;
•
limitations or warnings, including distribution or use restrictions or burdensome prescription requirements contained in the product’s approved labeling;
•
our ability, or the ability of our collaborators, to offer the product for sale at commercially acceptable prices;
•
the product’s convenience and ease of administration compared to alternative treatments;
•
the willingness of the target patient population to try, and of physicians to prescribe, the product;
•
the strength of sales, marketing and distribution support;
•
the approval of other new products for the same indications;
•
the extent and success of counter-detailing efforts by our competitors;
•
the pricing, extent of discounts or bundled products offered by our competitors;
•
the organization stability of our collaborators, if any;
•
changes in the standard of care for the targeted indications for the product;
•
the timing of market introduction of our approved products as well as competitive products; and
•
the availability and amount of reimbursement from government payors, managed care plans and other third-party payors.

The potential market opportunities for our product candidates are difficult to precisely estimate. Our estimates of the potential market opportunities are predicated on many assumptions, including industry knowledge and publications, third-party research reports and other surveys. While we believe that our internal assumptions are reasonable, these assumptions involve the exercise of significant judgment on the part of our management, are inherently uncertain and the reasonableness of these assumptions has not been assessed by an independent source. If any of the assumptions proves to be inaccurate, the actual markets for our product candidates could be smaller than our estimates of the potential market opportunities.
If any of our product candidates receives marketing approval and we, or others, later discover that the drug is less pure, homogeneous or stable than believed, less effective than previously believed, or causes undesirable side effects that were not previously identified or at a higher rate than was projected during clinical development, our ability to market the drug, or that of our collaborators, could be compromised.

Clinical trials of our product candidates are conducted in carefully defined subsets of patients who have agreed to enter into clinical trials. Consequently, it is possible that these individuals are not representative of the actual patient population or that our clinical trials may indicate an apparent positive effect of a product candidate that is greater than the actual positive effect, if any, or alternatively fail to identify undesirable side effects. If, following approval of a product candidate, we, or others, discover that the drug is less effective than previously believed or causes undesirable side effects that were not previously identified, any of the following adverse events could occur:
 
•
regulatory authorities may withdraw their approval of the drug and/or seize the drug;
•
we, or our collaborators, may be required to recall the drug or change the way the drug is administered;
•
additional restrictions may be imposed on the marketing of, or the manufacturing processes for, the particular drug, including the addition of labeling statements, such as a “black box” warning or a contraindication;
•
we may be subject to fines, injunctions or the imposition of civil or criminal penalties;
•
we, or our collaborators, may be required to operate under a Risk Evaluation and Mitigation Strategy, or REMS;
•
we, or our collaborators, could be sued and held liable for harm caused to patients; and
•
the drug may become less competitive.
Any of these events could have a material and adverse effect on our operations and business and could adversely impact our stock price.

46

If we are unable to establish sales, marketing and distribution capabilities or enter into sales, marketing and distribution arrangements with third parties, we may not be successful in commercializing any product candidates that we develop if and when those product candidates are approved.

We do not have a sales, marketing or distribution infrastructure and as a company have no experience in the sale, marketing or distribution of pharmaceutical products. To achieve commercial success for any approved product, we must either develop a sales and marketing organization or outsource these functions to third parties. We expect to use a combination of third-party collaboration, licensing and distribution arrangements and a focused in-house commercialization capability to sell any products that receive marketing approval.

We generally plan to seek to retain full commercialization rights for the United States for products that we can commercialize with a specialized sales force and to retain co-promotion or similar rights for the United States when feasible in indications requiring a larger commercial infrastructure. The development of sales, marketing and distribution capabilities will require substantial resources, will be time-consuming and could delay any product launch. If the commercial launch of a product candidate for which we recruit a sales force and establish marketing and distribution capabilities is delayed or does not occur for any reason, we could have prematurely or unnecessarily incurred these commercialization costs. This may be costly, and our investment could be lost if we cannot retain or reposition our sales and marketing personnel. In addition, we may not be able to hire or retain a sales force in the United States that is sufficient in size or has adequate expertise in the medical markets that we plan to target. If we are unable to establish or retain a sales force and marketing and distribution capabilities, our operating results may be adversely affected. If a potential partner has development or commercialization expertise that we believe is particularly relevant to one of our products, then we may seek to collaborate with that potential partner even if we believe we could otherwise develop and commercialize the product independently.

We currently expect to collaborate with third-parties for commercialization in the United States of any products that require a large sales, marketing and product distribution infrastructure. We also expect to commercialize our product candidates outside the United States through collaboration, licensing and distribution arrangements with third parties, if at all. As a result of entering into arrangements with third parties to perform sales, marketing and distribution services, our product revenues or the profitability of these product revenues may be lower, perhaps substantially lower, than if we were to directly market and sell products in those markets. Furthermore, we may be unsuccessful in entering into the necessary arrangements with third parties or may be unable to do so on terms that are favorable to us. In addition, we may have little or no control over such third parties, and any of them may fail to devote the necessary resources and attention to sell and market our products effectively, or may actively sell a competing product at the expense of selling ours.

If we do not establish sales and marketing capabilities, either on our own or in collaboration with third parties, we will not be successful in commercializing any of our product candidates that receive marketing approval.
We face substantial competition from other pharmaceutical and biotechnology companies and our operating results may suffer if we fail to compete effectively.

The development and commercialization of new drug products is highly competitive. We expect that we, and our collaborators, will face significant competition from major pharmaceutical companies, specialty pharmaceutical companies and biotechnology companies worldwide with respect to our product candidates that we, or they, may seek to develop or commercialize in the future. Specifically, there are a number of large pharmaceutical and biotechnology companies that currently market and sell products or are pursuing the development of product candidates for the treatment of neurologic disorders, autoimmune disorders and inflammation, which are key indications for our development programs. Our competitors may succeed in developing, acquiring or licensing technologies and drug products that attain preferred reimbursement by payors or are more effective, simpler to use, have fewer or more tolerable side effects or are less costly than any product candidates that we are currently developing or that we may develop or acquire, or which are marketed more effectively, which could render our product candidates obsolete and noncompetitive.

We are developing CTP-543 as an oral agent for the treatment of moderate-to-severe alopecia areata. If CTP-543 receives marketing approval for this indication, it may face competition from a number of other product candidates that are being studied for alopecia areata. A number of companies are pursuing development of oral JAK inhibitors with a range of subtype selectivities for the treatment of alopecia areata, including Eli Lilly and Company and Pfizer Inc.

We are developing CTP-692 as an adjunctive treatment of schizophrenia. There are a number of companies pursuing development for adjunctive treatment of schizophrenia, exploring cognitive or negative symptoms of the disease, including SyneuRx International [Taiwan] Corp.


47

Avanir is developing AVP-786 for the treatment of agitation associated with Alzheimer's disease, negative symptoms of schizophrenia and other neurologic or psychiatric disorders. There are competing marketed drugs and product candidates in clinical development for each indication. For instance, Axsome Therapeutics, Inc. and Otsuka, and their partner H. Lundbeck A/S, are developing treatments for agitation in patients with Alzheimer's disease.

Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than any products that we, or our collaborators, may develop. Our competitors also may obtain FDA or other marketing approval for their products before we, or our collaborators, are able to obtain approval for ours, which could reduce our ability to utilize expedited regulatory pathways and could result in our competitors establishing a strong market position before we, or our collaborators, are able to enter the market.

Many of our existing and potential future competitors have significantly greater financial resources and expertise in research and development, manufacturing, nonclinical testing, conducting clinical trials, obtaining marketing approvals and marketing approved products than we do. Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller or early stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs.
We also face competition in the development of deuterated compounds.

Many pharmaceutical and biotechnology companies have begun to cover deuterated analogs of their product candidates in patent applications and may develop these deuterated compounds. Some of these pharmaceutical and biotechnology companies may have significantly greater financial resources and expertise in research and development, manufacturing, nonclinical testing, conducting clinical trials, obtaining marketing approvals and marketing approved products than we do. In addition, other companies are utilizing deuterium substitution for drug development, including Alkeus Pharmaceuticals, Inc. and DeuteRx LLC. In some cases, these competitors may be interested in developing deuterated compounds that we may be interested in developing for ourselves. In addition, these competitors may enter into collaborative arrangements or business combinations that result in their ability to research and develop deuterated compounds more effectively than us. Our potential competitors also include academic institutions, government agencies and other public and private research organizations.

If our competitors in the development of deuterated compounds are able to grow their intellectual property estates and create new and successful deuterated compounds more effectively than us, our ability to identify additional compounds for nonclinical and clinical development and obtain product revenues in future periods could be compromised, which could result in significant harm to our operations and financial position.
If the FDA or comparable foreign regulatory authorities approve generic versions of any of our products that receive marketing approval, or such authorities do not grant our products appropriate periods of data exclusivity before approving generic versions of our products, the sales of our products could be adversely affected.

Once a new drug application, or NDA, is approved, the product covered thereby becomes a “reference listed drug” in the FDA’s publication, “Approved Drug Products with Therapeutic Equivalence Evaluations.” Manufacturers may seek approval of generic versions of reference listed drugs through submission of abbreviated new drug applications, or ANDAs, in the United States. In support of an ANDA, a generic manufacturer need not conduct clinical studies. Rather, the applicant generally must show that its product has the same active ingredient(s), dosage form, strength, route of administration and conditions of use or labeling as the reference listed drug and that the generic version is bioequivalent to the reference listed drug, meaning it is absorbed in the body at the same rate and to the same extent. Generic products may be significantly less costly to bring to market than the reference listed drug and companies that produce generic products are generally able to offer them at lower prices. Thus, following the introduction of a generic drug, a significant percentage of the sales of any branded product or reference listed drug is typically lost to the generic product.

The FDA may not approve an ANDA for a generic product until any applicable period of non-patent exclusivity for the reference listed drug has expired. The Federal Food, Drug, and Cosmetic Act, or FDCA, provides a period of five years of non-patent exclusivity for a new drug containing a new chemical entity. Specifically, in cases where such exclusivity has been granted, an ANDA may not be filed with the FDA until the expiration of five years unless the submission is accompanied by a Paragraph IV certification that a patent covering the reference listed drug is either invalid or will not be infringed by the generic product, in which case the applicant may submit its application four years following approval of the reference listed drug.

48

While we believe that our product candidates contain active ingredients that would be treated as new chemical entities by the FDA and, therefore, if approved, should be afforded at least five years of data exclusivity, the FDA may disagree with that conclusion and may approve generic products after a period that is less than five years. Manufacturers may seek to launch these generic products following the expiration of the applicable marketing exclusivity period, even if we still have patent protection for our product.

Competition that our products may face from generic versions of our products could materially and adversely impact our future revenue, profitability and cash flows and substantially limit our ability to obtain a return on the investments we have made in those product candidates.
To the extent we, or our collaborators, market products that are deuterated analogs of generic drugs that are approved or will be approved while we market our products in territories in which the generic drug is available, our products may compete against these generic products and the sales of our products could be adversely affected.

We anticipate that some of the products that we, or our collaborators, may develop will be deuterated analogs of approved drugs that are or will then be available on a generic basis. In addition, if we develop a product that is a deuterated analog of a non-generic approved drug, the FDA or comparable foreign regulatory authorities may also approve generic versions of the corresponding non-deuterated drug. If approved, we expect that our deuterated products will compete against these generic non-deuterated compounds if they are used in the same indications. Even if the approved indications are different for the deuterated and non-deuterated drugs, the generic non-deuterated drug may be used off-label, negatively affecting sales of our product. Efforts to educate the medical community and third-party payors on the benefits of any product that we develop as compared to the corresponding non-deuterated compound, or generic versions of it, may require significant resources and may not be successful. If physicians, rightly or wrongly, do not believe that a product that we, or our collaborators, develop offers substantial advantages over the corresponding non-deuterated compound, or generic versions of the corresponding non-deuterated compound, or that the advantages offered by our product as compared to the corresponding non-deuterated compound, or its generic versions, are not sufficient to merit the increased price over the corresponding non-deuterated compound, or its generic versions, that we, or our collaborators, would seek, physicians might not prescribe that product. In addition, third-party payors may refuse to provide reimbursement for a product that we, or our collaborators, develop when the corresponding non-deuterated compound, or generic versions of the corresponding non-deuterated compound, offer a cheaper alternative therapy in the same indication, or may otherwise encourage use of the corresponding non-deuterated compound, or generic versions of the corresponding non-deuterated compound, over our product, even if our product possesses favorable pharmaceutical properties or is labeled for a different indication.

Competition that our product candidates may face from any generic non-deuterated product on which our product candidate is based or a later-approved generic version of a branded non-deuterated product on which our product is based, could materially and adversely impact our future revenue, profitability and cash flows and substantially limit our ability to obtain a return on the investments we have made in those product candidates.
Even if we, or our collaborators, are able to commercialize any product candidate that we, or they, develop, the product may become subject to unfavorable pricing regulations, third-party payor reimbursement practices or healthcare reform initiatives that could harm our business.

The commercial success of our product candidates will depend substantially, both domestically and abroad, on the extent to which the costs of our product candidates will be paid by health maintenance, managed care, pharmacy benefit and similar healthcare management organizations, or reimbursed by government health administration authorities, private health coverage insurers and other third-party payors. Government authorities and third-party payors, such as private health insurers and health maintenance organizations, decide which medications they will cover and establish reimbursement levels. The healthcare industry is acutely focused on cost containment, both in the United States and elsewhere. Government authorities and third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications, which could affect our ability or that of our collaborators to sell our product candidates profitably. These payors may not view our products, if any, as cost-effective, and coverage and reimbursement may not be available to our customers, or those of our collaborators, or may not be sufficient to allow our products, if any, to be marketed on a competitive basis. Cost-control initiatives could cause us, or our collaborators, to decrease the price we, or they, might establish for products, which could result in lower than anticipated product revenues. If reimbursement is not available, or is available only to limited levels, we, or our collaborators, may not be able to successfully commercialize our product candidates. Even if coverage is provided, the approved reimbursement amount may not be high enough to allow us, or our collaborators, to establish or maintain pricing sufficient to realize a sufficient return on our, or their, investments.


49

There is significant uncertainty related to third-party payor coverage and reimbursement of newly approved drugs. Marketing approvals, pricing and reimbursement for new drug products vary widely from country to country. Some countries require approval of the sale price of a drug before it can be marketed. In many countries, the pricing review period begins after marketing or product licensing approval is granted. In some foreign markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. As a result, we, or our collaborators, might obtain marketing approval for a product in a particular country, but then be subject to price regulations that delay commercial launch of the product, possibly for lengthy time periods, which may negatively impact the revenues we are able to generate from the sale of the product in that country. Adverse pricing limitations may hinder our ability, or the ability of our collaborators, to recoup our, or their, investment in one or more product candidates, even if our product candidates obtain marketing approval.

Third-party payor coverage of newly approved drugs may be more limited than the indications for which the drugs are approved by the FDA or comparable foreign regulatory authorities. Moreover, eligibility for reimbursement does not imply that any drug will be paid for in all cases or at a rate that covers our costs, including research, development, manufacture, sale and distribution. Reimbursement rates may vary, by way of example, according to the use of the drug and the clinical setting in which it is used. Reimbursement rates may also be based on reimbursement levels already set for lower cost drugs or may be incorporated into existing payments for other services.

In addition, increasingly, third-party payors are requiring higher levels of evidence of the benefits and clinical outcomes of new technologies, requiring burdensome comparison studies with currently approved drugs and challenging the prices charged. We, and our collaborators, cannot be sure that coverage will be available for any product candidate that we, or they, commercialize and, if available, that the reimbursement rates will be adequate. Further, the net reimbursement for drug products may be subject to additional reductions if there are changes to laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States. An inability to promptly obtain coverage and adequate payment rates from both government-funded and private payors for any product candidates for which we, or our collaborators, obtain marketing approval could have a material adverse effect on our operating results, our ability to raise capital needed to commercialize products and our overall financial condition.
We may not be successful in our efforts to identify or discover additional potential product candidates.

A significant portion of our research involves the development of new deuterated compounds using our DCE Platform. These efforts may not be successful in creating compounds that have commercial value or therapeutic utility beyond the corresponding non-deuterated compound, or at all. Our research programs may initially show promise in creating potential product candidates, yet fail to yield viable product candidates for clinical development for a number of reasons, including:
 
•
deuterated analogs of existing non-deuterated compounds or newly designed deuterated compounds may not demonstrate satisfactory efficacy or other benefits, such as convenience of dosing, increased tolerability, enhanced formation of desirable active metabolites or reduced formation of toxic metabolites;
•
potential product candidates may, on further study, be shown to have harmful side effects or other characteristics that indicate that they are unlikely to be products that will receive marketing approval and achieve market acceptance; and
•
pharmaceutical and biotechnology companies have begun to claim deuterated analogs of their compounds in patent filings, resulting in otherwise promising deuterated product candidates already being covered by patents or patent applications.

If we are unable to identify suitable additional compounds for nonclinical and clinical development, our ability to develop product candidates and obtain product revenues in future periods could be compromised, which could result in significant harm to our financial position and adversely impact our stock price.
Product liability lawsuits against us could divert our resources, cause us to incur substantial liabilities and limit commercialization of any products that we may develop.

We face an inherent risk of product liability claims as a result of the clinical testing of our product candidates despite obtaining appropriate informed consents from our clinical trial participants. We will face an even greater risk if we, or our collaborators, commercially sell any product that we may, or they may, develop. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit commercialization of our product candidates. Regardless of the merits or eventual outcome, liability claims may result in:
 
•
decreased demand for our product candidates or products that we may develop;
•
injury to our reputation and significant negative media attention;

50

•
withdrawal of clinical trial participants;
•
significant costs to defend litigation;
•
distraction to our management diverting focus from business operations and strategy;
•
initiation of investigations by regulators;
•
product recalls, withdrawals or labeling, marketing or promotional restrictions;
•
substantial monetary awards to trial participants or patients;
•
loss of revenue; and
•
the inability to commercialize any products that we may develop.

Although we maintain product liability insurance coverage, it may not fully cover potential liabilities that we may incur. The cost of any product liability litigation or other proceeding, even if resolved in our favor, could be substantial. We will need to increase our insurance coverage if and when we begin selling any product candidate that receives marketing approval. In addition, insurance coverage is becoming increasingly expensive. If we are unable to obtain or maintain sufficient insurance coverage at an acceptable cost or to otherwise protect against potential product liability claims, it could prevent or inhibit the development and commercial production and sale of our product candidates, which could adversely affect our business, financial condition, results of operations and prospects.
RISKS RELATED TO OUR DEPENDENCE ON THIRD PARTIES
We depend on collaborations with third parties for the development and commercialization of some of our product candidates and expect to continue to do so in the future. Our prospects with respect to those product candidates will depend in significant part on the success of those collaborations.

We have entered into collaborations for the development and commercialization of certain of our product candidates and expect to enter into additional collaborations in the future. We have limited control over the amount and timing of resources that our collaborators dedicate to the development or commercialization of our product candidates, and our ability to generate revenues from these arrangements will depend on our collaborators’ abilities to successfully perform the functions assigned to them in these arrangements. In addition, our collaborators have the right to abandon research or development projects and terminate applicable agreements, including funding obligations, prior to or upon the expiration of the agreed upon terms.
Collaborations involving our product candidates pose a number of risks, including:
 
•
collaborators have significant discretion in determining the efforts and resources that they will apply to these collaborations;
•
collaborators may not perform their obligations as expected;
•
collaborators may not pursue development and commercialization of our product candidates or may elect not to continue or renew development or commercialization programs, based on clinical trial results, changes in the collaborators’ strategic focus or available funding or external factors, such as an acquisition, that divert resources or create competing priorities;
•
collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing;
•
collaborators may conduct their clinical trials poorly or inadequately, harming our products, including our products' development in other territories;
•
product candidates developed in collaboration with us, including in particular product candidates based on deuteration of a collaborator’s marketed drugs or advanced clinical candidates, may be viewed by our collaborators as competitive with their own product candidates or products, which may cause collaborators to cease to devote resources to the commercialization of our product candidates;
•
a collaborator with marketing and distribution rights to one or more products may not commit sufficient resources to the marketing and distribution of such product or products;
•
disagreements with collaborators, including disagreements over proprietary rights, contract interpretation or the preferred course of development, might cause delays or termination of the research, development or commercialization of product candidates, might lead to additional responsibilities for us with respect to product candidates, or might result in litigation or arbitration, any of which would be time-consuming and expensive;
•
collaborators may steal our trade secrets or may hire valuable employees from us;
•
collaborators may fail to protect our trade secrets;
•
collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential litigation;

51

•
collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability; and
•
collaborations may be terminated and, if terminated, may result in a need for additional capital to pursue further development or commercialization of the applicable product candidates.

Collaboration agreements may not lead to development or commercialization of product candidates in the most efficient manner or at all. If a collaborator of ours is involved in a business combination, it could decide to delay, diminish or terminate the development or commercialization of any product candidate licensed to it by us.
We expect to seek to establish additional collaborations, and if we are not able to establish them on commercially reasonable terms, we may have to alter our development and commercialization plans.

Our drug development programs and the potential commercialization of our product candidates will require substantial additional cash to fund expenses. We may seek one or more collaborators for the development and commercialization of one or more of our product candidates.

We face significant competition in seeking appropriate collaborators. Whether we reach a definitive agreement for collaboration will depend, among other things, upon our assessment of the collaborator’s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator’s evaluation of a number of factors. Those factors may include the potential differentiation of our product candidate from its corresponding non-deuterated analog, design or results of clinical trials, the likelihood of approval by the FDA or comparable foreign regulatory authorities and the regulatory pathway for any such approval, the potential market for the product candidate, the proposed collaborator’s perception of our freedom to operate in a particular market or markets without challenge, the costs and complexities of manufacturing and delivering the product to patients and the potential of competing products. The collaborator may also consider alternative product candidates or technologies that may be available for collaboration and whether such collaboration could be more attractive than the one with us for our product candidate.

Collaborations are complex and time-consuming to negotiate and document. In addition, there have been a significant number of recent business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators. We are also restricted under the terms of certain of our existing collaboration agreements from entering into collaborations regarding or otherwise developing specified compounds that are similar to the compounds that are subject to those agreements and collaboration agreements that we enter into in the future may contain further restrictions on our ability to enter into potential collaborations or to otherwise develop specified compounds.

We may not be able to negotiate collaborations for our product candidates on a timely basis, on acceptable terms, or at all. If we are unable to do so, we may have to limit the development of the product candidate for which we are seeking to collaborate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to increase our expenditures to fund development or commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we may not be able to further develop our product candidates or bring them to market and generate product revenue. In cases where we seek a collaborator for a product compound that is a deuterated analog of a compound that has been previously developed, failure to enter into a collaboration with the developer of the corresponding non-deuterated compound may result in a loss of the potential to obtain clearance from the FDA to follow expedited development programs that reference and rely on findings previously obtained from the developer’s prior nonclinical or clinical studies of the corresponding non-deuterated compound.
We rely on third parties to conduct our clinical trials and some aspects of our research and nonclinical testing. If they terminate their relationships with us or do not perform satisfactorily, our business may be materially harmed.

We do not independently conduct clinical trials of any of our product candidates. We rely on third parties, such as contract research organizations, clinical data management organizations, medical institutions and clinical investigators, to conduct these clinical trials and expect to rely on these third parties to conduct clinical trials of any other product candidate that we develop. We also rely on third parties to conduct some aspects of our research and nonclinical testing and expect to rely on these third parties in the future. Any of these third parties may terminate their engagements with us under certain circumstances. If any of our relationships with these third parties terminate, we may not be able to enter into arrangements with alternative third parties on commercially reasonable terms, or at all. Switching to or adding additional third parties would involve additional cost and require management time and focus. In addition, there is a natural transition period when a new third party commences work, which could result in delays in our product development activities. Although we seek to carefully manage our relationships

52

with our contract research organizations, any such challenges or delays could have a material adverse impact on our business, financial condition and prospects.

Our reliance on these third parties for clinical development activities limits our control over these activities but we remain responsible for ensuring that each of our studies is conducted in accordance with the applicable protocol, legal, regulatory and scientific standards. For example, notwithstanding the obligations of a contract research organization for a trial of one of our product candidates, we remain responsible for ensuring that each of our clinical trials is conducted in accordance with the general investigational plan and protocols for the trial. Moreover, the FDA requires us to comply with standards, commonly referred to as current Good Clinical Practices, or GCPs, for conducting, recording and reporting the results of clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity and confidentiality of trial participants are protected. The FDA enforces these GCPs through periodic inspections of trial sponsors, principal investigators, clinical trial sites and institutional review boards. If we or our third-party contractors fail to comply with applicable GCPs, the clinical data generated in our clinical trials may be deemed unreliable and the FDA may require us to perform additional clinical trials before approving our product candidates, which would delay the marketing approval process. We cannot be certain that, upon inspection, the FDA will determine that any of our clinical trials comply with GCPs.

Furthermore, these third parties are not our employees, and except for remedies available to us under our agreements with such contractors, we cannot control whether or not they devote sufficient time, skill and resources to our ongoing development programs. These contractors may also have relationships with other commercial entities, including our competitors, which could impede their ability to devote appropriate time to our clinical programs. If these third parties do not successfully carry out their contractual duties, meet expected deadlines or conduct their services in accordance with our contracts, regulatory requirements or our stated protocols, we may not be able to obtain, or may be delayed in obtaining, marketing approvals for our product candidates. If that occurs, we will not be able to, or may be delayed in our efforts to, successfully commercialize our product candidates. In such an event, our financial results and the commercial prospects for any product candidates that we seek to develop could be harmed, our costs could increase and our ability to generate revenues could be delayed, impaired or foreclosed.

We also rely on other third parties to store, label and distribute drug supplies for our clinical trials. Any performance failure on the part of our distributors could delay clinical development or marketing approval of our product candidates or commercialization of any resulting products, producing additional losses and depriving us of potential product revenue.

We are also required to register clinical trials and post the results of completed clinical trials on a government-sponsored database, such as ClinicalTrials.gov, within certain timeframes. Failure to do so can result in the inability to report our clinical results in certain publications, fines, adverse publicity and civil and criminal sanctions.
Because there are limited sources of deuterium, we, and our collaborators, are exposed to a number of risks and uncertainties associated with our deuterium supply.

We believe that all of the deuterium that we use in manufacturing our product candidates is currently derived, directly or indirectly, from deuterium oxide. For most of our deuterium supply, we rely on bulk supplies of deuterium oxide which we currently source from multiple suppliers, including two located in North America, one of which is in the United States.

In order to internationally transport any deuterium oxide that we purchase from our current or potential future foreign suppliers, we, or our suppliers, may be required to obtain an export license from the country of origin and we may be required to obtain an International Import Certificate or other governmental approvals or assurances from the country of destination. We are also required to obtain an export license from the Nuclear Regulatory Commission before shipping deuterium oxide from the United States to any contract manufacturer in another country. Export licenses and certain other required documents may specify the maximum amount of deuterium oxide that we, or our suppliers, are permitted to either import or export. In order for us to obtain supplies of deuterium oxide from foreign suppliers, they may be required to obtain an export license from the country of origin and we may be required to obtain domestic governmental approvals or assurances. In addition, our current U.S. export licenses may be insufficient to meet our future requirements. We, or our suppliers, may not be able to obtain such licenses, approvals or assurances in a timely manner or at all.

Certain of our manufacturing processes for our product candidates incorporate deuterium by using deuterated chemical intermediates or reagents that are derived from deuterium oxide. For the deuterated chemical intermediates and reagents, we are not subject to the license requirements applicable to deuterium oxide; however, the manufacturer of the deuterated chemical intermediate or reagent may themselves be required to obtain deuterium oxide under applicable licensing requirements. Most of the manufacturers of these deuterated chemical intermediates and reagents are not located in countries that produce bulk quantities of deuterium oxide. Therefore, our ability to source these deuterated chemical intermediates will depend on the

53

ability of these manufacturers to obtain deuterium oxide from other countries. Certain countries may also limit or prohibit the export of deuterium-containing products or intermediates. In the future we may arrange for supplies of deuterated chemical intermediates or reagents from manufacturers located in countries from which they can source deuterium oxide in bulk. However, contract manufacturers in these countries may not represent a viable alternative to our current suppliers. We do not have long-term agreements with our suppliers of deuterated chemical intermediates or reagents and we obtain some of these deuterated chemical intermediates or reagents from single sources, putting us at risk of uncontrolled cost increases or supply interruptions if we cannot establish alternative sourcing arrangements. Deuterated chemical intermediates may be expensive or difficult to obtain or may be produced by specialized techniques that are not widely practiced, and we may not be able to enter into arrangements for larger scale supply of deuterated chemical intermediates on acceptable terms, or at all.

We estimate that our current sources of deuterium oxide will be sufficient to meet our anticipated requirements; however, we do not have long-term agreements with our current suppliers. If we are not able to establish or maintain supply arrangements, or any relevant foreign governments decide to withhold authorizations for the export of deuterium oxide that we seek, we may be unable to secure alternative sources. If we are unable to obtain sufficient supplies of deuterium oxide from our current suppliers or our potential future foreign supplier, we would be forced to either seek alternative suppliers of deuterium oxide, likely in other countries, or alternative sources of deuterium. Such alternative supplies may not be available to us on acceptable terms, or at all.

If we are unable to obtain sufficient supplies of deuterium, our ability to produce our product candidates would be impeded and our business, financial condition and prospects could be harmed. In particular, certain of our manufacturing processes are projected to require particularly large quantities of deuterium for late-stage clinical trials and for commercialization. Consequently, any adverse impact on our ability to obtain deuterium oxide from our current suppliers, import deuterium oxide into the United States or export deuterium oxide to our contract manufacturers could have a particularly severe impact on our ability to develop or commercialize those product candidates.

Similarly, to develop and commercialize any of our licensed product candidates, our collaborators will need to obtain supplies of deuterium and will be subject to risks and requirements in connection with sourcing deuterium that are similar to the ones that we face. In addition, if any of our product candidates is approved by the FDA, then the FDA will also have regulatory jurisdiction over the manufacture and use of deuterium oxide and deuterated chemical intermediates or reagents in such products. Any adverse impact on our, or our collaborators’, ability to obtain deuterium could delay or prevent the development or commercialization of our product candidates, which could have a material adverse effect on our business.

We contract with third parties for the manufacture and distribution of our product candidates for nonclinical and clinical testing and expect to continue to do so in connection with our future development and commercialization efforts. This reliance on third parties increases the risk that we will not have sufficient quantities of our product candidates or such quantities at an acceptable cost, or that the product candidates will not be of sufficient quality or reproducibility or produced on our desired schedule, which could delay, prevent or impair our development or commercialization efforts.

We currently rely, and expect to continue to rely, on third-party contractors to manufacture nonclinical and clinical supplies of our product candidates and to package, label and ship these supplies. We expect to rely on third-party contractors to manufacture, formulate, package, label and distribute commercial quantities of any product candidate that we commercialize following approval for marketing by applicable regulatory authorities. Reliance on such third-party contractors entails risks, including:
 
•
manufacturing delays, including if our third-party contractors give greater priority to the supply of other products over our product candidates or if they otherwise do not satisfactorily perform according to the terms of the agreements between us and them;
•
potentially incorrect data analysis, resulting in falsely-positive, falsely-negative or misleading or uninterpretable results;
•
potential industrial accidents such as fires or explosions that compromise our product candidates or the ability of the contractors to timely deliver them;
•
the possible termination or nonrenewal of agreements by our third-party contractors at a time that is costly or inconvenient for us;
•
potentially limited numbers of available contractors due to the need for uncommon equipment or expertise, or pre-existing conflicts of interest;
•
the possible breach by the third-party contractors of our agreements with them;
•
possible theft of intellectual property or trade secrets;
•
possible theft of our materials, including starting materials, intermediates, active pharmaceutical ingredients or drug products;
•
the failure of third-party contractors to comply with applicable regulatory requirements;

54

•
the possible mislabeling of clinical supplies, potentially resulting in the wrong dose amounts being supplied or active drug or placebo not being properly identified;
•
possible contamination, or nonconformance with product or packaging specifications, of our product during or after its manufacture;
•
possible interruptions in our contractors’ operations, including departure of key personnel, disruption due to merger and acquisitions activities or supply chain disruptions;
•
the possibility of clinical supplies not being delivered to clinical sites on time, leading to clinical trial interruptions, or of drug supplies not being distributed to commercial vendors in a timely manner, resulting in lost sales; and
•
the possible misappropriation of our proprietary information, including our trade secrets and know-how.

If any of our product candidates are approved by any regulatory agency, we plan to enter into agreements with third-party contract manufacturers for the commercial production and distribution of those products. It may be difficult for us to reach agreement with a contract manufacturer on satisfactory terms or in a timely manner, especially if the manufacturer believes it is uniquely suited to use our deuterium chemistry manufacturing processes or otherwise has unusual market power, or that our deuterium chemistry manufacturing processes bear greater production risks than manufacture of non-deuterated compounds. In addition, we may face competition for access to manufacturing facilities as there are a limited number of contract manufacturers operating under current good manufacturing practices, or cGMPs, that are capable of manufacturing our product candidates. Consequently, we may not be able to reach agreement with third-party manufacturers on satisfactory terms, which could delay our commercialization efforts.

Third-party manufacturers are required to comply with cGMPs and similar regulatory requirements outside the United States. Facilities used by our third-party manufacturers must be approved by the FDA after we submit an NDA and before potential approval of the product candidate. Similar regulations apply to manufacturers of our product candidates for use or sale in foreign countries. We do not directly control the manufacturing process and are completely dependent on our third-party manufacturers for compliance with the applicable regulatory requirements for the manufacture of our product candidates. If our manufacturers fail to consistently manufacture material that conforms to the strict regulatory requirements of the FDA and any applicable foreign regulatory authority, or if they unacceptably deviate from standard operating procedures in the production of our product candidates, they will not be able to secure the applicable approval for their manufacturing facilities. If these facilities are not approved for commercial manufacture, we may need to find alternative manufacturing facilities, which could result in delays in obtaining approval for the applicable product candidate.

In addition, our manufacturers are subject to ongoing periodic inspections by the FDA and corresponding state and foreign agencies for compliance with cGMPs and similar regulatory requirements both prior to and following the receipt of marketing approval for any of our product candidates. Some of these inspections may be unannounced. Failure by any of our manufacturers to comply with applicable cGMPs or other regulatory requirements could result in sanctions being imposed on us, including fines, injunctions, civil penalties, delays, suspensions or withdrawals of approvals, operating restrictions, interruptions in supply and criminal prosecutions, any of which could significantly and adversely affect supplies of our product candidates and have a material adverse impact on our business, financial condition and results of operations.

Our current and anticipated future dependence upon others for the manufacture of our product candidates may adversely affect our future profit margins and our ability to commercialize any products that receive marketing approval on a timely and competitive basis.
RISKS RELATED TO OUR INTELLECTUAL PROPERTY
If we are unable to obtain and maintain sufficient patent protection for our product candidates, or if the scope of the patent protection is not sufficiently broad, our competitors could develop and commercialize products similar or identical to ours, and our ability to successfully commercialize our product candidates may be adversely affected.
Our success depends in large part on our ability to obtain and maintain patent protection in the United States and other countries with respect to our proprietary product candidates. If we do not adequately protect our intellectual property, competitors may be able to erode or negate any competitive advantage we may have, which could harm our business and ability to achieve profitability. To protect our proprietary position, we file patent applications in the United States and abroad related to our novel product candidates that are important to our business. The patent application and approval process is expensive, uncertain and time-consuming. We may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. Neither deuterium itself, nor the general concept of selective substitution of deuterium for hydrogen in existing pharmaceutical compounds, is patentable; therefore, we usually seek patents on a compound-by-compound basis or on a relatively narrow genus of compounds. We are not guaranteed that patents will issue protecting any particular deuterated compound for which we seek patent protection. We also cannot guarantee that another company will not

55

be able to find a different pattern of deuterium substitution that is equally or more effective in improving the characteristics of a non-deuterated compound, then patenting that deuterated compound and competing with us.
Our ability to obtain and maintain patent protection for our product candidates may be limited if disclosures of non-deuterated compounds are held to anticipate or make obvious claims of deuterated analogs of the same or similar compounds in any given territory. In addition, several large pharmaceutical and biotechnology companies have begun to pursue patent protection for deuterated analogs of their products and product candidates, and may in the future obtain patent protection that covers deuterated analogs of those product candidates. If patents directed primarily to non-deuterated compounds are deemed to protect deuterated analogs of those compounds or patent claims on deuterated analogs of compounds become common in the biotechnology and pharmaceutical industries, these factors may substantially limit our ability to seek and obtain patent protection for new product candidates based on deuterium modification of compounds. It may also limit our ability to develop new product candidates based on deuterium modification of such compounds without obtaining a license from those patent holders. In certain cases, a company that owns the patent on a non-deuterated compound may be able to file a continuation or divisional patent on deuterated analogs of their compounds that successfully claims priority to the original filing date of the non-deuterated composition, causing their patent to have priority over ours, even if filed later than ours was.
The patent position of biotechnology and pharmaceutical companies generally is highly uncertain. No consistent policy regarding the breadth of claims allowed in biotechnology and pharmaceutical patents has emerged to date in the United States or in many foreign jurisdictions. In addition, the determination of patent rights with respect to pharmaceutical compounds commonly involves complex legal and factual questions, which has in recent years been the subject of much litigation. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain.
Assuming the other requirements for patentability are met, currently, the first to file a patent application is generally entitled to the patent. However, prior to March 16, 2013, in the United States, the first to invent was entitled to the patent. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. Therefore, we cannot be certain that we were the first to make the inventions claimed in our patents or pending patent applications, or that we were the first to file for patent protection of such inventions.
We may also become involved in opposition, derivation, reexamination, PGR, IPR or interference proceedings, in the United States or elsewhere, challenging our patent rights or the patent rights of others. For example, in April 2017, Incyte Corporation filed an IPR petition with the PTAB, of the U.S. Patent and Trademark Office, or PTO, challenging the validity of the '149 patent, which claims deuterium-modified versions of ruxolitinib, including CTP-543. In October 2017, the PTAB declined to institute the IPR and in November 2017, Incyte filed a request for rehearing of the PTAB's decision. In April 2018, the PTAB granted the request and instituted the IPR. In April 2019, the PTAB issued a final written decision in connection with the IPR that found that the claims of the '149 patent are not patentable. In June 2019, we filed a Notice of Appeal with the U.S. Court of Appeals for the Federal Circuit, or Federal Circuit. Adverse determinations in any such submission, proceeding or litigation such as this could reduce the scope of, or invalidate, our patent rights, allow third parties to commercialize our technology or product candidates and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing third-party patent rights.
Our pending and future patent applications may not result in patents being issued that protect our product candidates, in whole or in part, or which effectively prevent others from commercializing competitive products. Changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of our patents or narrow the scope of our patent protection. In addition, the laws of foreign countries may not protect our rights to the same extent or in the same manner as the laws of the United States. For example, European patent law restricts the patentability of methods of treatment of the human body more than U.S. law does.
Even if our patent applications issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors from competing with us or otherwise provide us with any competitive advantage. Our competitors may be able to circumvent our patents by developing similar or alternative technologies or products in a non-infringing manner. Our competitors may also seek approval to market their own products similar to or otherwise competitive with our products. Alternatively, our competitors may seek to market generic versions of any approved products by submitting ANDAs to the FDA in which they claim that patents owned or licensed by us are invalid, unenforceable or not infringed. In these circumstances, we may need to defend or assert our patents, or both, including by filing lawsuits alleging patent infringement. In any of these types of proceedings, a court or other agency with jurisdiction may find our patents invalid or unenforceable, or that our competitors are competing in a non-infringing manner. In certain territories, losses to an infringing product may not be sufficiently great to justify the costs of challenging the infringer and asserting our rights. In some situations, governments have allowed or enabled the sale of competing products that infringe a company’s intellectual property.

56

Thus, even if we have valid and nominally enforceable patents, these patents still may not provide protection against competing products or processes sufficient to achieve our business objectives.
The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our owned and licensed patents may be challenged in the courts or patent offices in the United States and abroad, including challenges through the PTO post grant review procedures. Such challenges may result in loss of exclusivity or in patent claims being narrowed, invalidated or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and products. In addition, given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized.
If we are unable to protect the confidentiality of our trade secrets, the value of our technology could be materially adversely affected and our business would be harmed.
While we have obtained composition of matter patents with respect to our most advanced product candidates, our DCE Platform is not patented. In seeking to develop and maintain a competitive position through our DCE Platform and as to other aspects of our business, we rely on trade secrets, including unpatented know-how, technology and other proprietary information. We seek to protect these trade secrets, in part, by entering into non-disclosure and confidentiality agreements with parties who have access to them, such as our consultants, independent contractors, advisors, corporate collaborators, outside scientific collaborators, contract manufacturers, suppliers and other third parties. We also enter into confidentiality and invention or patent assignment agreements with employees and certain consultants. Any party with whom we have executed such an agreement may breach that agreement and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, if any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent such third party, or those to whom they communicate such technology or information, from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor, our business and competitive position could be harmed.
Third parties may sue us alleging that we are infringing their intellectual property rights, and such litigation could be costly and time consuming and could prevent or delay us from developing or commercializing our product candidates.
Our commercial success depends, in part, on our ability to develop, manufacture, market and sell our product candidates without infringing the intellectual property and other proprietary rights of third parties. Our CTP-543 compound is based, and potential future product candidates may be based, on products that are covered by issued patents or patent applications, the holders of which may attempt to assert claims against us. To date, we are not aware of any judicial decision holding that a patent that covers a non-deuterated compound should be construed to also cover deuterated analogs thereof, absent specific claims with respect to the deuterated analogs. However, any such judicial decision, or legal proceedings asserting such claims, could increase the likelihood of potential infringement claims being asserted against us. If any third-party patents or patent applications are found to cover our product candidates or their methods of use, we may not be free to manufacture or market our product candidates as planned without obtaining a license, which may not be available on commercially reasonable terms, or at all.
For example, CTP-543 is a deuterium-modified version of ruxolitinib. Ruxolitinib is marketed in the United States by Incyte Corporation under the name Jakafi. Incyte has patents covering ruxolitinib that may be unexpired if and when we seek marketing approval for CTP-543. Incyte also has a US patent that broadly claims deuterated analogs of ruxolitinib. On June 27, 2017, we filed a PGR with the PTAB seeking to invalidate all claims of Incyte's U.S. patent, which includes claims relating to deuterated ruxolitinib analogs. In January 2018, the PTAB did not grant our petition to challenge the validity of Incyte's patent. In May 2018, our request for reconsideration was denied. In October 2017, the PTAB denied a petition by Incyte to institute an IPR of the '149 patent. The '149 patent claims deuterated analogs of ruxolitinib including CTP-543. In November 2017, Incyte filed a request for rehearing of the PTAB's decision. In April 2018, the PTAB granted the request and instituted the IPR. In April 2019, the PTAB issued a final written decision in connection with the IPR that found that the claims of the '149 patent are not patentable. In June 2019, we filed a Notice of Appeal with the Federal Circuit.
In addition, Columbia University is the assignee of patents licensed to Aclaris, claiming the use of ruxolitinib, isotopic forms of ruxolitinib and other named JAK inhibitors for the treatment of hair loss disorders, including alopecia areata, which may be unexpired if and when we seek marketing approval for CTP-543. If we have to defend ourselves in a patent infringement suit, we may incur significant expenses in doing so. Such litigation could delay our ability to market, or prevent us from marketing, CTP-543.

57

There is a substantial amount of intellectual property litigation in the biotechnology and pharmaceutical industries, and we may become party to, or threatened with, litigation or other adversarial proceedings regarding intellectual property rights with respect to our products candidates, including interference proceedings before the PTO. Third parties may assert infringement claims against us based on existing or future intellectual property rights. The outcome of intellectual property litigation is subject to uncertainties that cannot be adequately quantified in advance. The coverage of patents is subject to interpretation by the courts, and the interpretation is not always uniform. If we are sued for patent infringement, we would need to demonstrate that our product candidates, products or methods either do not infringe the relevant patent claims or that these patent claims are invalid or unenforceable, and we may not be able to do this. Proving invalidity is difficult. For example, in the United States, proving invalidity under most circumstances requires a showing of clear and convincing evidence to overcome the presumption of validity enjoyed by issued patents. We may also assert that a patent claim for a corresponding non-deuterated compound does not cover our product. Even if we are successful in these proceedings, we may incur substantial costs and the time and attention of our management and scientific personnel could be diverted in pursuing these proceedings, which could have a material adverse effect on us. In addition, we may not have sufficient resources to bring these actions to a successful conclusion.
If we are found to infringe a third party’s intellectual property rights, we could be forced, including by court order, to cease developing, manufacturing or commercializing the infringing product candidate or product and could be required to pay potentially significant damages. Alternatively, we may be required to obtain a license from such third party in order to use the infringing technology and continue developing, manufacturing or marketing the infringing product candidate. However, we may not be able to obtain any required license on commercially reasonable terms, or at all. Even if we were able to obtain a license, it could be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. In addition, we could be found liable for monetary damages, including treble damages and attorneys’ fees if we are found to have willfully infringed a patent. A finding of infringement could prevent us from commercializing our product candidates or force us to cease some of our business operations, which could materially harm our business. Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar negative impact on our business.
We may become involved in lawsuits to protect or enforce our patents or other intellectual property, which could be expensive, time consuming and unsuccessful.
Competitors may infringe our patents, trademarks, copyrights or other intellectual property. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time consuming and divert the time and attention of our management and scientific personnel. In any patent infringement proceeding, there is a risk that a court will decide that a patent of ours is invalid or unenforceable, in whole or in part, and that we do not have the right to stop the other party from using the invention at issue. There is also a risk that, even if the validity and enforceability of such patents is upheld, the court will construe the patent’s claims narrowly or decide that we do not have the right to stop the other party from using the invention at issue on the grounds that our patent claims do not cover the invention. An adverse outcome in a litigation or proceeding involving our patents could limit our ability to assert our patents against those parties or other competitors, and may curtail or preclude our ability to exclude third parties from making and selling similar or competitive products. Any of these occurrences could adversely affect our competitive business position, business prospects and financial condition.
Even if we establish infringement, the court may decide not to grant an injunction against further infringing activity and instead award only monetary damages, which may not be an adequate remedy. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during litigation. Moreover, there can be no assurance that we will have sufficient financial or other resources to file and pursue such infringement claims, which typically last for years before they are concluded. Even if we ultimately prevail in such claims, the monetary cost of such litigation and the diversion of the attention of our management and scientific personnel could outweigh any benefit we receive as a result of the proceedings.
RISKS RELATED TO REGULATORY APPROVAL AND OTHER LEGAL COMPLIANCE MATTERS
Even if we complete the necessary nonclinical studies and clinical trials the marketing approval process is expensive, time consuming and uncertain and we may not obtain approvals for the commercialization of some or all of our product candidates. As a result, we cannot predict when or if, and in which territories, we, or our collaborators, will obtain marketing approval to commercialize a product candidate.
The research, testing, manufacturing, labeling, approval, selling, marketing, promotion and distribution of drug products are subject to extensive regulation by the FDA and comparable foreign regulatory authorities, which regulations differ from

58

country to country. Failure to obtain marketing approval for a product candidate in a given territory will prevent us, and our collaborators, from commercializing the product candidate in that territory. Our product candidates are in various stages of development and are subject to the risks of failure inherent in drug development. We, and our collaborators, have not submitted an application for or received marketing approval for any of our product candidates in the United States or in any other jurisdiction. We have limited experience in filing and supporting the applications necessary to gain marketing approvals.
The process of obtaining marketing approvals, both in the United States and abroad, is lengthy, expensive and uncertain. It may take many years, if approval is obtained at all, and can vary substantially based upon a variety of factors, including the type, complexity and novelty of the product candidates involved. This is the case even though the deuterated compounds that we produce and seek to develop can have similar pharmacological properties as their corresponding non-deuterated compounds. Even if, as a result of any such similarities, we, or our collaborators, obtain clearance from the FDA and other regulatory authorities to follow expedited development programs for some deuterated compounds that reference and rely on previous findings for non-deuterated compounds, the review and approval of our product candidates may still take a substantial period of time. Conversely, in certain countries regulators may consider our deuterated compounds to be equivalent to non-deuterated compounds that possess regulatory exclusivity and therefore refuse to approve our compounds until the expiration of that exclusivity.
In addition, changes in marketing approval policies during the development period, changes in or the enactment or promulgation of additional statutes, regulations or guidance or changes in regulatory review for each submitted product application, may cause delays in the approval or rejection of an application. Regulatory authorities have substantial discretion in the approval process and may refuse to accept any application or may decide that our data are insufficient for approval and require additional nonclinical, clinical or other studies. In addition, varying interpretations of the data obtained from nonclinical and clinical testing could delay, limit or prevent marketing approval of a product candidate. Any marketing approval we, or our collaborators, ultimately obtain may be limited or subject to restrictions or post-approval commitments that render the approved product not commercially viable.
Any delay in obtaining or failure to obtain required approvals could materially adversely affect our ability, or that of our collaborators, to generate revenue from the particular product candidate, which likely would result in significant harm to our financial position and adversely impact our stock price.
Failure to obtain marketing approval in international jurisdictions would prevent our product candidates from being marketed abroad.
In order to market and sell our products in the European Union and many other jurisdictions, we, or our collaborators, must obtain separate marketing approvals and comply with numerous and varying regulatory requirements. The approval procedure varies among countries and can involve additional testing. The time required to obtain approval may differ substantially from that required to obtain FDA approval. The marketing approval process outside the United States generally includes all of the risks associated with obtaining FDA approval. In addition, in many territories outside the United States, it is required that the product be approved for reimbursement before the product can be approved for sale in that territory. Our products may not receive commercially feasible prices in any given territory, or the price offered for our products in a territory may have an adverse effect on their prices in other territories if we were to accept. We, and our collaborators, may not obtain approvals from regulatory authorities outside the United States on a timely basis, if at all. Approval by the FDA does not ensure approval by regulatory authorities in other countries or jurisdictions, and approval by one regulatory authority outside the United States does not ensure approval by regulatory authorities in other countries or jurisdictions or by the FDA.
Even if we, or our collaborators, obtain marketing approvals for our product candidates, the terms of approvals and ongoing regulation of our products may limit how we, or they, manufacture and market our products, which could materially impair our ability to generate revenue.
Once marketing approval has been granted, an approved product and its manufacturer and marketer are subject to ongoing review and extensive regulation. We, and our collaborators, must therefore comply with requirements concerning advertising and promotion for any of our product candidates for which we or they obtain marketing approval. Promotional communications with respect to prescription drugs are subject to a variety of legal and regulatory restrictions and must be consistent with the information in the product’s approved labeling. Thus, we, and our collaborators, will not be able to promote any products we develop for indications or uses for which they are not approved.
In addition, manufacturers of approved products and those manufacturers’ facilities are required to comply with extensive FDA requirements, including ensuring that quality control and manufacturing procedures conform to cGMPs, which include requirements relating to quality control and quality assurance as well as the corresponding maintenance of records and

59

documentation and reporting requirements. We, our contract manufacturers, our collaborators and their contract manufacturers could be subject to periodic unannounced inspections by the FDA to monitor and ensure compliance with cGMPs.
Accordingly, assuming we, or our collaborators, receive marketing approval for one or more of our product candidates, we, and our collaborators, and our and their contract manufacturers will continue to expend time, money and effort in all areas of regulatory compliance, including manufacturing, production, product surveillance and quality control.
If we, and our collaborators, are not able to comply with post-approval regulatory requirements, we, and our collaborators, could have the marketing approvals for our products withdrawn by regulatory authorities and our, or our collaborators’, ability to market any future products could be limited, which could adversely affect our ability to achieve or sustain profitability. Further, the cost of compliance with post-approval regulations may have a negative effect on our operating results and financial condition.
Any of our product candidates for which we, or our collaborators, obtain marketing approval in the future could be subject to post-marketing restrictions or withdrawal from the market and we, or our collaborators, may be subject to substantial penalties if we, or they, fail to comply with regulatory requirements or if we, or they, experience unanticipated problems with our products following approval.
Any of our product candidates for which we, or our collaborators, obtain marketing approval in the future, as well as the manufacturing processes, post-approval studies and measures, labeling, advertising and promotional activities for such product, among other things, will be subject to continual requirements of and review by the FDA and other regulatory authorities. These requirements include submissions of safety and other post-marketing information and reports, registration and listing requirements, requirements relating to manufacturing, quality control, quality assurance and corresponding maintenance of records and documents, requirements regarding the distribution of samples to physicians and recordkeeping. Even if marketing approval of a product candidate is granted, the approval may be subject to limitations on the indicated uses for which the product may be marketed or to the conditions of approval, including the requirement to implement a REMS.
The FDA may also impose requirements for costly post-marketing studies or clinical trials and surveillance to monitor the safety or efficacy of a product. The FDA and other agencies, including the Department of Justice, closely regulate and monitor the post-approval marketing and promotion of products to ensure that they are manufactured, marketed and distributed only for the approved indications and in accordance with the provisions of the approved labeling. The FDA imposes stringent restrictions on manufacturers’ communications regarding off-label use and if we, or our collaborators, do not market any of our product candidates for which we, or they, receive marketing approval for only their approved indications, we, or they, may be subject to warnings or enforcement action for off-label marketing. Violation of the FDCA and other statutes, including the False Claims Act, relating to the promotion and advertising of prescription drugs may lead to investigations or allegations of violations of federal and state health care fraud and abuse laws and state consumer protection laws.
In addition, later discovery of previously unknown adverse events or other problems with our products or their manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may yield various results, including:
 
•
restrictions on such products, manufacturers or manufacturing processes;
•
restrictions on the indication, patient population or other parameters for which the drug is approved;
•
restrictions on the labeling or marketing of a product;
•
restrictions on product distribution or use;
•
requirements to conduct post-marketing studies or clinical trials;
•
warning letters or untitled letters;
•
withdrawal of the products from the market;
•
refusal to approve pending applications or supplements to approved applications that we submit;
•
recall of products;
•
fines, restitution or disgorgement of profits or revenues;
•
reputational damage;
•
suspension or withdrawal of marketing approvals;
•
refusal to permit the import or export of products;
•
product seizure; or
•
injunctions or the imposition of civil or criminal penalties.

60

Recently enacted and future legislation may increase the difficulty and cost for us and our collaborators to obtain marketing approval of and commercialize our product candidates and affect the prices we, or they, may obtain.
In the United States and some foreign jurisdictions, there have been a number of legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities and affect our ability, or the ability of our collaborators, to profitably sell any products for which we, or they, obtain marketing approval.
In the United States, the Medicare Prescription Drug, Improvement, and Modernization Act of 2003, or the MMA, changed the way Medicare covers and pays for pharmaceutical products. The legislation expanded Medicare coverage for drug purchases by the elderly and introduced a new reimbursement methodology based on average sales prices for physician administered drugs. In addition, this legislation provided authority for limiting the number of drugs that will be covered in any therapeutic class. Cost reduction initiatives and other provisions of this legislation could decrease the coverage and price that we receive for any approved products. While the MMA only addresses drug benefits for Medicare beneficiaries, private payors often follow Medicare coverage policy and payment limitations in setting their own reimbursement rates. Therefore, any reduction in reimbursement that results from the MMA may result in a similar reduction in payments from private payors.
In March 2010, President Obama signed into law the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Act, or collectively the PPACA.
Among the provisions of the PPACA of potential importance to our product candidates are the following:
 
•
an annual, non-deductible fee on any entity that manufactures or imports specified branded prescription drugs and biologic agents;
•
an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program;
•
expansion of healthcare fraud and abuse laws, including the False Claims Act and the Anti-Kickback Statute, new government investigative powers and enhanced penalties for noncompliance;
•
a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 50% point-of-sale discounts off negotiated prices;
•
extension of manufacturers’ Medicaid rebate liability;
•
expansion of eligibility criteria for Medicaid programs;
•
expansion of the entities eligible for discounts under the Public Health Service pharmaceutical pricing program new requirements to report financial arrangements with physicians and teaching hospitals;
•
a new requirement to annually report drug samples that manufacturers and distributors provide to physicians; and
•
a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research.
In addition, other legislative changes have been proposed and adopted since the PPACA was enacted. These changes included aggregate reductions to Medicare payments to providers of up to 2% per fiscal year, starting in 2013. In January 2013, President Obama signed into law the American Taxpayer Relief Act of 2012, which, among other things, reduced Medicare payments to several providers and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. These new laws may result in additional reductions in Medicare and other healthcare funding.
Legislative and regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional activities for pharmaceutical products. We cannot be sure whether additional legislative changes will be enacted, or whether the FDA regulations, guidance or interpretations will be changed, or what the impact of such changes on the marketing approvals of our product candidates, if any, may be. In addition, increased scrutiny by the U.S. Congress of the FDA’s approval process may significantly delay or prevent marketing approval, as well as subject us and our collaborators to more stringent product labeling and post-marketing testing and other requirements.
Our future relationships with customers and third-party payors will be subject to applicable anti-kickback, fraud and abuse and other healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm and diminished profits and future earnings.
Healthcare providers, physicians and third-party payors will play a primary role in the recommendation and prescription of any products for which we obtain marketing approval. Our future arrangements with third-party payors and customers, if any, will subject us to broadly applicable fraud and abuse and other healthcare laws and regulations. The laws and regulations may constrain the business or financial arrangements and relationships through which we market, sell and distribute any products

61

for which we obtain marketing approval. Restrictions under applicable federal and state healthcare laws and regulations in the United States include the following:
 
•
Anti-Kickback Statute. The federal healthcare anti-kickback statute prohibits, among other things, persons from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, order or recommendation or arranging of, any good or service, for which payment may be made under a federal healthcare program such as Medicare and Medicaid;
•
False Claims Act. The federal False Claims Act imposes criminal and civil penalties, including through civil whistleblower or qui tam actions, against individuals or entities for, among other things, knowingly presenting, or causing to be presented false or fraudulent claims for payment by a federal healthcare program or making a false statement or record material to payment of a false claim or avoiding, decreasing or concealing an obligation to pay money to the federal government, with potential liability including mandatory treble damages and significant per-claim penalties, currently set at $5,500 to $11,000 per false claim;
•
HIPAA. The federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, imposes criminal and civil liability for executing a scheme to defraud any healthcare benefit program or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement in connection with the delivery of or payment for healthcare benefits, items or services, and, as amended by the Health Information Technology for Economic and Clinical Health Act and its implementing regulations, also imposes obligations, including mandatory contractual terms and technical safeguards, with respect to maintaining the privacy, security and transmission of individually identifiable health information;
•
Transparency Requirements. Federal laws require applicable manufacturers of covered drugs to report payments and other transfers of value to physicians, other healthcare providers and teaching hospitals, as well as ownership and investment interests held by physicians and other healthcare providers and their immediate family members; and
•
Analogous State and Foreign Laws. Analogous state and foreign fraud and abuse laws and regulations, such as state anti-kickback and false claims laws can apply to sales or marketing arrangements and claims involving healthcare items or services. In addition, some state laws require pharmaceutical companies to comply with the pharmaceutical industry's voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government in addition to requiring drug manufacturers to report information related to payments to physicians and other health care providers or marketing expenditures and govern the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.
Some state laws require pharmaceutical companies to comply with the pharmaceutical industry’s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government and require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures. State and foreign laws also govern the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not pre-empted by HIPAA, thus complicating compliance efforts.
Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, imprisonment, exclusion of products from government funded healthcare programs, such as Medicare and Medicaid, and the curtailment or restructuring of our operations. If any of the physicians or other healthcare providers or entities with whom we expect to do business is found to be not in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs.
If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on our business.
We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. From time to time, our operations may involve the use of hazardous materials, including chemicals and biological materials, and may also produce hazardous waste products. Even if we contract with third parties for the disposal of these materials and waste products, we cannot completely eliminate the risk of contamination or injury resulting from these materials. In the event of contamination or injury resulting from the use or disposal of our hazardous materials, we could be held liable for any resulting damages, and any

62

liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties for failure to comply with such laws and regulations.
We maintain workers’ compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, but this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us.
In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. Current or future environmental laws and regulations may impair our research, development or production efforts, which could adversely affect our business, financial condition, results of operations or prospects. In addition, failure to comply with these laws and regulations may result in substantial fines, penalties or other sanctions.
Governments outside the United States tend to impose strict price controls, which may adversely affect our revenues, if any.
In some countries, such as the countries of the European Union, the pricing of prescription pharmaceuticals is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a product. To obtain reimbursement or pricing approval in some countries, we, or our collaborators, may be required to conduct a clinical trial that compares the cost-effectiveness of our product to other available therapies. If reimbursement of our products is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our business could be materially harmed.
RISKS RELATED TO EMPLOYEE MATTERS AND MANAGING GROWTH
Our future success depends on our ability to retain our Chief Executive Officer and other key executives and to attract, retain and motivate qualified personnel.
Our industry has experienced a high rate of turnover of management personnel in recent years. Our ability to compete in the highly competitive biotechnology and pharmaceuticals industries depends upon our ability to attract and retain highly qualified managerial, scientific and medical personnel. We are highly dependent on the pharmaceutical research and development and business development expertise of Roger D. Tung, our President and Chief Executive Officer, as well as the other principal members of our management, scientific and development team. Although we have formal employment agreements with our executive officers, these agreements do not prevent them from terminating their employment with us at any time. In addition, although we maintain a key-man insurance policy with respect to Dr. Tung, we do not carry key-man insurance on any of our other executive officers or employees and may not carry any key-man insurance in the future.
If we lose one or more of our executive officers, our ability to implement our business strategy successfully could be seriously harmed. Furthermore, replacing executive officers may be difficult and may take an extended period of time because of the limited number of individuals in our industry with the breadth of skills and experience required to develop, gain marketing approval of and commercialize products successfully. Competition to hire from this limited pool is intense, and we may be unable to hire, train, retain or motivate these additional key personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. We also experience competition for the hiring of scientific and clinical personnel from universities and research institutions. In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and development and commercialization strategy. Our consultants and advisors may be employed by employers other than us and may have commitments under consulting or advisory contracts with other entities that may limit their availability to us. If we are unable to continue to attract and retain high quality personnel, our ability to develop and commercialize product candidates will be limited.
We expect to grow our organization and, as a result, we may encounter difficulties in managing our growth, which could disrupt our operations.
As our pipeline grows and matures, we expect to experience significant growth in the number of our employees and the scope of our operations, including in the areas of drug manufacturing, regulatory affairs and sales, clinical development, marketing and distribution. Our management may need to divert a disproportionate amount of its attention away from our day-to-day activities to devote time to managing these growth activities. To manage these growth activities, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities and continue to recruit and train additional qualified personnel. Due to our limited financial resources and the limited experience of our management team in managing a company with such anticipated growth, we may not be able to effectively manage the expansion of our

63

operations or recruit and train additional qualified personnel. Moreover, the expected expansion of our operations may lead to significant costs and may divert our business development resources. Any inability to manage growth could delay the execution of our business plans or disrupt our operations.
RISKS RELATED TO OUR COMMON STOCK
The price of our common stock may be volatile and fluctuate substantially, which could result in substantial losses for purchasers of our common stock.
The trading price of our comment stock has been, and may continue to be, volatile and could be subject to wide fluctuations in response to various factors, some of which are beyond our control. The stock market in general and the market for smaller pharmaceutical and biotechnology companies in particular have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. The market price for our common stock may be influenced by many factors, including:
 
•
the success or failure of existing or new competitive products or technologies;
•
the timing, advancement of and results of nonclinical studies and clinical trials of any of our product candidates;
•
commencement or termination of collaborations for our development programs;
•
failure, delays, changes to or discontinuation of any of our development programs;
•
regulatory or legal developments in the United States and other countries;
•
regulatory actions relating to our product candidates;
•
developments or disputes concerning patent applications, issued patents or other proprietary rights;
•
the recruitment or departure of key personnel;
•
disclosures by our collaborators relating to our product candidates or competitive programs;
•
merger or acquisition activity of our collaborators;
•
the level of expenses related to any of our product candidates or clinical development programs;
•
the results of our efforts to develop additional product candidates or products;
•
actual or anticipated changes in estimates as to financial results, development timelines or recommendations by securities analysts;
•
announcement or expectation of additional financing efforts;
•
receipt or expectation of receipt of revenues such as milestones, royalties, grants and license fees;
•
sales of our common stock by us, our insiders or other stockholders;
•
programmed trading based on technical stock chart or other inputs;
•
portfolio restructuring by large stockholders or decisions by stockholders to rapidly acquire or sell our shares;
•
addition or removal of our stock from stock indices;
•
variations in our financial results or those of companies that are perceived to be similar to us;
•
changes in estimates or recommendations by securities analysts that cover our stock;
•
actions by short-sellers or supporters of our stock, including social media postings or reports;
•
changes in the structure of healthcare payment systems;
•
market conditions in the pharmaceutical and biotechnology sectors;
•
legalization or the anticipation of possible legalization of drug reimportation from other countries;
•
actual or anticipated changes in FDA practices;
•
general economic, industry and market conditions; and
•
the other factors described in this “Risk Factors” section.
An active trading market for our common stock may not be sustained.
Although we have listed our common stock on the Nasdaq Global Market, an active trading market for our common stock may not be sustained. In the absence of an active trading market for our common stock, investors may not be able to sell their common stock at or above the price at which they acquired their shares or at the times that they would like to sell. An inactive trading market may also impair our ability to raise capital to continue to fund operations by selling shares and may impair our ability to acquire other companies or technologies by using our shares as consideration.
We have broad discretion in the use of our cash reserves and may not use them effectively.
Our management has broad discretion to use our cash reserves and could use our cash reserves in ways that do not improve our results of operations or enhance the value of our common stock. The failure by our management to apply these funds effectively could result in financial losses that could have a material adverse effect on our business, cause the price of our

64

common stock to decline and delay the development of our product candidates. Pending their use, we may invest our cash reserves in a manner that does not produce income or that loses value.
We are an “emerging growth company,” and the reduced disclosure requirements applicable to emerging growth companies may make our common stock less attractive to investors.
We are an “emerging growth company,” as defined in the Jumpstart Our Business Startups Act, or JOBS Act, and will only remain an emerging growth company through the end of 2019. For so long as we remain an emerging growth company, we are permitted and plan to rely on exemptions from certain disclosure requirements that are applicable to other public companies that are not emerging growth companies. These exemptions include not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, or SOX Section 404, not being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor’s report providing additional information about the audit and the financial statements, reduced disclosure obligations regarding executive compensation and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. Even after we no longer qualify as an emerging growth company, we may still continue to qualify as a “smaller reporting company,” which would allow us to continue to take advantage of many of the same exemptions from disclosure requirements. We cannot predict whether investors will find our common stock less attractive if we rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile.
In addition, the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. This allows an emerging growth company to delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have irrevocably elected not to avail ourselves of this exemption from new or revised accounting standards and, therefore, we are subject to the same new or revised accounting standards as other public companies that are not emerging growth companies.
We will continue to incur increased costs as a result of operating as a public company, and our management will be required to devote substantial time to new compliance initiatives and corporate governance practices.
As a public company, we are incurring and expect to incur additional significant legal, accounting and other expenses that we did not incur as a private company. We expect that these expenses will further increase as we are no longer an “emerging growth company." The Sarbanes-Oxley Act of 2002, or SOX, the Dodd-Frank Wall Street Reform and Consumer Protection Act, the listing requirements of the Nasdaq Global Market and other applicable securities rules and regulations impose various requirements on public companies, including establishment and maintenance of effective disclosure and financial controls and corporate governance practices. We expect that we will need to hire additional personnel to comply with the requirements of being a public company, and our management and other personnel will need to devote a substantial amount of time towards maintaining compliance with these requirements. These rules and regulations are often subject to varying interpretations, in many cases due to their lack of specificity, and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices.
Pursuant to SOX Section 404 we are required to evaluate the effectiveness of our internal control over financial reporting as of the end of each fiscal year and to report on this evaluation in our Annual Report on Form 10-K for the year. However, as an emerging growth company, we have previously not been required to include an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. We will need to continue to dedicate internal resources, potentially engage outside consultants and adopt a detailed work plan to assess and document the adequacy of internal control over financial reporting, continue steps to improve control processes as appropriate, validate through testing that controls are functioning as documented and implement a continuous reporting and improvement process for internal control over financial reporting. Despite our efforts, there is a risk that when we are required to deliver the attestation report we will not be able to conclude that our internal control over financial reporting is effective as required by SOX Section 404. If we identify one or more material weaknesses, it could result in an adverse reaction in the financial markets due to a loss of confidence in the reliability of our financial statements.

65

A significant portion of our total outstanding shares may be sold into the market in the near future, which could cause the market price of our common stock to decline significantly, even if our business is doing well.
Sales of a substantial number of shares of our common stock in the public market could occur at any time. These sales, or the perception in the market that the holders of a large number of shares of common stock intend to sell shares, could reduce the market price of our common stock.
In addition, as of November 4, 2019, there were 4,608,354 shares subject to outstanding options and restricted stock units under our equity compensation plans, all of which shares we have registered under the Securities Act on a registration statement on Form S-8. These shares will be able to be freely sold in the public market upon exercise, as permitted by any applicable vesting requirements, except to the extent they are held by our affiliates, in which case such shares will become eligible for sale in the public market as permitted by Rule 144 under the Securities Act. Furthermore, as of November 4, 2019, there were 61,273 shares subject to an outstanding warrant to purchase common stock. These shares will become eligible for sale in the public market, to the extent such warrant is exercised, as permitted by Rule 144 under the Securities Act.
We do not anticipate paying any cash dividends on our capital stock in the foreseeable future, accordingly, stockholders must rely on capital appreciation, if any, for any return on their investment.
We have never declared or paid cash dividends on our capital stock. We currently plan to retain all of our future earnings, if any, to finance the operation, development and growth of our business. Furthermore, any future debt agreements may preclude us from paying dividends. As a result, capital appreciation, if any, of our common stock will be the sole source of gain for our stockholders for the foreseeable future.
Our executive officers, directors and principal stockholders, if they choose to act together, have the ability to substantially influence all matters submitted to stockholders for approval.
As of September 30, 2019, our executive officers and directors, combined with our stockholders who owned more than 5% of our outstanding common stock, and all affiliates, in the aggregate, beneficially owned shares representing approximately 51.7% of our capital stock. As a result, if these stockholders were to choose to act together, they would be able to substantially influence all matters submitted to our stockholders for approval, as well as our management and affairs. For example, these persons, if they choose to act together, would substantially influence the election of directors and approval of any merger, consolidation or sale of all or substantially all of our assets. This concentration of ownership control may:
 
•
delay, defer or prevent a change in control;
•
entrench our management or the board of directors; or
•
impede a merger, consolidation, takeover or other business combination involving us that other stockholders may desire.

Future sales of a substantial number of our common shares by our principal stockholders could depress the trading price of our common stock.

If our principal stockholders sell substantial amounts of shares of our common stock in the public market or if the market anticipates that these sales could occur, the market price of shares of our common stock could decline. These sales may make it more difficult for us to sell equity or equity-related securities in the future at a time and price that we deem appropriate, or to use equity as consideration for future acquisitions.
Provisions in our corporate charter documents and under Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management.
Provisions in our corporate charter and our by-laws may discourage, delay or prevent a merger, acquisition or other change in control of us that stockholders may consider favorable, including transactions in which our stockholders might otherwise receive a premium for their shares. These provisions could also limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. In addition, because our board of directors is responsible for appointing the members of our management team, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors. Among other things, these provisions:
 
•
establish a classified board of directors such that all members of the board are not elected at one time;
•
allow the authorized number of our directors to be changed only by resolution of our board of directors;

66

•
limit the manner in which stockholders can remove directors from the board;
•
establish advance notice requirements for nominations for election to the board of directors or for proposing matters that can be acted on at stockholder meetings;
•
require that stockholder actions must be effected at a duly called stockholder meeting and prohibit actions by our stockholders by written consent;
•
limit who may call a special meeting of stockholders;
•
authorize our board of directors to issue preferred stock without stockholder approval, which could be used to institute a “poison pill” that would work to dilute the stock ownership of a potential hostile acquirer, effectively preventing acquisitions that have not been approved by our board of directors; and
•
require the approval of the holders of at least 75% of the votes that all our stockholders would be entitled to cast to amend or repeal certain provisions of our charter or by-laws.

Moreover, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner. This could discourage, delay or prevent someone from acquiring us or merging with us, whether or not it is desired by, or beneficial to, our stockholders.
If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our share price and trading volume could decline.
The trading market for our common stock depends on the research and reports that securities or industry analysts publish about us or our business. We do not have any control over these analysts. There can be no assurance that analysts will cover us, or provide favorable coverage. If one or more analysts downgrade our stock or change their opinion of our stock, our share price may decline. In addition, if one or more analysts cease coverage of our Company or fail to regularly publish reports on us, we could lose visibility in the financial markets, which could cause our share price or trading volume to decline.

67


Item 6.
Exhibits.


Exhibit
number
  
Description
  
 
 
  
 
 
  
 
 
  
 
 
101.INS*
  
XBRL Instance Document
 
 
101.SCH*
  
XBRL Taxonomy Extension Schema Document
 
 
101.CAL*
  
XBRL Taxonomy Extension Calculation Linkbase Document
 
 
101.DEF*
  
XBRL Taxonomy Extension Definition Linkbase Document
 
 
101.LAB*
  
XBRL Taxonomy Extension Label Linkbase Document
 
 
101.PRE*
  
XBRL Taxonomy Extension Presentation Linkbase Document
 
*    Filed herewith.
**    Furnished herewith.




68

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 
 
CONCERT PHARMACEUTICALS, INC.
 
 
 
 
Date:
November 7, 2019
By:
 
/s/ Marc A. Becker
 
 
 
 
 
 
 
 
Marc A. Becker
Chief Financial Officer
(Principal Financial Officer)


69
 EX-31.1 2 q32019exhibit311.htm EXHIBIT 31.1 Exhibit


Exhibit 31.1
CERTIFICATION PURSUANT TO RULE 13a-14(a)
OF THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Roger D. Tung, certify that:
 
1.
I have reviewed this Quarterly Report on Form 10-Q of Concert Pharmaceuticals, Inc.;
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.
The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.
The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date:
November 7, 2019
 
 
/s/ Roger D. Tung
Roger D. Tung
President and Chief Executive Officer
(Principal Executive Officer)


 EX-31.2 3 q32019exhibit312.htm EXHIBIT 31.2 Exhibit


Exhibit 31.2
CERTIFICATION PURSUANT TO RULE 13a-14(a)
OF THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Marc A. Becker, certify that:
 
1.
I have reviewed this Quarterly Report on Form 10-Q of Concert Pharmaceuticals, Inc.;
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.
The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.
The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date:
November 7, 2019
 
 
/s/ Marc A. Becker
Marc A. Becker
Chief Financial Officer
(Principal Financial Officer)



 EX-32.1 4 q32019exhibit321.htm EXHIBIT 32.1 Exhibit


Exhibit 32.1
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report on Form 10-Q of Concert Pharmaceuticals, Inc. (the “Company”) for the period ended September 30, 2019, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Roger D. Tung, President and Chief Executive Officer of the Company, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:
 
(1)
the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)
the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated:
November 7, 2019
/s/ Roger D. Tung
 
 
Roger D. Tung
 
 
President and Chief Executive Officer
 
 
(Principal Executive Officer)
A signed original of this written statement required by Section 906 has been provided to Concert Pharmaceuticals, Inc. and will be retained by Concert Pharmaceuticals, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.



 EX-32.2 5 q32019exhibit322.htm EXHIBIT 32.2 Exhibit


Exhibit 32.2
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report on Form 10-Q of Concert Pharmaceuticals, Inc. (the “Company”) for the period ended September 30, 2019, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Marc A. Becker, Chief Financial Officer of the Company, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:
 
(1)
the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)
the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated:
November 7, 2019
/s/ Marc A. Becker
 
 
Marc A. Becker
 
 
Chief Financial Officer
 
 
(Principal Financial Officer)
A signed original of this written statement required by Section 906 has been provided to Concert Pharmaceuticals, Inc. and will be retained by Concert Pharmaceuticals, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.



 EX-101.INS 6 cnce-20190930.xml XBRL INSTANCE DOCUMENT 0001367920 2019-01-01 2019-09-30 0001367920 2019-11-04 0001367920 2018-12-31 0001367920 2019-09-30 0001367920 2019-07-01 2019-09-30 0001367920 2018-01-01 2018-09-30 0001367920 2018-07-01 2018-09-30 0001367920 cnce:LicenseandResearchandDevelopmentRevenueMember 2019-07-01 2019-09-30 0001367920 cnce:LicenseandResearchandDevelopmentRevenueMember 2018-01-01 2018-09-30 0001367920 cnce:LicenseandResearchandDevelopmentRevenueMember 2018-07-01 2018-09-30 0001367920 cnce:LicenseandResearchandDevelopmentRevenueMember 2019-01-01 2019-09-30 0001367920 us-gaap:AdditionalPaidInCapitalMember 2018-07-01 2018-09-30 0001367920 us-gaap:CommonStockMember 2018-01-01 2018-03-31 0001367920 2018-01-01 2018-03-31 0001367920 us-gaap:TreasuryStockMember 2018-07-01 2018-09-30 0001367920 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-04-01 2018-06-30 0001367920 2018-04-01 2018-06-30 0001367920 us-gaap:CommonStockMember 2018-09-30 0001367920 us-gaap:CommonStockMember 2017-12-31 0001367920 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-07-01 2018-09-30 0001367920 us-gaap:TreasuryStockMember 2018-06-30 0001367920 us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-03-31 0001367920 us-gaap:RetainedEarningsMember 2017-12-31 0001367920 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0001367920 us-gaap:RetainedEarningsMember 2018-04-01 2018-06-30 0001367920 us-gaap:RetainedEarningsMember 2018-01-01 2018-03-31 0001367920 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-09-30 0001367920 us-gaap:TreasuryStockMember 2018-01-01 2018-03-31 0001367920 us-gaap:AdditionalPaidInCapitalMember 2018-06-30 0001367920 us-gaap:RetainedEarningsMember 2018-07-01 2018-09-30 0001367920 us-gaap:AdditionalPaidInCapitalMember 2018-09-30 0001367920 us-gaap:CommonStockMember 2018-04-01 2018-06-30 0001367920 us-gaap:CommonStockMember 2018-06-30 0001367920 us-gaap:AccountingStandardsUpdate201409Member 2018-01-01 0001367920 us-gaap:CommonStockMember 2018-03-31 0001367920 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-06-30 0001367920 us-gaap:AdditionalPaidInCapitalMember 2018-04-01 2018-06-30 0001367920 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-12-31 0001367920 us-gaap:TreasuryStockMember 2018-03-31 0001367920 us-gaap:AccountingStandardsUpdate201409Member us-gaap:RetainedEarningsMember 2018-01-01 0001367920 us-gaap:RetainedEarningsMember 2018-06-30 0001367920 us-gaap:RetainedEarningsMember 2018-03-31 0001367920 us-gaap:AdditionalPaidInCapitalMember 2018-03-31 0001367920 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-03-31 0001367920 us-gaap:TreasuryStockMember 2018-09-30 0001367920 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-01 2018-03-31 0001367920 us-gaap:CommonStockMember 2018-07-01 2018-09-30 0001367920 us-gaap:TreasuryStockMember 2017-12-31 0001367920 2018-09-30 0001367920 us-gaap:RetainedEarningsMember 2018-09-30 0001367920 2017-12-31 0001367920 2018-06-30 0001367920 2018-03-31 0001367920 us-gaap:CommonStockMember 2019-09-30 0001367920 2019-01-01 2019-03-31 0001367920 2019-04-01 2019-06-30 0001367920 us-gaap:CommonStockMember 2019-01-01 2019-03-31 0001367920 us-gaap:CommonStockMember 2019-03-31 0001367920 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0001367920 us-gaap:RetainedEarningsMember 2019-07-01 2019-09-30 0001367920 us-gaap:AdditionalPaidInCapitalMember 2019-04-01 2019-06-30 0001367920 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-04-01 2019-06-30 0001367920 us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0001367920 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-03-31 0001367920 us-gaap:RetainedEarningsMember 2019-09-30 0001367920 us-gaap:TreasuryStockMember 2019-01-01 2019-03-31 0001367920 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-09-30 0001367920 us-gaap:RetainedEarningsMember 2018-12-31 0001367920 us-gaap:CommonStockMember 2018-12-31 0001367920 us-gaap:CommonStockMember 2019-06-30 0001367920 2019-03-31 0001367920 us-gaap:TreasuryStockMember 2019-03-31 0001367920 2019-06-30 0001367920 us-gaap:AdditionalPaidInCapitalMember 2019-09-30 0001367920 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0001367920 us-gaap:AdditionalPaidInCapitalMember 2019-07-01 2019-09-30 0001367920 us-gaap:RetainedEarningsMember 2019-03-31 0001367920 us-gaap:CommonStockMember 2019-07-01 2019-09-30 0001367920 us-gaap:TreasuryStockMember 2018-12-31 0001367920 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001367920 us-gaap:TreasuryStockMember 2019-06-30 0001367920 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-03-31 0001367920 us-gaap:CommonStockMember 2019-04-01 2019-06-30 0001367920 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-06-30 0001367920 us-gaap:RetainedEarningsMember 2019-06-30 0001367920 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-03-31 0001367920 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-07-01 2019-09-30 0001367920 us-gaap:RetainedEarningsMember 2019-04-01 2019-06-30 0001367920 us-gaap:RetainedEarningsMember 2019-01-01 2019-03-31 0001367920 us-gaap:TreasuryStockMember 2019-09-30 0001367920 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember cnce:InvestmentswithMaturityPeriodTwoMember 2018-12-31 0001367920 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember cnce:InvestmentswithMaturityPeriodOneMember 2018-12-31 0001367920 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember cnce:MarketableEquitySecuritiesCorporateEquitySecuritiesMember 2018-12-31 0001367920 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember cnce:InvestmentswithMaturityPeriodOneMember 2018-12-31 0001367920 us-gaap:FairValueMeasurementsRecurringMember cnce:MarketableEquitySecuritiesCorporateEquitySecuritiesMember 2018-12-31 0001367920 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember cnce:InvestmentswithMaturityPeriodOneMember 2018-12-31 0001367920 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember cnce:InvestmentswithMaturityPeriodOneMember 2018-12-31 0001367920 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember cnce:InvestmentswithMaturityPeriodOneMember 2018-12-31 0001367920 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember cnce:InvestmentswithMaturityPeriodTwoMember 2018-12-31 0001367920 us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001367920 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember cnce:MarketableEquitySecuritiesCorporateEquitySecuritiesMember 2018-12-31 0001367920 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember cnce:InvestmentswithMaturityPeriodTwoMember 2018-12-31 0001367920 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001367920 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember cnce:InvestmentswithMaturityPeriodTwoMember 2018-12-31 0001367920 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember cnce:InvestmentswithMaturityPeriodOneMember 2018-12-31 0001367920 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember cnce:InvestmentswithMaturityPeriodTwoMember 2018-12-31 0001367920 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember cnce:MarketableEquitySecuritiesCorporateEquitySecuritiesMember 2018-12-31 0001367920 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueMeasurementsRecurringMember cnce:InvestmentswithMaturityPeriodTwoMember 2018-12-31 0001367920 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueMeasurementsRecurringMember cnce:InvestmentswithMaturityPeriodOneMember 2018-12-31 0001367920 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember cnce:InvestmentswithMaturityPeriodOneMember 2018-12-31 0001367920 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001367920 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember cnce:InvestmentswithMaturityPeriodTwoMember 2018-12-31 0001367920 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001367920 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember cnce:InvestmentswithMaturityPeriodTwoMember 2018-12-31 0001367920 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember cnce:MarketableEquitySecuritiesCorporateEquitySecuritiesMember 2019-09-30 0001367920 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember cnce:InvestmentswithMaturityPeriodOneMember 2019-09-30 0001367920 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember cnce:InvestmentswithMaturityPeriodTwoMember 2019-09-30 0001367920 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember cnce:InvestmentswithMaturityPeriodOneMember 2019-09-30 0001367920 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember cnce:InvestmentswithMaturityPeriodTwoMember 2019-09-30 0001367920 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember cnce:InvestmentswithMaturityPeriodOneMember 2019-09-30 0001367920 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember cnce:InvestmentswithMaturityPeriodOneMember 2019-09-30 0001367920 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember cnce:InvestmentswithMaturityPeriodOneMember 2019-09-30 0001367920 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember cnce:InvestmentswithMaturityPeriodOneMember 2019-09-30 0001367920 us-gaap:FairValueMeasurementsRecurringMember 2019-09-30 0001367920 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember cnce:InvestmentswithMaturityPeriodTwoMember 2019-09-30 0001367920 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember cnce:InvestmentswithMaturityPeriodOneMember 2019-09-30 0001367920 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember cnce:MarketableEquitySecuritiesCorporateEquitySecuritiesMember 2019-09-30 0001367920 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-09-30 0001367920 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-09-30 0001367920 us-gaap:FairValueMeasurementsRecurringMember cnce:MarketableEquitySecuritiesCorporateEquitySecuritiesMember 2019-09-30 0001367920 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember cnce:InvestmentswithMaturityPeriodTwoMember 2019-09-30 0001367920 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember cnce:InvestmentswithMaturityPeriodTwoMember 2019-09-30 0001367920 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember cnce:MarketableEquitySecuritiesCorporateEquitySecuritiesMember 2019-09-30 0001367920 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember cnce:InvestmentswithMaturityPeriodTwoMember 2019-09-30 0001367920 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember cnce:InvestmentswithMaturityPeriodTwoMember 2019-09-30 0001367920 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember cnce:InvestmentswithMaturityPeriodOneMember 2019-09-30 0001367920 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueMeasurementsRecurringMember cnce:InvestmentswithMaturityPeriodTwoMember 2019-09-30 0001367920 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-09-30 0001367920 us-gaap:USTreasurySecuritiesMember 2018-12-31 0001367920 us-gaap:AvailableforsaleSecuritiesMember 2018-12-31 0001367920 cnce:MarketableEquitySecuritiesCorporateEquitySecuritiesMember 2018-12-31 0001367920 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2018-12-31 0001367920 us-gaap:CashMember 2018-12-31 0001367920 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:MeasurementInputExpectedTermMember 2018-12-31 0001367920 us-gaap:USTreasurySecuritiesMember 2018-12-31 0001367920 us-gaap:USTreasurySecuritiesMember us-gaap:MeasurementInputExpectedTermMember 2018-01-01 2018-12-31 0001367920 us-gaap:MoneyMarketFundsMember 2018-12-31 0001367920 us-gaap:USTreasurySecuritiesMember us-gaap:MeasurementInputExpectedTermMember 2018-12-31 0001367920 cnce:MarketableEquitySecuritiesCorporateEquitySecuritiesMember 2019-09-30 0001367920 us-gaap:MoneyMarketFundsMember 2019-09-30 0001367920 us-gaap:CashMember 2019-09-30 0001367920 us-gaap:AvailableforsaleSecuritiesMember 2019-09-30 0001367920 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:MeasurementInputExpectedTermMember 2019-09-30 0001367920 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2019-09-30 0001367920 us-gaap:USTreasurySecuritiesMember 2019-09-30 0001367920 us-gaap:USTreasurySecuritiesMember us-gaap:MeasurementInputExpectedTermMember 2019-09-30 0001367920 us-gaap:USTreasurySecuritiesMember us-gaap:MeasurementInputExpectedTermMember 2019-01-01 2019-09-30 0001367920 us-gaap:USTreasurySecuritiesMember 2019-09-30 0001367920 2018-01-01 2018-12-31 0001367920 cnce:ProcessaMember 2018-03-21 2018-03-21 0001367920 cnce:GskMember 2019-09-30 0001367920 cnce:CiplaMember 2019-01-16 2019-01-16 0001367920 cnce:ProcessaMember 2019-01-01 2019-09-30 0001367920 cnce:ProcessaMember 2018-01-01 2018-03-31 0001367920 cnce:CiplaMember cnce:AchievementofCertainMilestonesMember 2019-01-16 0001367920 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember us-gaap:IndemnificationGuaranteeMember cnce:AssetsforSynthesisandResearchandDevelopmentforTreatingCysticFibrosisMember 2019-02-01 2019-02-28 0001367920 cnce:CiplaMember cnce:FirstMilestoneMember 2019-01-16 0001367920 cnce:CiplaMember 2019-01-16 0001367920 cnce:ContingentConsiderationAssetAfterAchievementofMilestoneEventsMember us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember cnce:AssetsforSynthesisandResearchandDevelopmentforTreatingCysticFibrosisMember 2017-03-03 0001367920 cnce:ProcessaMember 2018-03-19 2018-03-19 0001367920 cnce:CelgeneMember cnce:CTP730Member 2019-09-30 0001367920 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember cnce:AssetsforSynthesisandResearchandDevelopmentforTreatingCysticFibrosisMember 2017-03-03 0001367920 cnce:ProcessaMember 2019-07-01 2019-09-30 0001367920 cnce:CelgeneMember 2019-09-30 0001367920 cnce:CelgeneMember cnce:OtherAdditionalLicenseProgramMember 2019-09-30 0001367920 cnce:ProcessaMember 2018-07-01 2018-09-30 0001367920 cnce:CiplaMember 2019-01-01 2019-09-30 0001367920 cnce:ProcessaMember 2018-01-01 2018-09-30 0001367920 cnce:CiplaMember 2019-07-01 2019-09-30 0001367920 us-gaap:GeneralAndAdministrativeExpenseMember 2019-01-01 2019-09-30 0001367920 us-gaap:ResearchAndDevelopmentExpenseMember 2018-07-01 2018-09-30 0001367920 us-gaap:ResearchAndDevelopmentExpenseMember 2019-01-01 2019-09-30 0001367920 us-gaap:GeneralAndAdministrativeExpenseMember 2018-07-01 2018-09-30 0001367920 us-gaap:ResearchAndDevelopmentExpenseMember 2019-07-01 2019-09-30 0001367920 us-gaap:GeneralAndAdministrativeExpenseMember 2019-07-01 2019-09-30 0001367920 us-gaap:ResearchAndDevelopmentExpenseMember 2018-01-01 2018-09-30 0001367920 us-gaap:GeneralAndAdministrativeExpenseMember 2018-01-01 2018-09-30 0001367920 us-gaap:RestrictedStockUnitsRSUMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2017-07-06 2017-07-06 0001367920 us-gaap:RestrictedStockUnitsRSUMember 2019-08-15 2019-08-15 0001367920 us-gaap:RestrictedStockUnitsRSUMember 2019-09-30 0001367920 us-gaap:RestrictedStockUnitsRSUMember 2017-07-06 2017-07-06 0001367920 cnce:TwoThousandFourteenStockIncentivePlanMember 2019-09-30 0001367920 us-gaap:RestrictedStockUnitsRSUMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2017-07-06 2017-07-06 0001367920 srt:MinimumMember 2019-01-01 2019-09-30 0001367920 us-gaap:RestrictedStockUnitsRSUMember 2019-01-01 2019-09-30 0001367920 us-gaap:EmployeeStockOptionMember 2019-09-30 0001367920 srt:MaximumMember 2019-01-01 2019-09-30 0001367920 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-09-30 0001367920 cnce:TwoThousandFourteenStockIncentivePlanMember 2019-01-01 2019-01-01 0001367920 us-gaap:RestrictedStockUnitsRSUMember 2018-12-31 0001367920 us-gaap:RestrictedStockUnitsRSUMember 2018-01-01 2018-09-30 0001367920 us-gaap:WarrantMember 2019-07-01 2019-09-30 0001367920 us-gaap:WarrantMember 2018-07-01 2018-09-30 0001367920 us-gaap:EmployeeStockOptionMember 2019-07-01 2019-09-30 0001367920 us-gaap:EmployeeStockOptionMember 2018-01-01 2018-09-30 0001367920 us-gaap:RestrictedStockUnitsRSUMember 2019-07-01 2019-09-30 0001367920 us-gaap:EmployeeStockOptionMember 2018-07-01 2018-09-30 0001367920 us-gaap:RestrictedStockUnitsRSUMember 2018-07-01 2018-09-30 0001367920 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-09-30 0001367920 us-gaap:WarrantMember 2019-01-01 2019-09-30 0001367920 us-gaap:RestrictedStockUnitsRSUMember 2019-01-01 2019-09-30 0001367920 us-gaap:WarrantMember 2018-01-01 2018-09-30 0001367920 2019-01-01 0001367920 us-gaap:AccountingStandardsUpdate201602Member 2019-01-01 0001367920 us-gaap:SubsequentEventMember 2019-11-04 0001367920 us-gaap:SubsequentEventMember 2019-11-04 2019-11-04 0001367920 2019-03-01 0001367920 us-gaap:SubsequentEventMember 2019-03-01 2019-11-04 xbrli:pure iso4217:USD utreg:sqft xbrli:shares cnce:extension cnce:segment iso4217:USD xbrli:shares 1476000 1687000 1000000 1000000 71000 589000 0 55522 P31D P52D 300000 90000000 0 0 2926000 5016000 16000000 161000 0 2082000 10452000 0 2090301 2090301 0.03 -445000 2 500000 2800000 P12M 0 50000 50000000 0.030 0.030 50000 0.07 false --12-31 Q3 2019 2019-09-30 10-Q 0001367920 23841155 Yes true true Accelerated Filer CONCERT PHARMACEUTICALS, INC. false true 1277000 1302000 15000 11000 234000 899000 390000 0 5669000 4434000 672000 502000 -2900000 -137000 -35000 284369000 293469000 3299000 3299000 2804000 2804000 2731000 2731000 2929000 2929000 2362000 2362000 2420000 2420000 206000 206000 2731000 1520000 1211000 8834000 4822000 4012000 2420000 1230000 1190000 7711000 3983000 3728000 515000 133000 132000 758000 214000 132000 214000 410000 61000 290000 72000 72000 192547000 151957000 180149000 131116000 115752000 36708000 0 152460000 96488000 22603000 0 119091000 9000 7000 2000 48000 34000 14000 69000 60000 9000 9000 1000 8000 135604000 100748000 34856000 88126000 49443000 38683000 64733000 35962000 0 100695000 34103000 746000 0 34849000 135544000 100695000 34849000 26873000 22603000 0 49476000 38689000 0 0 38689000 88165000 49476000 38689000 135544000 88165000 99000 0 39597000 17770000 8379000 7643000 1748000 33384000 7893000 21253000 4238000 17770000 8379000 7643000 1748000 7643000 0 0 7643000 1748000 0 0 1748000 33384000 7893000 21253000 4238000 21253000 0 0 21253000 4238000 0 0 4238000 121500000 29222000 41154000 18927000 34541000 11932000 15614000 0.001 0.001 0.001 100000000 100000000 23518690 24030711 23437587 23841155 23000 23000 -17300000 -35009000 -17224000 -57577000 16000000 16000000 0 0 10500000 10500000 7800000 1400000 6400000 2800000 1413000 7783000 9120000 2750000 57000000 3000000.0 15752000 15752000 0 0 0 0 P153D P151D P88D P169D 2850000 875000 1256000 160000000 -0.74 -1.51 -0.72 -2.43 3067000 2245000 P2Y6M18D 4000000 17400000 7525000 5435000 10451000 10451000 0 0 0 0 -1359000 -2090000 -52000 -4000 6320000 17464000 4742000 15329000 0 0 4088000 -4500000 -17369000 -34877000 -17185000 -57679000 18000 298000 0 0 2322000 2358000 50000 453000 457000 207000 -155000 -4000 372000 -390000 -115000 -265000 -100000 -827000 0 -16000000 1000000 -16000 0 2033000 0 77000 36000 -26000 16000 4000 1091000 556000 291000 703000 2003000 724000 2474000 7525000 0 0 7525000 5435000 0 0 5435000 454000 0 0.13 29502000 17223000 3150000 3058000 2969000 2406000 696000 13077000 P5Y P10Y 24807000 32694000 192547000 151957000 8749000 13754000 7525000 5435000 -732000 -1359000 334000 -2091000 -272000 1439000 44619000 47860000 -32415000 -33685000 -4463000 -4463000 -13325000 -13325000 -17387000 -17387000 -35175000 -21826000 -21826000 -18668000 -18668000 -17185000 -17185000 -57679000 1 1 17351000 46013000 18253000 59126000 -17340000 -35521000 -18243000 -58062000 1800000 0 16425000 16900000 0 235000 0 16190000 2082000 0 0 9317000 9500000 0.0000 0.1308 P10Y3M P9Y3M 0 16000 -75000 -75000 154000 154000 87000 87000 166000 97000 97000 44000 44000 -39000 -39000 102000 47000 46000 0 4996000 0 1206000 741000 46120000 93326000 2405000 520000 0.001 0.001 5000000 5000000 0 0 0 0 0 0 2739000 3830000 0 174000 93144000 141706000 23000 934000 36000 1006000 0 1000000 300000 8919000 7993000 11031000 28549000 13511000 43797000 1557000 1157000 1157000 -116515000 -174200000 -174194000 10500000 1000000 10500000 10500000 11000 10500000 10492000 0 2000 10000 1000000 24000 1064000 400000 36167 8834000 7711000 P2Y P4Y P3Y P1Y10M18D 25600 13.87 500000 400000 412220 10.27 228150 412220 13.87 10.27 202550 13.87 0 0 0 0 0.0298 0.0265 0.0159 0.0216 0.7772 0.7719 0.7437 0.7686 937503 1192083 2429295 13.70 187000 2539000 59000 1167000 184474 18.44 1032250 10.42 17.92 6.46 8.95 390000 3557406 4202674 15.26 14.96 390000 4049442 14.90 8.33 13.25 0.5 0.5 0.35 P10Y P6Y P6Y P6Y P6Y 390000 P6Y0M11D P6Y11M27D P6Y11M5D 2110000 5839000 2234000 7070000 23148000 8000 23467000 78000 23492000 78000 23509000 23519000 81000 23946000 189000 23986000 189000 24031000 189000 36000 174000 53000 202000 61000 145000 17000 25000 17000 154000 47000 40000 9000 202508 330000 330000 1206000 1206000 741000 741000 658000 658000 253000 253000 38000 38000 3000 805000 805000 165000 165000 36000 36000 196432000 -407000 273059000 23000 -76243000 210397000 -482000 275810000 23000 -64954000 200283000 -328000 278867000 23000 -78279000 185752000 -241000 281636000 23000 -95666000 81000 167740000 -137000 284369000 23000 -116515000 149798000 -40000 288156000 23000 -138341000 133701000 4000 290683000 23000 -157009000 119263000 -35000 293469000 23000 -174194000 5000000 23421000 23349000 23807000 23703000 <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:450px;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:296px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:56px;" rowspan="1" colspan="1"></td><td style="width:11px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:56px;" rowspan="1" colspan="1"></td><td style="width:11px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Supplemental balance sheet information:</font></div></td><td colspan="6" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">For the nine months ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating lease right-of-use assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,317</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating lease liability</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,425</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted average remaining lease term</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.25</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.25</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted average discount rate</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13.08</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Cash, Cash Equivalents, Investments and Marketable Equity Securities</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash equivalents include all highly liquid investments maturing within 90 days from the date of purchase. Investments consist of securities with original maturities greater than 90 days when purchased. The Company classifies these investments as available-for-sale and records them at fair value in the accompanying consolidated balance sheets. In accordance with ASU 2016-01, unrealized gains or losses from equity securities are included in net income. Unrealized gains or losses from other investments, including debt securities, are included in accumulated other comprehensive income (loss). Premiums or discounts from par value are amortized to investment income over the life of the underlying investment. </font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash, cash equivalents, available for sale investments, and marketable equity securities included the following at </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;"> and December&#160;31, 2018:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.0234375%;border-collapse:collapse;text-align:left;"><tr><td colspan="19" rowspan="1"></td></tr><tr><td style="width:35%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Average maturity</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Amortized cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Unrealized gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Unrealized losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair value</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">September 30, 2019</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,893</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,893</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market funds</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,253</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,253</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. Treasury obligations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">52 days</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,238</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,238</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,384</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,384</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. Treasury obligations</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">169 days</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38,683</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38,689</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Government agency securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">88 days</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49,443</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49,476</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Investments, available for sale</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">88,126</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">48</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">88,165</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">September 30, 2019</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Acquisition value</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Unrealized gains</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Unrealized losses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair value</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Marketable equity securities (Note 8)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,451</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,435</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.0234375%;border-collapse:collapse;text-align:left;"><tr><td colspan="19" rowspan="1"></td></tr><tr><td style="width:35%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Average maturity</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Amortized cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Unrealized gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Unrealized losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair value</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31, 2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,379</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,379</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market funds</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,643</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,643</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. Treasury obligations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31 days</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,748</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,748</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,770</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,770</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. Treasury obligations</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">151 days</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34,856</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34,849</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Government agency securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">153 days</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100,748</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(60</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100,695</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Investments, available for sale</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">135,604</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(69</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">135,544</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31, 2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Acquisition value</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Unrealized gains</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Unrealized losses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair value</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Marketable equity securities (Note 8)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,451</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,926</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,525</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Although available to be sold to meet operating needs or otherwise (and therefore classified as current assets), securities are generally held through maturity. The cost of securities sold is determined based on the specific identification method for purposes of&#160;recording realized gains and losses. During 2019 and 2018, there were no realized gains or losses on sales of investments, and no investments were adjusted other than for temporary declines in fair value.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Use of Estimates and Summary of Significant Accounting Policies</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of the consolidated financial statements in conformity with U.S. generally accepted accounting principles, or GAAP, requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenue, expenses and the disclosure of contingent assets and liabilities and the Company's ability to continue as a going concern. In preparing the consolidated financial statements, management used estimates in the following areas, among others: revenue recognition; lease accounting; income tax expense; stock-based compensation expense; accrued expenses; and the evaluation of the existence of conditions and events that raise substantial doubt regarding the Company&#8217;s ability to continue as a going concern. Actual results could differ from those estimates.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">With the exception of the adoption of Accounting Standards Update, or ASU, 2016-02 during the nine months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;"> discussed in Note 11, there have been no material changes to the significant accounting policies previously disclosed in the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2018.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Accrued Expenses and Other Liabilities</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued expenses and other liabilities consisted of the following:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:67%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">September&#160;30, <br clear="none"/>2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31, <br clear="none"/>2018</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued professional fees and other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">502</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">672</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Employee compensation and benefits</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,245</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,067</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,687</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,476</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred lease incentive, current portion</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">454</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,434</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,669</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Basis of Presentation</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form&#160;10-Q and Article&#160;10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments, consisting of normal recurring accruals and revisions of estimates, considered necessary for a fair presentation of the condensed consolidated financial statements have been included. Interim results for the three and nine months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;"> are not necessarily indicative of the results that may be expected for the fiscal year ending December&#160;31, 2019 or any other future period.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying condensed consolidated financial statements reflect the accounts of Concert and its subsidiaries. All intercompany transactions between the Company and its subsidiaries have been eliminated. Management has determined that the Company operates in </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> segment: the development of pharmaceutical products on its own behalf or in collaboration with others. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the Company&#8217;s consolidated financial statements and the accompanying notes included in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2018 filed with the Securities and Exchange Commission, or SEC, on February&#160;28, 2019.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Basis of Presentation and Significant Accounting Policies</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Basis of Presentation</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form&#160;10-Q and Article&#160;10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments, consisting of normal recurring accruals and revisions of estimates, considered necessary for a fair presentation of the condensed consolidated financial statements have been included. Interim results for the three and nine months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;"> are not necessarily indicative of the results that may be expected for the fiscal year ending December&#160;31, 2019 or any other future period.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying condensed consolidated financial statements reflect the accounts of Concert and its subsidiaries. All intercompany transactions between the Company and its subsidiaries have been eliminated. Management has determined that the Company operates in </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> segment: the development of pharmaceutical products on its own behalf or in collaboration with others. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the Company&#8217;s consolidated financial statements and the accompanying notes included in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2018 filed with the Securities and Exchange Commission, or SEC, on February&#160;28, 2019.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Use of Estimates and Summary of Significant Accounting Policies</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of the consolidated financial statements in conformity with U.S. generally accepted accounting principles, or GAAP, requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenue, expenses and the disclosure of contingent assets and liabilities and the Company's ability to continue as a going concern. In preparing the consolidated financial statements, management used estimates in the following areas, among others: revenue recognition; lease accounting; income tax expense; stock-based compensation expense; accrued expenses; and the evaluation of the existence of conditions and events that raise substantial doubt regarding the Company&#8217;s ability to continue as a going concern. Actual results could differ from those estimates.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">With the exception of the adoption of Accounting Standards Update, or ASU, 2016-02 during the nine months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;"> discussed in Note 11, there have been no material changes to the significant accounting policies previously disclosed in the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2018.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Recently Adopted Accounting Pronouncements</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2016, the Financial Accounting Standards Board, or FASB, issued ASU 2016-02,&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Leases</font><font style="font-family:inherit;font-size:10pt;">, or Topic 842. ASU 2016-02 requires lessees to recognize assets and liabilities on the balance sheet for the rights and obligations created by leases. On January 1, 2019, the Company adopted ASU 2016-02 and all related amendments. For discussion regarding the impact of this accounting pronouncement, refer to Note 11 appearing elsewhere in this Quarterly Report on Form 10-Q.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2018, the FASB issued ASU&#160;2018-07, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Improvements to Nonemployee Share-Based Payment Accounting</font><font style="font-family:inherit;font-size:10pt;">,</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> </font><font style="font-family:inherit;font-size:10pt;">that expands the scope of Topic 718, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Compensation - Stock Compensation</font><font style="font-family:inherit;font-size:10pt;">, to include share-based payment transactions for acquiring goods and services from nonemployees. ASU 2018-07 provides that an entity should apply the requirements of Topic 718 to nonemployee awards except for certain exemptions specified in the amendment. The Company adopted this new standard effective January 1, 2019, and it did not have a material effect on the consolidated financial statements and related disclosures. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2018, the SEC issued Release No. 33-10532 that amends and clarifies certain financial reporting requirements. The principal change to the Company&#8217;s financial reporting is the inclusion of the annual disclosure requirement of changes in stockholders&#8217; equity in Rule 3-04 of Regulation S-X to interim periods. The Company adopted this new rule beginning with its first Quarterly Report on Form 10-Q for the quarter ended March 31, 2019.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Pending Accounting Pronouncements</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2016, the FASB issued ASU 2016-13, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Financial Instruments-Credit Losses</font><font style="font-family:inherit;font-size:10pt;">. The new standard requires entities to measure all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions and reasonable and supportable forecasts. ASU 2016-13 will become effective for the Company for fiscal years beginning after December 15, 2019, with early adoption permitted. The Company is currently evaluating the impact ASU 2016-13 will have on its financial statements and related disclosures.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2018, the FASB issued ASU 2018-15, Intangible-Goodwill and Other Internal-Use Software (Subtopic 350-40): </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement that is a Service Contract.</font><font style="font-family:inherit;font-size:10pt;"> The standard aligns the requirements for capitalizing implementation costs in a cloud computing arrangement service contract with the requirements for capitalizing implementation costs incurred for internal-use software. The new guidance also prescribes the balance sheet, income statement and cash flow classification of the capitalized implementation costs and related amortization expense, and requires additional quantitative and qualitative disclosures.&#160;ASU 2018-15 is effective for fiscal years beginning after December 15, 2019 and early adoption is permitted. The Company is currently evaluating the impact ASU 2018-15 will have on its financial statements and related disclosures.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Restricted Cash</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restricted cash as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;"> and 2018 is held as collateral for stand-by letters of credit issued by the Company to its landlords in connection with the current and previous leases of the Company's Lexington, Massachusetts facilities. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash, cash equivalents and restricted cash consisted of the following:</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:67%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">September&#160;30, <br clear="none"/>2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">September&#160;30, <br clear="none"/>2018</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,384</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39,597</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restricted cash</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,157</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,557</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total cash, cash equivalents and restricted cash shown in the statements of cash flows</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34,541</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41,154</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Revenue</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company's revenue is generated through collaborative licensing agreements, patent assignments, and sales of intellectual property. The Company generates its revenue through </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> segment and the revenue recognized under each of the Company's arrangements during the current and prior period is described below. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 1, 2018, the Company adopted ASU 2014-19, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers</font><font style="font-family:inherit;font-size:10pt;">, or</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> </font><font style="font-family:inherit;font-size:10pt;">ASC 606. The Company adopted ASC 606 using the modified retrospective approach. For detailed information regarding the adoption of&#160;ASC 606, the impact on its consolidated financial statements and its collaboration arrangements, see Note 2 and Note 12 to the accompanying consolidated financial statements appearing in the Company's Annual Report on Form&#160;10-K filed with the SEC on February 28, 2019.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Contract Assets</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company did </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;">t have a contract asset as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;"> as compared to </font><font style="font-family:inherit;font-size:10pt;">$16.0 million</font><font style="font-family:inherit;font-size:10pt;"> as of December 31, 2018. The decrease in the contract asset balance is the result of the receipt of the </font><font style="font-family:inherit;font-size:10pt;">$16.0 million</font><font style="font-family:inherit;font-size:10pt;"> that had initially been held in escrow for indemnification purposes related to the asset purchase by Vertex Pharmaceuticals, Inc., or Vertex, and was released to the Company in February 2019. </font></div><div style="line-height:120%;padding-top:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Contract Liabilities</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;"> and December 31, 2018, the Company had </font><font style="font-family:inherit;font-size:10pt;">$10.5 million</font><font style="font-family:inherit;font-size:10pt;"> in contract liabilities related to unsatisfied performance obligations as well as variable consideration paid in advance but currently constrained from recognition.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The contract liabilities consist of the following deferred revenue:</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:40px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:16px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$7.8 million</font><font style="font-family:inherit;font-size:10pt;"> related to the Company's collaboration with Celgene Corporation, or Celgene, </font><font style="font-family:inherit;font-size:10pt;">$1.4 million</font><font style="font-family:inherit;font-size:10pt;"> of which is attributable to the CTP-730 program and is currently expected to be recognized as revenue in the next twelve months as the Company satisfies its remaining research and development activities pursuant to mutually agreed upon development plans, and </font><font style="font-family:inherit;font-size:10pt;">$6.4 million</font><font style="font-family:inherit;font-size:10pt;"> of which is attributable to two additional license programs that the Company will not recognize as revenue unless Celgene exercises its rights with respect to those programs, or in the second quarter of 2020 at such time that Celgene's rights lapse; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:40px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:16px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$2.8 million</font><font style="font-family:inherit;font-size:10pt;"> related to a payment received from GlaxoSmithKline, or GSK, that the Company will not recognize as revenue until all repayment obligations lapse.</font></div></td></tr></table><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenue Arrangements</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Vertex</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On March 3, 2017, the Company and Vertex entered into an Asset Purchase Agreement, or the Vertex Agreement, pursuant to which, subject to the satisfaction or waiver of the conditions therein, the Company sold and assigned to Vertex, CTP-656, a deuterated analog of ivacaftor, now known as VX-561, and other cystic fibrosis assets of the Company. On July 25, 2017, or the Vertex Closing Date, the transaction contemplated by the Vertex Agreement closed and Vertex paid the Company&#160;</font><font style="font-family:inherit;font-size:10pt;">$160 million</font><font style="font-family:inherit;font-size:10pt;">&#160;in cash consideration. In addition, Vertex has agreed to pay the Company an aggregate of up to </font><font style="font-family:inherit;font-size:10pt;">$90 million</font><font style="font-family:inherit;font-size:10pt;"> upon the achievement of certain milestone events. In February 2019, the&#160;</font><font style="font-family:inherit;font-size:10pt;">$16.0 million</font><font style="font-family:inherit;font-size:10pt;"> initially&#160;held in escrow was released to the Company.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of December 31, 2018, the Vertex indemnification variable consideration represented a contract asset to be released from escrow&#160;18 months&#160;following the Vertex Closing Date and was classified as a current asset in the accompanying consolidated balance sheet. In February 2019, the&#160;</font><font style="font-family:inherit;font-size:10pt;">$16.0 million</font><font style="font-family:inherit;font-size:10pt;">&#160;initially held in escrow was released to the Company. Additionally, the variable consideration related to the regulatory milestone payments are fully constrained due to the uncertainty associated with the achievement of the respective milestones. Accordingly, no contract asset was recorded as of September 30, 2019.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Processa</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On October 4, 2017, the Company entered into a License and Option Agreement, or the Option, with Promet Therapeutics, LLC, or Promet, pursuant to which the Company granted Promet an option to obtain an exclusive license to CTP-499, a deuterated analog of 1-(S)-5-hydroxyhexyl-3,7-dimethylxanthine, or HDX, an active metabolite of pentoxifylline, provided certain conditions were met. On October 5, 2017, Promet closed an asset purchase agreement with Heatwurx, Inc., a public company, creating Processa Pharmaceuticals, Inc., or Processa.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On March 21, 2018, the Company entered into an Amendment to the Option, or the Amendment, and a Securities Purchase Agreement, both with Promet and Processa. Pursuant to the Amendment, the Company granted Promet, who then assigned to Processa, an exclusive, worldwide, royalty-bearing license to develop, manufacture and commercialize CTP-499, now known as PCS-499. Upon transfer of the license and as consideration for the license, the Company received </font><font style="font-family:inherit;font-size:10pt;">2,090,301</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock of Processa. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company is also eligible to receive royalties on worldwide net sales.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Amendment contained one performance obligation: an exclusive, worldwide, royalty-bearing license to develop, commercialize and sublicense CTP-499. The Company determined that the transaction price was </font><font style="font-family:inherit;font-size:10pt;">$10.5 million</font><font style="font-family:inherit;font-size:10pt;">, which was based on the fair value of the non-cash consideration received on March 19, 2018, which consisted of </font><font style="font-family:inherit;font-size:10pt;">2,090,301</font><font style="font-family:inherit;font-size:10pt;"> shares of publicly traded common stock of Processa. The transaction price of </font><font style="font-family:inherit;font-size:10pt;">$10.5 million</font><font style="font-family:inherit;font-size:10pt;"> was allocated to the single performance obligation. The performance obligation was considered satisfied at contract inception as the exclusive license transferred control to the customer at this point in time. Accordingly, revenue of </font><font style="font-family:inherit;font-size:10pt;">$10.5 million</font><font style="font-family:inherit;font-size:10pt;"> was recognized during the first quarter of 2018. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Subsequent changes to the fair value of the underlying securities are recognized as unrealized gains or losses on marketable equity securities within the condensed consolidated statement of operations and comprehensive loss.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Amendment contains consideration that is variable based on royalties upon the customer's commercial success with the licensed product. The consideration related to royalty payments is considered variable consideration that is fully constrained in accordance with the royalty recognition constraint. The variable consideration related to royalties will be recognized in the period the products are sold by Processa and the Company has a present right to payment.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the three and nine months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">, the Company recognized </font><font style="font-family:inherit;font-size:10pt;">$2 thousand</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$24 thousand</font><font style="font-family:inherit;font-size:10pt;"> in revenue, respectively, related to intellectual property cost reimbursements. For the three months and nine months ended September 30, 2018, the Company recognized </font><font style="font-family:inherit;font-size:10pt;">$10.5 million</font><font style="font-family:inherit;font-size:10pt;"> in revenue related to the transfer of the license.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Cipla</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company entered into a License Agreement, or the Cipla Agreement, on January 16, 2019, or the Cipla Closing Date, with Cipla Technologies LLC, or Cipla, pursuant to which the Company granted Cipla an exclusive, worldwide, royalty-bearing license to develop, manufacture and commercialize CTP-354, a novel GABA</font><font style="font-family:inherit;font-size:10pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:7pt">A</sub></font><font style="font-family:inherit;font-size:10pt;">&#160;receptor subtype-selective modulator. As consideration for the license, the Company received an upfront payment of </font><font style="font-family:inherit;font-size:10pt;">$1.0 million</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Cipla Agreement also provides Cipla the option to purchase the Company&#8217;s existing inventory of CTP-354 held as of the Effective Date, valued in aggregate at </font><font style="font-family:inherit;font-size:10pt;">$0.3 million</font><font style="font-family:inherit;font-size:10pt;">. Additionally, upon the achievement of certain milestone events, Cipla has agreed to pay the Company an aggregate of up to </font><font style="font-family:inherit;font-size:10pt;">$57.0 million</font><font style="font-family:inherit;font-size:10pt;">. The first milestone payment the Company may be entitled to receive is </font><font style="font-family:inherit;font-size:10pt;">$3.0 million</font><font style="font-family:inherit;font-size:10pt;"> when the first IND for the first CTP-354 product goes into effect. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Furthermore, the Company is eligible to receive royalties on worldwide net sales of future product sales at defined percentages ranging from the mid-single to high-single digits. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Cipla Agreement contained one performance obligation: an exclusive, worldwide, royalty-bearing license to develop, manufacture, commercialize and sublicense CTP-354, referred to as the Transfer of License Performance Obligation. The Company concluded the option to purchase existing inventory did not provide Cipla a material right, and as such, was treated as a separate contract. The transaction price was determined to be </font><font style="font-family:inherit;font-size:10pt;">$1.0 million</font><font style="font-family:inherit;font-size:10pt;"> based on the upfront consideration received as of the Cipla Closing Date. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of the Cipla Closing Date, the Transfer of License Performance Obligation was satisfied as the control of CTP-354 transferred to Cipla, the customer. As a result, the full transaction price was recognized as revenue on the Cipla Closing Date. The sale of existing inventory is recognized as goods are transferred to the customer.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The arrangement with Cipla contains consideration that is variable based on the customer&#8217;s achievement of certain development and regulatory milestones in addition to royalties upon the customer&#8217;s commercial success with the licensed product. The next milestone payment the Company may be entitled to receive of </font><font style="font-family:inherit;font-size:10pt;">$3.0 million</font><font style="font-family:inherit;font-size:10pt;"> related to the first IND for the first CTP-354 product going into effect is considered variable consideration that is fully constrained due to the uncertainty associated with the achievement of the development milestone. The consideration related to royalties is also variable consideration that is fully constrained in accordance with the royalty recognition constraint. The variable consideration related to royalties will be recognized in the period the products are sold by Cipla and the Company has a present right to payment. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company did not recognize revenue for the three months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">. The Company recognized </font><font style="font-family:inherit;font-size:10pt;">$1.0 million</font><font style="font-family:inherit;font-size:10pt;"> in revenue associated with the sale of existing inventory and the Transfer of License Performance Obligation for the nine months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Stock-Based Compensation</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s equity incentive plans provide for the issuance of a variety of stock-based awards, including incentive stock options,&#160;nonstatutory&#160;stock options and awards of stock, to directors, officers and employees of the Company, as well as consultants and advisors to the Company. As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">, the Company has granted awards in the form of stock options and restricted stock units, or RSUs. The stock options generally have been granted with an exercise price equal to the fair value of the underlying common stock on the date of grant, a vesting period of </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> or </font><font style="font-family:inherit;font-size:10pt;">four years</font><font style="font-family:inherit;font-size:10pt;">, and an expiration date no later than </font><font style="font-family:inherit;font-size:10pt;">ten years</font><font style="font-family:inherit;font-size:10pt;"> from the date of grant. </font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Effective January&#160;1, 2019, an additional </font><font style="font-family:inherit;font-size:10pt;">937,503</font><font style="font-family:inherit;font-size:10pt;"> shares were added to the Company&#8217;s 2014 Stock Incentive Plan, or the 2014 Plan, for future issuance pursuant to the terms of the 2014 Plan. As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">, there were </font><font style="font-family:inherit;font-size:10pt;">1,192,083</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock available for future award grants under the 2014 Plan.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total stock-based compensation expense related to all stock-based options and awards recognized in the condensed consolidated statements of operations and comprehensive loss consisted of:</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:83.7890625%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three&#160;Months&#160;Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,190</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,211</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,728</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,012</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,230</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,520</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,983</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,822</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total stock-based compensation expense</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,420</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,731</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,711</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,834</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Stock Options</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock options are valued using the Black-Scholes-Merton option valuation model, and compensation cost is recognized based on such fair value over the period of vesting. The weighted average fair value of options granted in the three and nine months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;"> and 2018 reflect the following weighted-average assumptions:</font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:83.0078125%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:48%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three&#160;Months&#160;Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected volatility</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">74.37</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">77.72</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">76.86</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">77.19</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected term</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.0 years</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.0 years</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.0 years</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.0 years</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.59</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.98</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.16</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.65</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected dividend yield</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the three and nine months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;"> and 2018, expected volatility was estimated using a weighted-average of the Company's historical volatility of its common stock and the historical volatility of the common stock of a group of similar companies that were publicly traded. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table provides certain information related to the Company's outstanding stock options:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:79.1015625%;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td style="width:42%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Nine Months Ended </font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands, except per share data)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted average fair value of options granted, per option</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.46</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.42</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.95</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17.92</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Aggregate grant date fair value of options vested during the period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,234</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,110</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,070</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,839</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total cash received from exercises of stock options</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,006</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">934</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total intrinsic value of stock options exercised</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">59</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">187</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,167</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,539</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following is a summary of stock option activity for the nine months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Number&#160;of</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Option&#160;Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exercise</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Price&#160;per</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Remaining</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Contractual</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Term</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Aggregate</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Intrinsic</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Value</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(In years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(In&#160;thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at December&#160;31, 2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,557,406</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15.26</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,032,250</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13.25</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(202,508</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.33</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;Forfeited or expired</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(184,474</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18.44</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at September 30, 2019</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,202,674</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14.96</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.99</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">390</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercisable at September 30, 2019</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,429,295</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13.70</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.03</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">390</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested and expected to vest at September 30, 2019</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,049,442</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14.90</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.93</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">390</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:40px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:16px;"><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup>&#160;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">This represents the number of vested stock option shares as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">, plus the number of unvested stock option shares that the Company estimated as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;"> would vest, based on the unvested stock option shares at </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;"> and an estimated forfeiture rate of </font><font style="font-family:inherit;font-size:10pt;">7%</font><font style="font-family:inherit;font-size:10pt;">.</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">, there was </font><font style="font-family:inherit;font-size:10pt;">$17.4 million</font><font style="font-family:inherit;font-size:10pt;"> of unrecognized compensation cost related to stock options that are expected to vest. The stock option costs are expected to be recognized over a weighted average remaining vesting period of </font><font style="font-family:inherit;font-size:10pt;">2.5 years</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Restricted Stock Units</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On July 6, 2017, the Company granted </font><font style="font-family:inherit;font-size:10pt;">0.5 million</font><font style="font-family:inherit;font-size:10pt;"> RSUs, or the 2017 RSU grant, to executives and employees. The awards granted to non-executive employees were service-based, whereas the awards granted to executives were a blend of service-based and performance-based. Assuming all service and performance conditions were achieved, </font><font style="font-family:inherit;font-size:10pt;">fifty</font><font style="font-family:inherit;font-size:10pt;"> percent of the RSUs would vest on March 31, 2018, and the remaining </font><font style="font-family:inherit;font-size:10pt;">fifty</font><font style="font-family:inherit;font-size:10pt;"> percent of the RSUs would vest on March 31, 2019. Certain executive awards were subject to the achievement of defined performance criteria prior to March 31, 2018, including the closing of the asset purchase contemplated by the Vertex Agreement and the institution by the Patent Trial and Appeal Board, or PTAB, of the Post Grant Review, or PGR, petition filed by the Company against Incyte Corporation. In January 2018, the PTAB decided not to institute the PGR petition and, as a result, the corresponding performance-based awards did not vest on March 31, 2018.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company used the accelerated attribution method to recognize expense over the required service period based on its estimate of the number of performance-based awards that vested. For any change in the estimate of the number of performance-based awards that were probable of vesting, the Company cumulatively adjusted compensation expense in the period that the change in estimate was made. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On August 15, 2019, or the 2019 RSU grant date, the Company granted </font><font style="font-family:inherit;font-size:10pt;">0.4 million</font><font style="font-family:inherit;font-size:10pt;"> RSUs, or the 2019 RSU grant, to certain executives and employees. All awards are service-based and vest ratably over </font><font style="font-family:inherit;font-size:10pt;">two years</font><font style="font-family:inherit;font-size:10pt;">. On the first anniversary of the 2019 RSU grant date, </font><font style="font-family:inherit;font-size:10pt;">thirty-five</font><font style="font-family:inherit;font-size:10pt;"> percent of the RSUs will vest. The remainder of the RSUs will vest on the second anniversary of the 2019 RSU grant date. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">RSUs are not included in issued and outstanding common stock until the shares are vested and settled. As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">, all achieved RSUs from the 2017 RSU grant had vested, and no RSUs from the 2019 RSU grant had vested. The fair value of an RSU is measured based on the market price of the underlying common stock as of the date of grant.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following is a summary of RSU activity, including both service-based and performance-based RSUs for the nine months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:71.09375%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:61%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Number&#160;of</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">RSU Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Grant Date Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at December&#160;31, 2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">228,150</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13.87</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">412,220</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.27</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;Released</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(202,550</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13.87</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;Forfeited</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(25,600</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13.87</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at September 30, 2019</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">412,220</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.27</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-left:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">, there was </font><font style="font-family:inherit;font-size:10pt;">$4.0 million</font><font style="font-family:inherit;font-size:10pt;"> of unrecognized compensation cost related to RSUs that are expected to vest. The RSU costs are expected to be recognized over a weighted average remaining vesting period of </font><font style="font-family:inherit;font-size:10pt;">1.9 years</font><font style="font-family:inherit;font-size:10pt;">.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Loss Per Share</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic net loss per common share is calculated by dividing net loss allocable to common stockholders by the weighted-average common shares outstanding during the period, without consideration of common stock equivalents. For purposes of the diluted net loss per share calculation, common stock equivalents are excluded from the calculation if their effect would be anti-dilutive. As such, basic and diluted net loss per share applicable to common stockholders are the same for periods with a net loss.</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table illustrates the determination of loss per share for each period presented.</font></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:83.7890625%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:48%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:3%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Nine Months Ended</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands, except per share amounts)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Numerator:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss applicable to common stockholders - basic and diluted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(17,185</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(17,387</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(57,679</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(35,175</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Denominator:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted average shares outstanding - basic and diluted</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,807</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,421</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,703</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,349</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss per share applicable to common stockholders - basic and diluted</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.72</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.74</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2.43</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.51</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Anti-dilutive potential common stock equivalents excluded&#160;from the calculation of net loss per share:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock options</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">214</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">515</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">290</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">758</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restricted stock units</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">410</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">133</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">72</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">214</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Warrants</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">61</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">132</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">72</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">132</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value Measurements</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has certain financial assets and liabilities that are recorded at fair value which have been classified as Level&#160;1, 2 or 3 within the fair value hierarchy as described in the accounting standards for fair value measurements:<br clear="none"/> <br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 1&#8212;quoted prices for identical instruments in active markets;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 2&#8212;quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, and model-derived valuations in which all significant inputs and significant value drivers are observable in active markets; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 3&#8212;valuations derived from valuation techniques in which one or more significant value drivers are unobservable.</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The tables below present information about the Company&#8217;s financial assets and liabilities that are measured and carried at fair value as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;"> and December 31, 2018 (in thousands) and indicate the level within the fair value hierarchy where each measurement is classified.</font></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level&#160;2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level&#160;3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">September 30, 2019</font></div></td><td colspan="11" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash equivalents:</font></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,253</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,253</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. Treasury obligations</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,238</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,238</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Investments, available for sale:</font></div></td><td colspan="11" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. Treasury obligations</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38,689</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38,689</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Government agency securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26,873</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,603</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49,476</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Marketable equity securities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate equity securities (Note 8)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,435</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,435</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">96,488</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,603</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">119,091</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level&#160;2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level&#160;3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31, 2018</font></div></td><td colspan="11" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash equivalents:</font></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,643</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,643</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. Treasury obligations</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,748</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,748</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Investments, available for sale:</font></div></td><td colspan="11" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. Treasury obligations</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34,103</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">746</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34,849</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Government agency securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">64,733</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35,962</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100,695</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Marketable equity securities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate equity securities (Note 8)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,525</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,525</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">115,752</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36,708</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">152,460</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Income Taxes</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred tax assets and deferred tax liabilities are recognized based on temporary differences between the financial reporting and tax basis of assets and liabilities using statutory rates. A valuation allowance is recorded against deferred tax assets if it is more likely than not that some or all of the deferred tax assets will not be realized.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s ability to use its operating loss carryforwards and tax credits to offset future taxable income is subject to restrictions under Sections&#160;382 and 383 of the United States Internal Revenue Code, or the Internal Revenue Code. Net operating loss and tax credit carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant stockholders over a three-year period in excess of 50 percent, as defined under Sections 382 and 383 of the Internal Revenue Code. Such changes would limit the Company&#8217;s use of its operating loss carryforwards and tax credits. In such a situation, the Company may be required to pay income taxes, even though significant operating loss carryforwards and tax credits exist.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company records a provision or benefit for income taxes on ordinary pre-tax income or loss based on its estimated effective tax rate for the year. As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">, the Company forecasts an ordinary pre-tax loss for the year ended December&#160;31, 2019 and, since it maintains a full valuation allowance on its deferred tax assets, the Company did not record an income tax benefit for the three or nine months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:450px;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:320px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:116px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Supplemental cash flow information:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">For the nine months ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</font></div></td></tr><tr><td colspan="4" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash paid for amounts included in the measurement of lease liabilities</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating cash flows from operating leases</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,082</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:451px;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:322px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:95px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:20px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Maturities of lease liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">For the twelve months ended December 31,</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands)</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">696</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,406</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2021</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,969</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2022</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,058</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2023</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,150</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Thereafter</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,223</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total lease payments</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,502</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less imputed interest</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(13,077</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,425</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">* Excludes the nine months ended September 30, 2019</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Lease</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The FASB issued ASU 2016-02, or the leasing standard or ASC 842, in February 2016. ASU 2016-02 requires lessees to recognize assets and liabilities on the balance sheet for the rights and obligations created by all leases with terms of more than 12 months. ASU 2016-02 also requires certain qualitative and quantitative disclosures designed to give financial statement users information on the amount, timing and uncertainty of cash flows arising from leases. </font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company adopted ASU 2016-02 effective January 1, 2019. The Company has elected to employ the transitionary relief recently offered by the FASB under ASU 2018-11, and implement the new standard without the restatement of comparative periods&#8217; financial information. ASU 2018-11 also provides for recognizing the effects of applying ASU 2016-02 as a cumulative-effect adjustment to retained earnings as of January 1, 2019; however, no such adjustment was required as of January 1, 2019.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has elected to employ the package of practical expedients offered under ASC 842, which allow the Company to not reassess the following:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the presence of a lease in any expired or existing contracts;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the lease classification for any expired or existing leases; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the initial direct costs for any existing leases.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company currently leases </font><font style="font-family:inherit;font-size:10pt;">55,522</font><font style="font-family:inherit;font-size:10pt;"> square feet of office and laboratory space, or the Lease, located at 65 Hayden Avenue, Lexington, Massachusetts, or the Premises, which was classified as an operating lease under ASC 840. The Lease is also classified as an operating lease under ASC 842 in accordance with the Company&#8217;s election of the practical expedient under ASC 842. Pursuant to the package of practical expedients, the Company will also not reassess initial direct costs for the Premises. Additionally, the Company has made the policy election to adopt the practical expedient to not separate lease components from nonlease components for the right-to-use asset class of office and laboratory space. This policy election results in the Company accounting for the lease component, the use of the Premises and the non-lease components, which include the use of the parking garage, building elevators and HVAC, as a single lease component. </font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company occupied the Premises in the third quarter of 2018; however, the Company gained access to the space on January 1, 2018 in order to start making certain tenant improvements. Accordingly, for accounting purposes the lease commencement date was determined to be January 1, 2018 under the prior guidance of ASC 840, and therefore the Company had begun recognizing lease expense as of that date. The Lease term extends </font><font style="font-family:inherit;font-size:10pt;">ten years</font><font style="font-family:inherit;font-size:10pt;"> following January 1, 2019. The Company is entitled to </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;">-year options to extend the Lease; however, these options were not included in the calculation of the Lease asset or liability. The Company has elected to employ the provision under ASC 842 to use hindsight with respect to determining the lease term (i.e., consideration of the actual outcome of lease renewals, termination options and purchase options) and in assessing any impairment of right-of-use assets for existing leases. The Company notes no events such as renewals or termination options have occurred with respect to the Lease for the Premises. Therefore, the hindsight practical expedient under ASC 842 has no impact on the accounting term as previously determined under ASC 840. As of September 30, 2019, the remaining lease term for the Premises is </font><font style="font-family:inherit;font-size:10pt;">9 years and 3 months</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Lease provides for annual base rent of approximately </font><font style="font-family:inherit;font-size:10pt;">$2.8 million</font><font style="font-family:inherit;font-size:10pt;"> in the first year following the Base Rent Commencement Date of January 1, 2019, which increases on a yearly basis by </font><font style="font-family:inherit;font-size:10pt;">3.0%</font><font style="font-family:inherit;font-size:10pt;"> (subject to an abatement of base rent of approximately </font><font style="font-family:inherit;font-size:10pt;">$0.5 million</font><font style="font-family:inherit;font-size:10pt;"> at the beginning of the second year of the Lease term if the Company is not in default under the Lease). There are no variable payments, exercise purchase options, penalties, fees or residual value guarantees under the Lease. The Company is also obligated to pay the Landlord for certain costs, taxes and operating expenses related to the Premises, subject to certain exclusions; however, the Company has concluded that these payments are not in-substance fixed payments and therefore are not included in the calculation of the related lease liability and asset under ASC 842.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company recorded the liability associated with the Lease for the Premises at the present value of the lease payments not yet paid, discounted using the discount rate for the Lease established at the commencement date. As the Lease does not provide an implicit rate, the Company had to estimate the incremental borrowing rate, or IBR, as of the commencement date. The IBR is defined under ASC 842 as the rate of interest that the Company would have to pay to borrow on a collateralized basis over a similar term for an amount equal to the lease payments in a similar economic environment. </font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The IBR for the Lease was determined by establishing a credit rating of the Company using the Rank Order Model. Based on the established credit rating, the Company determined a borrowing rate using the Recovery Rate method, adjusted for the risk-free rate, which resulted in an IBR of approximately </font><font style="font-family:inherit;font-size:10pt;">13%</font><font style="font-family:inherit;font-size:10pt;">. The Company used this IBR of </font><font style="font-family:inherit;font-size:10pt;">13%</font><font style="font-family:inherit;font-size:10pt;"> to discount the remaining lease payments over the remaining lease term and recorded a lease liability of </font><font style="font-family:inherit;font-size:10pt;">$16.9 million</font><font style="font-family:inherit;font-size:10pt;"> on January 1, 2019. This lease liability will be amortized over the remaining lease term in an amount equal to the difference between the cash rent paid and the monthly interest calculated on the remaining lease liability. As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">, the Company had a current lease liability of </font><font style="font-family:inherit;font-size:10pt;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;"> and a non-current lease liability of </font><font style="font-family:inherit;font-size:10pt;">$16.2 million</font><font style="font-family:inherit;font-size:10pt;"> recorded in its condensed consolidated balance sheets.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company received an improvement allowance from the Landlord of approximately </font><font style="font-family:inherit;font-size:10pt;">$5.0 million</font><font style="font-family:inherit;font-size:10pt;"> for certain permitted costs related to the design of Company improvements to the Premises, consisting of normal tenant improvements. The Company is deemed to be the owner of these tenant improvements during the lease term.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> These </font><font style="font-family:inherit;font-size:10pt;">$5.0 million</font><font style="font-family:inherit;font-size:10pt;"> of improvements are included in the Company&#8217;s property, plant and equipment balances in its condensed consolidated balance sheets as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;"> and are depreciated over the shorter of their useful life or the related lease term. </font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 1, 2019, the Company recorded a right-of-use asset in the amount </font><font style="font-family:inherit;font-size:10pt;">$9.5 million</font><font style="font-family:inherit;font-size:10pt;">, which represents the lease liability of </font><font style="font-family:inherit;font-size:10pt;">$16.9 million</font><font style="font-family:inherit;font-size:10pt;">, adjusted for previously accrued rent of </font><font style="font-family:inherit;font-size:10pt;">$2.9 million</font><font style="font-family:inherit;font-size:10pt;"> and previously recorded unamortized lease incentives (the improvement allowance) in the amount of </font><font style="font-family:inherit;font-size:10pt;">$4.5 million</font><font style="font-family:inherit;font-size:10pt;">. The right-of-use asset will be amortized over the remaining lease term in an amount equal to the difference between the calculated straight-line expense of the total lease payments less the monthly interest calculated on the remaining lease liability. As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">, the Company had a long-term lease asset of </font><font style="font-family:inherit;font-size:10pt;">$9.3 million</font><font style="font-family:inherit;font-size:10pt;"> recorded in its condensed consolidated balance sheets.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company will recognize lease expense, calculated as the remaining cost of the lease allocated over the remaining lease term, on a straight-line basis. Lease expense will be presented as part of continuing operations in the condensed consolidated statement of operations and comprehensive loss. For the nine months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">, the Company recognized </font><font style="font-family:inherit;font-size:10pt;">$1.8 million</font><font style="font-family:inherit;font-size:10pt;"> in lease expense.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the nine months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">, the Company paid </font><font style="font-family:inherit;font-size:10pt;">$2.1 million</font><font style="font-family:inherit;font-size:10pt;"> in rent relating to the Lease. As a payment arising from an operating lease, the </font><font style="font-family:inherit;font-size:10pt;">$2.1 million</font><font style="font-family:inherit;font-size:10pt;"> will be classified within operating activities in the Condensed Consolidated Statements of Cash Flows. </font></div><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:450px;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:320px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:116px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Supplemental cash flow information:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">For the nine months ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</font></div></td></tr><tr><td colspan="4" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash paid for amounts included in the measurement of lease liabilities</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating cash flows from operating leases</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,082</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:450px;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:296px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:56px;" rowspan="1" colspan="1"></td><td style="width:11px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:56px;" rowspan="1" colspan="1"></td><td style="width:11px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Supplemental balance sheet information:</font></div></td><td colspan="6" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">For the nine months ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating lease right-of-use assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,317</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating lease liability</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,425</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted average remaining lease term</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.25</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.25</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted average discount rate</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13.08</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:451px;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:322px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:95px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:20px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Maturities of lease liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">For the twelve months ended December 31,</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands)</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">696</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,406</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2021</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,969</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2022</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,058</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2023</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,150</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Thereafter</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,223</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total lease payments</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,502</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less imputed interest</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(13,077</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,425</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">* Excludes the nine months ended September 30, 2019</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Nature of Business</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Concert Pharmaceuticals, Inc., or Concert or the Company, was incorporated on April&#160;12, 2006 as a Delaware corporation with operations based in Lexington, Massachusetts. The Company is a clinical stage biopharmaceutical company that applies its extensive knowledge of deuterium chemistry to discover and develop novel small molecule drugs. The Company&#8217;s approach starts with previously studied compounds, including approved drugs, that the Company believes can be improved with deuterium substitution to provide better pharmacokinetic or metabolic properties, enhancing clinical safety, tolerability or efficacy. The Company believes this approach may enable drug discovery and clinical development that is more efficient and less expensive than conventional small molecule drug research and development. The Company&#8217;s pipeline includes multiple clinical stage candidates and a number of preclinical compounds that it is currently assessing.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company had cash and cash equivalents and investments of </font><font style="font-family:inherit;font-size:10pt;">$121.5 million</font><font style="font-family:inherit;font-size:10pt;"> at </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">. The Company believes that its cash and cash equivalents and investments at </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;"> will be sufficient to allow the Company to fund its current operating plan for at least the next </font><font style="font-family:inherit;font-size:10pt;">twelve months</font><font style="font-family:inherit;font-size:10pt;">. The Company may pursue additional cash resources through public or private financings, by establishing collaborations with or licensing its technology to other companies and through other arrangements.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Since its inception, the Company has generated an accumulated deficit of </font><font style="font-family:inherit;font-size:10pt;">$174.2 million</font><font style="font-family:inherit;font-size:10pt;"> through </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">. The Company's operating results may fluctuate significantly from year to year, depending on the timing and magnitude of clinical trial and other development activities under its current development programs. Substantially all the Company's net losses have resulted from costs incurred in connection with its research and development programs and from general and administrative costs associated with its operations. The Company expects to continue to incur significant expenses and increasing operating losses for at least the next several years. </font></div><div style="line-height:120%;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company is subject to risks common to companies in the biotechnology industry, including, but not limited to, risks of failure or unsatisfactory results of nonclinical studies and clinical trials, the need to obtain additional financing to fund the future development of its pipeline, the need to obtain marketing approval for its product candidates, the need to successfully commercialize and gain market acceptance of its product candidates, dependence on key personnel, protection of proprietary technology, compliance with government regulations, development by competitors of technological innovations and ability to transition from pilot-scale manufacturing to large-scale production of products.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unless otherwise indicated, all amounts in the following tables are in thousands except share and per share amounts</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Recently Adopted Accounting Pronouncements</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2016, the Financial Accounting Standards Board, or FASB, issued ASU 2016-02,&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Leases</font><font style="font-family:inherit;font-size:10pt;">, or Topic 842. ASU 2016-02 requires lessees to recognize assets and liabilities on the balance sheet for the rights and obligations created by leases. On January 1, 2019, the Company adopted ASU 2016-02 and all related amendments. For discussion regarding the impact of this accounting pronouncement, refer to Note 11 appearing elsewhere in this Quarterly Report on Form 10-Q.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2018, the FASB issued ASU&#160;2018-07, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Improvements to Nonemployee Share-Based Payment Accounting</font><font style="font-family:inherit;font-size:10pt;">,</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> </font><font style="font-family:inherit;font-size:10pt;">that expands the scope of Topic 718, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Compensation - Stock Compensation</font><font style="font-family:inherit;font-size:10pt;">, to include share-based payment transactions for acquiring goods and services from nonemployees. ASU 2018-07 provides that an entity should apply the requirements of Topic 718 to nonemployee awards except for certain exemptions specified in the amendment. The Company adopted this new standard effective January 1, 2019, and it did not have a material effect on the consolidated financial statements and related disclosures. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2018, the SEC issued Release No. 33-10532 that amends and clarifies certain financial reporting requirements. The principal change to the Company&#8217;s financial reporting is the inclusion of the annual disclosure requirement of changes in stockholders&#8217; equity in Rule 3-04 of Regulation S-X to interim periods. The Company adopted this new rule beginning with its first Quarterly Report on Form 10-Q for the quarter ended March 31, 2019.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Pending Accounting Pronouncements</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2016, the FASB issued ASU 2016-13, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Financial Instruments-Credit Losses</font><font style="font-family:inherit;font-size:10pt;">. The new standard requires entities to measure all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions and reasonable and supportable forecasts. ASU 2016-13 will become effective for the Company for fiscal years beginning after December 15, 2019, with early adoption permitted. The Company is currently evaluating the impact ASU 2016-13 will have on its financial statements and related disclosures.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2018, the FASB issued ASU 2018-15, Intangible-Goodwill and Other Internal-Use Software (Subtopic 350-40): </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement that is a Service Contract.</font><font style="font-family:inherit;font-size:10pt;"> The standard aligns the requirements for capitalizing implementation costs in a cloud computing arrangement service contract with the requirements for capitalizing implementation costs incurred for internal-use software. The new guidance also prescribes the balance sheet, income statement and cash flow classification of the capitalized implementation costs and related amortization expense, and requires additional quantitative and qualitative disclosures.&#160;ASU 2018-15 is effective for fiscal years beginning after December 15, 2019 and early adoption is permitted. The Company is currently evaluating the impact ASU 2018-15 will have on its financial statements and related disclosures. </font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued expenses and other liabilities consisted of the following:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:67%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">September&#160;30, <br clear="none"/>2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31, <br clear="none"/>2018</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued professional fees and other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">502</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">672</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Employee compensation and benefits</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,245</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,067</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,687</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,476</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred lease incentive, current portion</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">454</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,434</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,669</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash, cash equivalents, available for sale investments, and marketable equity securities included the following at </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;"> and December&#160;31, 2018:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.0234375%;border-collapse:collapse;text-align:left;"><tr><td colspan="19" rowspan="1"></td></tr><tr><td style="width:35%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Average maturity</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Amortized cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Unrealized gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Unrealized losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair value</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">September 30, 2019</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,893</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,893</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market funds</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,253</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,253</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. Treasury obligations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">52 days</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,238</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,238</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,384</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,384</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. Treasury obligations</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">169 days</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38,683</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38,689</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Government agency securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">88 days</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49,443</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49,476</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Investments, available for sale</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">88,126</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">48</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">88,165</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">September 30, 2019</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Acquisition value</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Unrealized gains</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Unrealized losses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair value</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Marketable equity securities (Note 8)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,451</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,435</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.0234375%;border-collapse:collapse;text-align:left;"><tr><td colspan="19" rowspan="1"></td></tr><tr><td style="width:35%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Average maturity</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Amortized cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Unrealized gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Unrealized losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair value</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31, 2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,379</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,379</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market funds</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,643</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,643</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. Treasury obligations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31 days</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,748</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,748</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,770</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,770</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. Treasury obligations</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">151 days</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34,856</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34,849</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Government agency securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">153 days</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100,748</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(60</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100,695</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Investments, available for sale</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">135,604</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(69</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">135,544</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31, 2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Acquisition value</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Unrealized gains</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Unrealized losses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair value</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Marketable equity securities (Note 8)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,451</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,926</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,525</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table illustrates the determination of loss per share for each period presented.</font></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:83.7890625%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:48%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:3%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Nine Months Ended</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands, except per share amounts)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Numerator:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss applicable to common stockholders - basic and diluted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(17,185</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(17,387</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(57,679</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(35,175</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Denominator:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted average shares outstanding - basic and diluted</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,807</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,421</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,703</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,349</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss per share applicable to common stockholders - basic and diluted</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.72</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.74</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2.43</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.51</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Anti-dilutive potential common stock equivalents excluded&#160;from the calculation of net loss per share:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock options</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">214</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">515</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">290</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">758</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restricted stock units</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">410</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">133</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">72</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">214</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Warrants</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">61</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">132</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">72</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">132</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total stock-based compensation expense related to all stock-based options and awards recognized in the condensed consolidated statements of operations and comprehensive loss consisted of:</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:83.7890625%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three&#160;Months&#160;Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,190</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,211</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,728</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,012</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,230</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,520</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,983</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,822</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total stock-based compensation expense</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,420</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,731</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,711</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,834</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The tables below present information about the Company&#8217;s financial assets and liabilities that are measured and carried at fair value as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;"> and December 31, 2018 (in thousands) and indicate the level within the fair value hierarchy where each measurement is classified.</font></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level&#160;2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level&#160;3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">September 30, 2019</font></div></td><td colspan="11" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash equivalents:</font></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,253</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,253</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. Treasury obligations</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,238</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,238</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Investments, available for sale:</font></div></td><td colspan="11" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. Treasury obligations</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38,689</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38,689</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Government agency securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26,873</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,603</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49,476</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Marketable equity securities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate equity securities (Note 8)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,435</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,435</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">96,488</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,603</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">119,091</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level&#160;2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level&#160;3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31, 2018</font></div></td><td colspan="11" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash equivalents:</font></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,643</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,643</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. Treasury obligations</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,748</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,748</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Investments, available for sale:</font></div></td><td colspan="11" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. Treasury obligations</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34,103</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">746</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34,849</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Government agency securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">64,733</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35,962</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100,695</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Marketable equity securities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate equity securities (Note 8)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,525</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,525</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">115,752</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36,708</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">152,460</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash, cash equivalents and restricted cash consisted of the following:</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:67%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">September&#160;30, <br clear="none"/>2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">September&#160;30, <br clear="none"/>2018</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,384</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39,597</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restricted cash</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,157</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,557</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total cash, cash equivalents and restricted cash shown in the statements of cash flows</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34,541</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41,154</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table provides certain information related to the Company's outstanding stock options:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:79.1015625%;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td style="width:42%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Nine Months Ended </font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands, except per share data)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted average fair value of options granted, per option</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.46</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.42</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.95</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17.92</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Aggregate grant date fair value of options vested during the period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,234</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,110</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,070</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,839</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total cash received from exercises of stock options</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,006</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">934</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total intrinsic value of stock options exercised</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">59</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">187</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,167</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,539</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following is a summary of RSU activity, including both service-based and performance-based RSUs for the nine months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:71.09375%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:61%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Number&#160;of</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">RSU Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Grant Date Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at December&#160;31, 2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">228,150</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13.87</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">412,220</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.27</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;Released</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(202,550</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13.87</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;Forfeited</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(25,600</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13.87</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at September 30, 2019</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">412,220</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.27</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-left:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following is a summary of stock option activity for the nine months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Number&#160;of</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Option&#160;Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exercise</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Price&#160;per</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Remaining</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Contractual</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Term</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Aggregate</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Intrinsic</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Value</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(In years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(In&#160;thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at December&#160;31, 2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,557,406</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15.26</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,032,250</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13.25</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(202,508</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.33</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;Forfeited or expired</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(184,474</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18.44</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at September 30, 2019</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,202,674</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14.96</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.99</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">390</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercisable at September 30, 2019</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,429,295</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13.70</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.03</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">390</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested and expected to vest at September 30, 2019</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,049,442</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14.90</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.93</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">390</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:40px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:16px;"><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup>&#160;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">This represents the number of vested stock option shares as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">, plus the number of unvested stock option shares that the Company estimated as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;"> would vest, based on the unvested stock option shares at </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;"> and an estimated forfeiture rate of </font><font style="font-family:inherit;font-size:10pt;">7%</font><font style="font-family:inherit;font-size:10pt;">.</font></div></td></tr></table></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The weighted average fair value of options granted in the three and nine months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;"> and 2018 reflect the following weighted-average assumptions:</font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:83.0078125%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:48%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three&#160;Months&#160;Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected volatility</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">74.37</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">77.72</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">76.86</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">77.19</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected term</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.0 years</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.0 years</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.0 years</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.0 years</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.59</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.98</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.16</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.65</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected dividend yield</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Open Market Sale Agreement</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On March 1, 2019, the Company entered into an Open Market Sale Agreement, or the ATM Agreement, with Jefferies LLC, or Jefferies, with respect to an at-the-market offering program under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock, par value </font><font style="font-family:inherit;font-size:10pt;">$0.001</font><font style="font-family:inherit;font-size:10pt;"> per share, having an aggregate offering price of up to </font><font style="font-family:inherit;font-size:10pt;">$50 million</font><font style="font-family:inherit;font-size:10pt;">, referred to as Placement Shares, through Jefferies as its sales agent. The Company will pay Jefferies a commission equal to </font><font style="font-family:inherit;font-size:10pt;">3.0%</font><font style="font-family:inherit;font-size:10pt;"> of the gross sales proceeds of any Placement Shares sold through Jefferies under the ATM Agreement, and also has provided Jefferies with customary indemnification and contribution rights. In addition, the Company has agreed to reimburse certain legal expenses and fees by Jefferies in connection with the offering up to a maximum of </font><font style="font-family:inherit;font-size:10pt;">$50,000</font><font style="font-family:inherit;font-size:10pt;">, in addition to certain ongoing disbursements of Jefferies' counsel. As of </font><font style="font-family:inherit;font-size:10pt;">November&#160;4, 2019</font><font style="font-family:inherit;font-size:10pt;">, the Company has sold </font><font style="font-family:inherit;font-size:10pt;">36,167</font><font style="font-family:inherit;font-size:10pt;"> shares of its common stock in accordance with the ATM Agreement for net proceeds of </font><font style="font-family:inherit;font-size:10pt;">$0.4 million</font><font style="font-family:inherit;font-size:10pt;">, after payment of cash commissions of </font><font style="font-family:inherit;font-size:10pt;">3.0</font><font style="font-family:inherit;font-size:10pt;"> percent of the gross proceeds to its sales agent. Additionally, the Company incurred approximately </font><font style="font-family:inherit;font-size:10pt;">$0.3 million</font><font style="font-family:inherit;font-size:10pt;"> related to legal, accounting and other fees in connection with the ATM Agreement as of September 30, 2019.</font></div></div> EX-101.SCH 7 cnce-20190930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 2106100 - Disclosure - Accrued Expenses and Other Liabilities link:presentationLink link:calculationLink link:definitionLink 2406402 - Disclosure - Accrued Expenses and Other Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 2306301 - Disclosure - Accrued Expenses and Other Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 2102100 - Disclosure - Basis of Presentation and Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 2402402 - Disclosure - Basis of Presentation and Significant Accounting Policies - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2202201 - Disclosure - Basis of Presentation and Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 2104100 - Disclosure - Cash, Cash Equivalents, Investments and Marketable Equity Securities link:presentationLink link:calculationLink link:definitionLink 2404403 - Disclosure - Cash, Cash Equivalents, Investments and Marketable Equity Securities - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2404402 - Disclosure - Cash, Cash Equivalents, Investments and Marketable Equity Securities - Cash Equivalents and Short-term and Long-term Investments (Details) link:presentationLink link:calculationLink link:definitionLink 2304301 - Disclosure - Cash, Cash Equivalents, Investments and Marketable Equity Securities (Tables) link:presentationLink link:calculationLink link:definitionLink 1001000 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 1001501 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1003000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 1002000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 1002000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 1002001 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (UNAUDITED) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0001000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 2103100 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 2403402 - Disclosure - Fair Value Measurements - Financial Assets and Liabilities Recognized at Fair Value (Details) link:presentationLink link:calculationLink link:definitionLink 2303301 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 2107100 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 2111100 - Disclosure - Lease link:presentationLink link:calculationLink link:definitionLink 2411402 - Disclosure - Lease - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2411405 - Disclosure - Lease - Lease Maturities (Details) link:presentationLink link:calculationLink link:definitionLink 2411404 - Disclosure - Lease - Supplemental Balance Sheet Information (Details) link:presentationLink link:calculationLink link:definitionLink 2411403 - Disclosure - Lease - Supplemental Cash Flow Information (Details) link:presentationLink link:calculationLink link:definitionLink 2311301 - Disclosure - Lease (Tables) link:presentationLink link:calculationLink link:definitionLink 2110100 - Disclosure - Loss Per Share link:presentationLink link:calculationLink link:definitionLink 2410402 - Disclosure - Loss Per Share - Computation of Basic and Diluted Earnings (Loss) Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 2310301 - Disclosure - Loss Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 2101100 - Disclosure - Nature of Business link:presentationLink link:calculationLink link:definitionLink 2401401 - Disclosure - Nature of Business - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2112100 - Disclosure - Open Market Sale Agreement link:presentationLink link:calculationLink link:definitionLink 2412401 - Disclosure - Open Market Sale Agreement (Details) link:presentationLink link:calculationLink link:definitionLink 2105100 - Disclosure - Restricted Cash link:presentationLink link:calculationLink link:definitionLink 2405402 - Disclosure - Restricted Cash (Details) link:presentationLink link:calculationLink link:definitionLink 2305301 - Disclosure - Restricted Cash (Tables) link:presentationLink link:calculationLink link:definitionLink 2108100 - Disclosure - Revenue link:presentationLink link:calculationLink link:definitionLink 2408401 - Disclosure - Revenue - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2408408 - Disclosure - Revenue - Cipla (Details) link:presentationLink link:calculationLink link:definitionLink 2408407 - Disclosure - Revenue - Processa (Details) link:presentationLink link:calculationLink link:definitionLink 2408404 - Disclosure - Revenue - Vertex (Details) link:presentationLink link:calculationLink link:definitionLink 2109100 - Disclosure - Stock-Based Compensation link:presentationLink link:calculationLink link:definitionLink 2409402 - Disclosure - Stock-Based Compensation - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2409404 - Disclosure - Stock-Based Compensation - Estimated Weighted-Average Assumptions of Options Granted (Details) link:presentationLink link:calculationLink link:definitionLink 2409405 - Disclosure - Stock-Based Compensation - Fair Value of Options (Details) link:presentationLink link:calculationLink link:definitionLink 2409403 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense Related to All Stock Based Awards Recognized in Statements of Operations and Comprehensive Income (Loss) (Details) link:presentationLink link:calculationLink link:definitionLink 2409407 - Disclosure - Stock-Based Compensation - Summary of RSU Activity (Details) link:presentationLink link:calculationLink link:definitionLink 2409406 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink 2309301 - Disclosure - Stock-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 cnce-20190930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 9 cnce-20190930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 10 cnce-20190930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Accounting Policies [Abstract] Basis of Presentation and Significant Accounting Policies Basis of Presentation and Significant Accounting Policies [Text Block] Fair Value Disclosures [Abstract] Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Investment Type [Axis] Investment Type [Axis] Investments [Domain] Investments [Domain] Shorter maturity Investments with Maturity Period One [Member] Investments with Maturity Period One [Member] Longer maturity Investments with Maturity Period Two [Member] Investments with Maturity Period Two [Member] Corporate equity securities Marketable Equity Securities, Corporate Equity Securities [Member] Marketable Equity Securities, Corporate Equity Securities [Member] Measurement Frequency [Axis] Measurement Frequency [Axis] Measurement Frequency [Domain] Measurement Frequency [Domain] Fair value measurements Fair Value, Recurring [Member] Asset Class [Axis] Asset Class [Axis] Asset Class [Domain] Asset Class [Domain] Money market funds Money Market Funds [Member] U.S. Treasury obligations US Treasury Securities [Member] Government agency securities US Government Agencies Debt Securities [Member] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Level 1 Fair Value, Inputs, Level 1 [Member] Level 2 Fair Value, Inputs, Level 2 [Member] Level 3 Fair Value, Inputs, Level 3 [Member] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair value, cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Fair value, investments available-for-sale securities Debt Securities, Available-for-sale Fair value, marketable equity securities Investments, Fair Value Disclosure Total financial assets at fair value Assets, Fair Value Disclosure Earnings Per Share [Abstract] Computation of Basic and Diluted Earnings (Loss) Per Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Leases [Abstract] Operating lease right-of-use assets Operating Lease, Right-of-Use Asset Operating lease liability Operating Lease, Liability Weighted average remaining lease term Operating Lease, Weighted Average Remaining Lease Term Weighted average discount rate Operating Lease, Weighted Average Discount Rate, Percent Loss Per Share Earnings Per Share [Text Block] Lease, Cost Lease, Cost [Table Text Block] Assets and Liabilities, Lessee Assets and Liabilities, Lessee [Table Text Block] Assets and Liabilities, Lessee [Table Text Block] Lessee, Operating Lease, Liability, Maturity Lessee, Operating Lease, Liability, Maturity [Table Text Block] Document And Entity Information [Abstract] Document And Entity Information [Abstract] Entity Current Reporting Status Entity Current Reporting Status Document Type Document Type Amendment Flag Amendment Flag Document Period End Date Document Period End Date Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Entity Filer Category Entity Filer Category Entity Small Business Entity Small Business Entity Emerging Growth Company Entity Emerging Growth Company Entity Ex Transition Period Entity Ex Transition Period Entity Shell Company Entity Shell Company Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Cash and Cash Equivalents [Abstract] Restricted Cash Cash and Cash Equivalents Disclosure [Text Block] Equity [Abstract] Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table] Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table] Subsequent Event Type [Axis] Subsequent Event Type [Axis] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Subsequent Event Subsequent Event [Member] Subsidiary, Sale of Stock [Line Items] Subsidiary, Sale of Stock [Line Items] Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Sale of stock, authorized amount Sale of Stock, Authorized Amount Sale of Stock, Authorized Amount Sale of stock, commission rate Sale of Stock, Commission Rate Sale of Stock, Commission Rate Legal expense maximum Sale of Stock, Legal Expense Maximum Sale of Stock, Legal Expense Maximum Number of shares issued in transaction (in shares) Sale of Stock, Number of Shares Issued in Transaction Proceeds from issuance of common stock Sale of Stock, Consideration Received on Transaction Professional fees Professional Fees Share-based Payment Arrangement [Abstract] Stock-Based Compensation Share-based Payment Arrangement [Text Block] Stock-Based Compensation Expense Related to All Stock Based Awards Recognized in Statements of Operations and Comprehensive Income (Loss) Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Estimated Weighted-Average Assumptions of Options Granted Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Certain Information Related to Outstanding Stock Options Schedule of Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Grant Date Intrinsic Value [Table Text Block] Summary of Stock Option Activity Share-based Payment Arrangement, Option, Activity [Table Text Block] Summary of RSU Activity Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block] Lease Lessee, Operating Leases [Text Block] Statement of Financial Position [Abstract] Assets Assets [Abstract] Current assets: Assets, Current [Abstract] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Investments, available for sale Debt Securities, Available-for-sale, Current Marketable equity securities Marketable Securities, Current Interest receivable Interest Receivable, Current Accounts receivable Accounts Receivable, after Allowance for Credit Loss, Current Contract asset (Note 8) Contract with Customer, Asset, Net, Current Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Total current assets Assets, Current Property and equipment, net Property, Plant and Equipment, Net Restricted cash Restricted Cash, Noncurrent Other assets Other Assets, Noncurrent Income taxes receivable Income Taxes Receivable Operating lease right-of-use assets, long-term (Note 11) Total assets Assets Liabilities and stockholders’ equity Liabilities and Equity [Abstract] Current liabilities: Liabilities, Current [Abstract] Accounts payable Accounts Payable, Current Accrued expenses and other liabilities Accrued Liabilities and Other Liabilities Income taxes payable Accrued Income Taxes, Current Deferred revenue, current portion Contract with Customer, Liability, Current Lease liability, current portion (Note 11) Operating Lease, Liability, Current Total current liabilities Liabilities, Current Deferred revenue, net of current portion Contract with Customer, Liability, Noncurrent Deferred lease incentive, net of current portion Incentive from Lessor Deferred rent, net of current portion Deferred Rent Credit, Noncurrent Lease liability, net of current portion (Note 11) Operating Lease, Liability, Noncurrent Total liabilities Liabilities Commitments (Note 11) Commitments and Contingencies Stockholders’ equity: Stockholders' Equity Attributable to Parent [Abstract] Preferred stock, $0.001 par value per share; 5,000,000 shares authorized; no shares issued and outstanding in 2019 and 2018, respectively Preferred Stock, Value, Issued Common stock, $0.001 par value per share; 100,000,000 shares authorized; 24,030,711 and 23,518,690 shares issued and 23,841,155 and 23,437,587 outstanding in 2019 and 2018, respectively Common Stock, Value, Issued Additional paid-in capital Additional Paid in Capital, Common Stock Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated deficit Retained Earnings (Accumulated Deficit) Total stockholders’ equity Stockholders' Equity Attributable to Parent Total liabilities and stockholders’ equity Liabilities and Equity Cash, Cash Equivalents, Investments and Marketable Equity Securities Cash, Cash Equivalents and Investments [Text Block] Cash, Cash Equivalents and Investments [Text Block] Fair Value Measurements Fair Value Disclosures [Text Block] Organization, Consolidation and Presentation of Financial Statements [Abstract] Revenue Collaborative Arrangement Disclosure [Text Block] Income Tax Disclosure [Abstract] Income Taxes Income Tax Disclosure [Text Block] Revenue Recognition, Milestone Method [Table] Revenue Recognition, Milestone Method [Table] Counterparty Name [Axis] Counterparty Name [Axis] Counterparty Name [Domain] Counterparty Name [Domain] Processa Processa [Member] Processa [Member] Revenue Recognition, Milestone Method [Line Items] Revenue Recognition, Milestone Method [Line Items] Equity received from sale (in shares) Noncash or Part Noncash Transaction, Equity Received From Sale Of License Noncash or Part Noncash Transaction, Equity Received From Sale Of License Allocable arrangement consideration Revenue from Contract with Customer, Excluding Assessed Tax Nature of Business Nature of Operations [Text Block] Debt securities, realized gain Debt Securities, Available-for-sale, Realized Gain Debt securities, realized loss Debt Securities, Available-for-sale, Realized Loss Equity securities, realized gain Equity Securities, FV-NI, Realized Gain Equity securities, realized loss Equity Securities, FV-NI, Realized Loss Other than temporary impairment losses, investments Other than Temporary Impairment Losses, Investments Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities [Axis] Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Stock options Share-based Payment Arrangement, Option [Member] Restricted stock units Restricted Stock Units (RSUs) [Member] Warrants Warrant [Member] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Numerator: Net Income (Loss) Available to Common Stockholders, Basic [Abstract] Net loss applicable to common stockholders - basic and diluted Net Income (Loss) Attributable to Parent Denominator: Weighted Average Number of Shares Outstanding, Diluted [Abstract] Weighted-average number of common shares used in net loss per share applicable to common stockholders - basic and diluted (in shares) Weighted Average Number of Shares Outstanding, Basic and Diluted Net loss per share applicable to common stockholders - basic and diluted (in dollars per share) Earnings Per Share, Basic and Diluted Anti-dilutive potential common stock equivalents excluded from the calculation of net income (loss) per share: Antidilutive Securities Excluded From Computation Earnings Per Share [Abstract] Antidilutive Securities Excluded From Computation Earnings Per Share [Abstract] Anti-dilutive stock options, restricted stock units, and warrants (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Cash Equivalents and Short-term and Long-term Investments Cash, Cash Equivalents and Investments [Table Text Block] Open Market Sale Agreement Stockholders' Equity Note Disclosure [Text Block] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Statistical Measurement [Axis] Statistical Measurement [Axis] Statistical Measurement [Domain] Statistical Measurement [Domain] Minimum Minimum [Member] Maximum Maximum [Member] Plan Name [Axis] Plan Name [Axis] Plan Name [Domain] Plan Name [Domain] 2014 Stock Incentive Plan Two Thousand Fourteen Stock Incentive Plan [Member] Two Thousand Fourteen Stock Incentive Plan [Member] Award Type [Axis] Award Type [Axis] Award Type [Domain] Award Type [Domain] Vesting [Axis] Vesting [Axis] Vesting [Domain] Vesting [Domain] Tranche one Share-based Payment Arrangement, Tranche One [Member] Tranche two Share-based Payment Arrangement, Tranche Two [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Vesting period Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period Awards expiration period Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period Additional shares issued under the plan (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized Common stock available for future award grant (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant Total unrecognized compensation cost related to unvested options Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Total unrecognized compensation cost, weighted-average recognition period Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Number of RSU shares, granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Award vesting percentage Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage Total unrecognized compensation cost related to restricted stock units Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount Revenue from Contract with Customer [Abstract] Revenue, Initial Application Period Cumulative Effect Transition [Table] Revenue, Initial Application Period Cumulative Effect Transition [Table] Cipla Cipla [Member] Cipla [Member] Deferred Revenue Arrangement Type [Axis] Deferred Revenue Arrangement Type [Axis] Deferred Revenue [Domain] Deferred Revenue [Domain] Achievement of Certain Milestones Achievement of Certain Milestones [Member] Achievement of Certain Milestones [Member] First Milestone First Milestone [Member] First Milestone [Member] Revenue, Initial Application Period Cumulative Effect Transition [Line Items] Revenue, Initial Application Period Cumulative Effect Transition [Line Items] Deferred revenue Increase (Decrease) in Contract with Customer, Liability Option to purchase inventory, valuation Collaboration Agreement, Option to Purchase Inventory, Valuation Collaboration Agreement, Option to Purchase Inventory, Valuation Eligible payments receivable Contracts Receivable, Claims and Uncertain Amounts License and research and development revenue Financial Assets and Liabilities Recognized at Fair Value Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] 2019 Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year 2020 Lessee, Operating Lease, Liability, Payments, Due Year Two 2021 Lessee, Operating Lease, Liability, Payments, Due Year Three 2022 Lessee, Operating Lease, Liability, Payments, Due Year Four 2023 Lessee, Operating Lease, Liability, Payments, Due Year Five Thereafter Lessee, Operating Lease, Liability, Payments, Due after Year Five Total lease payments Lessee, Operating Lease, Liability, Payments, Due Less imputed interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Total Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding Common stock, shares authorized (in shares) Common Stock, Shares Authorized Common stock, shares issued (in shares) Common Stock, Shares, Issued Common stock, shares outstanding (in shares) Common Stock, Shares, Outstanding Number of RSU Shares Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Number of RSU shares, Outstanding beginning balance (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Number of RSU shares, Granted (in shares) Number of RSU shares, Released (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Number of RSU shares, Forfeited (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period Number of RSU shares, Outstanding ending balance (in shares) Weighted Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Weighted average grant date fair value, Outstanding at beginning of year (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Weighted average grant date fair value, Granted (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Weighted average grant date fair value, Released (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Weighted average grant date fair value, Forfeited (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Weighted average grant date fair value, Outstanding at ending of year (in dollars per share) Statement of Stockholders' Equity [Abstract] Statement [Table] Statement [Table] Adjustments for New Accounting Pronouncements [Axis] Adjustments for New Accounting Pronouncements [Axis] Type of Adoption [Domain] Type of Adoption [Domain] ASC 606 Accounting Standards Update 2014-09 [Member] Equity Components [Axis] Equity Components [Axis] Equity Component [Domain] Equity Component [Domain] Common Stock Common Stock [Member] In Treasury Treasury Stock [Member] Additional paid-in capital Additional Paid-in Capital [Member] Accumulated other comprehensive income AOCI Attributable to Parent [Member] Accumulated deficit Retained Earnings [Member] Statement [Line Items] Statement [Line Items] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Beginning balance (in shares) Shares, Outstanding Beginning balance Exercise of stock options (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Exercise of stock options Stock Issued During Period, Value, Stock Options Exercised Release of restricted stock units (in shares) Stock Issued During Period, Shares, Restricted Stock Award, Forfeited Release of restricted stock units Stock Issued During Period, Value, Restricted Stock Award, Forfeitures Unrealized gain (loss) on short-term investments Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, after Tax Stock-based compensation expense APIC, Share-based Payment Arrangement, Increase for Cost Recognition Proceeds from at-the-market offering (in shares) Stock Issued During Period, Shares, New Issues Proceeds from at-the-market offering Stock Issued During Period, Value, New Issues Exercise of stock warrants (in shares) Adjustments to Additional Paid in Capital, Warrant Exercised, Shares Adjustments to Additional Paid in Capital, Warrant Exercised, Shares Exercise of stock warrants Adjustments to Additional Paid in Capital, Warrant Exercised Adjustments to Additional Paid in Capital, Warrant Exercised Offering expenses incurred Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs Adoption of ASC 606 as of January 1, 2018 Cumulative Effect of New Accounting Principle in Period of Adoption Net loss Ending balance (in shares) Ending balance Number of Option Shares Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Number of options, Outstanding beginning balance (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Number of options, Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Number of options, Exercised (in shares) Number of options, Forfeited or expired (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period Number of options, Outstanding ending balance (in shares) Number of options, Exercisable (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Number of options, Vested and expected to vest (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Weighted Average Exercise Price per Share Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Weighted average exercise price per share, Outstanding at beginning of year (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Weighted average exercise price per share, Granted (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Weighted average exercise price per share, Exercised (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Weighted average exercise price per share, Forfeited or expired (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price Weighted average exercise price per share, Outstanding ending balance (in dollars per share) Weighted average exercise price per share, Exercisable (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Weighted average exercise price per share, Vested and expected to vest (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Weighted Average Remaining Contractual Term (In years) Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract] Weighted average remaining contractual term, Outstanding Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Weighted average remaining contractual term, Exercisable Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Weighted average remaining contractual term, Vested and expected to vest Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Aggregate Intrinsic Value Share Based Compensation Arrangement By Share Based Payment Award Aggregate Intrinsic Value [Abstract] Share Based Compensation Arrangement By Share Based Payment Award Aggregate Intrinsic Value [Abstract] Aggregate intrinsic value, Outstanding Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Aggregate intrinsic value, Exercisable Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value Aggregate intrinsic value, Vested and expected to vest Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Estimated forfeiture rate Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Estimated Forfeiture Rate Used In Determining Amount Of Stock Based Compensation Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Estimated Forfeiture Rate Used In Determining Amount Of Stock Based Compensation Payables and Accruals [Abstract] Accrued Expenses and Other Liabilities Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block] Accrued Expenses and Other Liabilities Schedule of Accounts Payable and Accrued Liabilities [Table Text Block] Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Use of Estimates and Summary of Significant Accounting Policies Use Of Estimates And Summary Of Significant Accounting Policies [Policy Text Block] Use Of Estimates And Summary Of Significant Accounting Policies [Policy Text Block] Recently Adopted Accounting Pronouncements and Pending Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Guarantor Obligations, Nature [Axis] Guarantor Obligations, Nature [Axis] Guarantor Obligations, Nature [Domain] Guarantor Obligations, Nature [Domain] Indemnification agreement Indemnification Agreement [Member] Disposal Group Classification [Axis] Disposal Group Classification [Axis] Disposal Group Classification [Domain] Disposal Group Classification [Domain] Disposed of by sale, not discontinued operations Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member] Disposal Group Name [Axis] Disposal Group Name [Axis] Disposal Group Name [Domain] Disposal Group Name [Domain] Assets for synthesis and research and development for treating Cystic Fibrosis Assets for Synthesis and Research and Development for Treating Cystic Fibrosis [Member] Assets for Synthesis and Research and Development for Treating Cystic Fibrosis [Member] Celgene Celgene [Member] Celgene. GSK Gsk [Member] Gsk. Project [Axis] Project [Axis] Project [Domain] Project [Domain] CTP-730 CTP-730 [Member] CTP-730 [Member] One of the other additional license programs Other Additional License Program [Member] Other additional license program. Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Number of segments Number of Reportable Segments Contract asset Amount released Guarantor Obligations, Amount Released Guarantor Obligations, Amount Released Contract liability Contract with Customer, Liability Restricted cash Total cash, cash equivalents and restricted cash shown in the statements of cash flows Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Cash and cash equivalents and investments Cash, Cash Equivalents, and Short-term Investments Period of sufficiency of cash resources to fund operating plan Operating Plan, Sufficiency of Cash, Cash and Investments to Fund Plan, Time Period Operating Plan, Sufficiency of Cash, Cash and Investments to Fund Plan, Time Period Accumulated deficit Number of segments Number of Operating Segments Contingent Consideration by Type [Axis] Contingent Consideration by Type [Axis] Contingent Consideration Type [Domain] Contingent Consideration Type [Domain] Contingent consideration asset, After achievement of milestone events Contingent Consideration Asset, After Achievement of Milestone Events [Member] Contingent Consideration Asset, After Achievement of Milestone Events [Member] Cash consideration Disposal Group, Including Discontinued Operation, Consideration Contingent consideration receivable Disposal Group, Including Discontinued Operation, Contingent Consideration Arrangements, Range of Outcomes, Value, High Disposal Group, Including Discontinued Operation, Contingent Consideration Arrangements, Range of Outcomes, Value, High Weighted average grant date fair value of options granted, per option (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Aggregate grant date fair value of options vested during the period Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value Total cash received from exercises of stock options Proceeds from Stock Options Exercised Total intrinsic value of stock options exercised Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value Statement of Cash Flows [Abstract] Operating activities Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Depreciation and amortization Depreciation, Depletion and Amortization, Nonproduction Stock-based compensation expense Share-based Payment Arrangement, Noncash Expense Accretion of premiums and discounts on investments Accretion (Amortization) of Discounts and Premiums, Investments Amortization of deferred lease incentive Amortization Of Deferred Lease Incentives Amortization Of Deferred Lease Incentives Non-cash license consideration (Note 8) Noncash Revenue Recognized Noncash Revenue Recognized Other noncash items Other Noncash Income (Expense) Unrealized loss on marketable equity securities Equity Securities, FV-NI, Unrealized Gain (Loss) Loss on disposal of asset Gain (Loss) on Disposition of Assets Non-cash lease expense (Note 11) Lease Expense, Operating Activities, Noncash Expense Lease Expense, Operating Activities, Noncash Expense Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Accounts receivable Increase (Decrease) in Accounts Receivable Interest receivable Increase (Decrease) in Accrued Interest Receivable, Net Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense and Other Assets Contract asset Increase (Decrease) in Contract with Customer, Asset Other assets Increase (Decrease) in Other Operating Assets Accounts payable Increase (Decrease) in Accounts Payable Accrued expenses and other liabilities Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities Income taxes receivable Increase (Decrease) in Income Taxes Receivable Income taxes payable Increase (Decrease) in Income Taxes Payable Deferred rent Increase (Decrease) in Deferred Liabilities Operating lease liability (Note 11) Operating Lease, Liability, Increase (Decrease) Operating Lease, Liability, Increase (Decrease) Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Investing activities Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract] Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Purchases of investments Payments to Acquire Investments Maturities of investments Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale Net cash provided by investing activities Net Cash Provided by (Used in) Investing Activities Financing activities Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract] Proceeds from exercises of stock options Proceeds from exercise of warrants Proceeds from Warrant Exercises Repurchase of common stock pursuant to share surrender Payments for Repurchase of Common Stock Proceeds from at-the-market offering, net of issuance costs Proceeds from Issuance of Common Stock Net cash provided by (used in) financing activities Net Cash Provided by (Used in) Financing Activities Net increase in cash and cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect Cash, cash equivalents and restricted cash at beginning of period Cash, cash equivalents and restricted cash at end of period Supplemental cash flow information: Supplemental Cash Flow Information [Abstract] Cash paid for income taxes Income Taxes Paid Purchases of property and equipment unpaid at period end Capital Expenditures Incurred but Not yet Paid Public offering costs unpaid at period end Public Offering Costs Incurred But Not Yet Paid Public Offering Costs Incurred But Not Yet Paid Cash paid included in measurement of lease liabilities Lease Liabilities, Cash Paid Lease Liabilities, Cash Paid Tenant improvements paid by landlord Payments for (Proceeds from) Tenant Allowance Income Statement [Abstract] Product and Service [Axis] Product and Service [Axis] Product and Service [Domain] Product and Service [Domain] License and Research and Development Revenue License and Research and Development Revenue [Member] License and Research and Development Revenue [Member] Revenue: Revenues [Abstract] Operating expenses: Operating Expenses [Abstract] Research and development Research and Development Expense General and administrative General and Administrative Expense Total operating expenses Operating Expenses Loss from operations Operating Income (Loss) Investment income Investment Income, Dividend Unrealized gain (loss) on marketable equity securities Marketable Securities, Unrealized Gain (Loss) Loss before tax provision Income (Loss) Attributable to Parent, before Tax Provision for income taxes Income Tax Expense (Benefit) Net Loss Other comprehensive income: Other Comprehensive Income (Loss), Net of Tax [Abstract] Unrealized (loss) gain on investments, available for sale Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Income Statement Location [Axis] Income Statement Location [Axis] Income Statement Location [Domain] Income Statement Location [Domain] Research and development Research and Development Expense [Member] General and administrative General and Administrative Expense [Member] Stock-based compensation expense Share-based Payment Arrangement, Expense Unrealized gain on short-term investments, tax Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, Tax New Accounting Pronouncements or Change in Accounting Principle [Table] New Accounting Pronouncements or Change in Accounting Principle [Table] Accounting Standards Update 2016-02 Accounting Standards Update 2016-02 [Member] New Accounting Pronouncements or Change in Accounting Principle [Line Items] New Accounting Pronouncements or Change in Accounting Principle [Line Items] Area of leased office and laboratory space Area Of Leased Office And Laboratory Space Area of leased office and laboratory space. Term of contract Lessee, Operating Lease, Term of Contract Number of extensions Operating Lease, Option to Extend, Number of Extensions Operating Lease, Option to Extend, Number of Extensions Length of extension Lessee, Operating Lease, Renewal Term Annual base rent amount Operating Leases, Annual Base Rent Amount Operating Leases, Annual Base Rent Amount Annual rent increase, percent Operating Lease, Annual Rent Increase, Percent Operating Lease, Annual Rent Increase, Percent Abatement of base rent amount Operating Leases, Abatement Of Base Rent Amount Operating Leases, Abatement Of Base Rent Amount Discount rate Lessee, Operating Lease, Discount Rate Lease liability, current portion Lease liability, net of current portion Tenant improvement allowance Tenant Improvements Reduction to accrued rent Accrued Rent Reduction to incentive to lessee Incentive to Lessee Operating lease, expense Operating Lease, Expense Operating lease, payments Operating Lease, Payments Expected volatility Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate Expected term Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Risk-free interest rate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Expected dividend yield Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate Accrued professional fees and other Accrued Professional Fees, Current Employee compensation and benefits Employee-related Liabilities, Current Research and development expenses Accrued Research And Development Expense Current Accrued Research And Development Expense Current Deferred lease incentive, current portion Lease Incentive, Payable, Current Accrued expenses and other liabilities Restrictions on Cash and Cash Equivalents Restrictions on Cash and Cash Equivalents [Table Text Block] Operating cash flows from operating leases Measurement Input Type [Axis] Measurement Input Type [Axis] Measurement Input Type [Domain] Measurement Input Type [Domain] Measurement Input, Expected Term Measurement Input, Expected Term [Member] Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Domain] Cash and Cash Equivalents [Domain] Cash Cash [Member] Investments, available for sale Available-for-sale Securities [Member] Marketable equity securities Cash and Cash Equivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract] Amortized cost, cash and cash equivalents Fair value, cash and cash equivalent Cash and Cash Equivalents, Term Cash and Cash Equivalents, Term Cash and Cash Equivalents, Term Debt Securities Debt Securities [Abstract] Average maturity Debt Securities, Available-for-sale, Term Amortized cost, investments available for sale Debt Securities, Available-for-sale, Amortized Cost Unrealized gains Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax Unrealized losses Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax Fair value, available-for-sale securities Marketable Securities Marketable Securities [Abstract] Amortized cost Equity Securities, FV-NI, Cost Unrealized gains Equity Securities, FV-NI, Accumulated Gross Unrealized Gain, before Tax Equity Securities, FV-NI, Accumulated Gross Unrealized Gain, before Tax Unrealized losses Equity Securities, FV-NI, Accumulated Gross Unrealized Loss, before Tax Equity Securities, FV-NI, Accumulated Gross Unrealized Loss, before Tax Fair value Equity Securities, FV-NI EX-101.PRE 11 cnce-20190930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 12 patientsaltimprovementv2a01.jpg begin 644 patientsaltimprovementv2a01.jpg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ⅅ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pipelineoct2019.jpg begin 644 pipelineoct2019.jpg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end GRAPHIC 14 respondersgreatera01.jpg begin 644 respondersgreatera01.jpg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end XML 15 R25.htm IDEA: XBRL DOCUMENT v3.19.3
Stock-Based Compensation (Tables)
 9 Months Ended
Sep. 30, 2019
Share-based Payment Arrangement [Abstract]  
Stock-Based Compensation Expense Related to All Stock Based Awards Recognized in Statements of Operations and Comprehensive Income (Loss)
Total stock-based compensation expense related to all stock-based options and awards recognized in the condensed consolidated statements of operations and comprehensive loss consisted of:

 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2019
 
2018
 
2019
 
2018
Research and development
$
1,190

 
$
1,211

 
$
3,728

 
$
4,012

General and administrative
1,230

 
1,520

 
3,983

 
4,822

Total stock-based compensation expense
$
2,420

 
$
2,731

 
$
7,711

 
$
8,834
Estimated Weighted-Average Assumptions of Options Granted
The weighted average fair value of options granted in the three and nine months ended September 30, 2019 and 2018 reflect the following weighted-average assumptions:
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2019
 
2018
 
2019
 
2018
Expected volatility
74.37
%
 
77.72
%
 
76.86
%
 
77.19
%
Expected term
6.0 years

 
6.0 years

 
6.0 years

 
6.0 years

Risk-free interest rate
1.59
%
 
2.98
%
 
2.16
%
 
2.65
%
Expected dividend yield
—
%
 
—
%
 
—
%
 
—
%
Certain Information Related to Outstanding Stock Options
The following table provides certain information related to the Company's outstanding stock options:
 
 
Three Months Ended
September 30,
 
Nine Months Ended
September 30,
 
 
2019
 
2018
 
2019
 
2018
 
 
(in thousands, except per share data)
Weighted average fair value of options granted, per option
 
$
6.46

 
$
10.42

 
$
8.95

 
$
17.92

Aggregate grant date fair value of options vested during the period
 
$
2,234

 
$
2,110

 
$
7,070

 
$
5,839

Total cash received from exercises of stock options
 
$
36

 
$
23

 
$
1,006

 
$
934

Total intrinsic value of stock options exercised
 
$
59

 
$
187

 
$
1,167

 
$
2,539
Summary of Stock Option Activity
The following is a summary of stock option activity for the nine months ended September 30, 2019:
 
Number of
Option Shares
 
Weighted
Average
Exercise
Price per
Share
 
Weighted
Average
Remaining
Contractual
Term
 
Aggregate
Intrinsic
Value
 
 
 
 
 
(In years)
 
(In thousands)
Outstanding at December 31, 2018
3,557,406

 
$
15.26

 
 
 
 
      Granted
1,032,250

 
$
13.25

 
 
 
 
      Exercised
(202,508
)
 
$
8.33

 
 
 
 
      Forfeited or expired
(184,474
)
 
$
18.44

 
 
 
 
Outstanding at September 30, 2019
4,202,674

 
$
14.96

 
6.99
 
$
390

Exercisable at September 30, 2019
2,429,295

 
$
13.70

 
6.03
 
$
390

Vested and expected to vest at September 30, 2019(1)
4,049,442

 
$
14.90

 
6.93
 
$
390


(1) 
This represents the number of vested stock option shares as of September 30, 2019, plus the number of unvested stock option shares that the Company estimated as of September 30, 2019 would vest, based on the unvested stock option shares at September 30, 2019 and an estimated forfeiture rate of 7%.
Summary of RSU Activity
The following is a summary of RSU activity, including both service-based and performance-based RSUs for the nine months ended September 30, 2019:

 
Number of
RSU Shares
 
Weighted
Average
Grant Date Fair Value
 
 
 
 
Outstanding at December 31, 2018
228,150

 
$
13.87

      Granted
412,220

 
$
10.27

      Released
(202,550
)
 
$
13.87

      Forfeited
(25,600
)
 
$
13.87

Outstanding at September 30, 2019
412,220

 
$
10.27
XML 16 R21.htm IDEA: XBRL DOCUMENT v3.19.3
Fair Value Measurements (Tables)
 9 Months Ended
Sep. 30, 2019
Fair Value Disclosures [Abstract]  
Financial Assets and Liabilities Recognized at Fair Value
The tables below present information about the Company’s financial assets and liabilities that are measured and carried at fair value as of September 30, 2019 and December 31, 2018 (in thousands) and indicate the level within the fair value hierarchy where each measurement is classified.
 
Level 1
 
Level 2
 
Level 3
 
Total
September 30, 2019
 
 
 
Cash equivalents:
 
 
 
Money market funds
$
21,253

 
$
—

 
$
—

 
$
21,253

U.S. Treasury obligations
4,238

 
—

 
—

 
4,238

Investments, available for sale:
 
 

U.S. Treasury obligations
38,689

 
—

 
—

 
38,689

Government agency securities
26,873

 
22,603

 
—

 
49,476

Marketable equity securities:
 
 
 
 
 
 
 
Corporate equity securities (Note 8)
5,435

 
—

 
—

 
5,435

Total
$
96,488

 
$
22,603

 
$
—

 
$
119,091



 
Level 1
 
Level 2
 
Level 3
 
Total
December 31, 2018
 
 
 
Cash equivalents:
 
 
 
Money market funds
$
7,643

 
$
—

 
$
—

 
$
7,643

U.S. Treasury obligations
1,748

 
—

 
—

 
1,748

Investments, available for sale:
 
 
 
U.S. Treasury obligations
34,103

 
746

 
—

 
34,849

Government agency securities
64,733

 
35,962

 
—

 
100,695

Marketable equity securities:
 
 
 
 
 
 
 
Corporate equity securities (Note 8)
7,525

 
—

 
—

 
7,525

Total
$
115,752

 
$
36,708

 
$
—

 
$
152,460
XML 17 R29.htm IDEA: XBRL DOCUMENT v3.19.3
Basis of Presentation and Significant Accounting Policies - Additional Information (Details)
 9 Months Ended
Sep. 30, 2019
segment
Accounting Policies [Abstract]  
Number of segments 1
ZIP 18 0001367920-19-000057-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001367920-19-000057-xbrl.zip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�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Ó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end XML 19 R48.htm IDEA: XBRL DOCUMENT v3.19.3
Lease - Supplemental Balance Sheet Information (Details) - USD ($)
$ in Thousands
Sep. 30, 2019
Jan. 01, 2019
Dec. 31, 2018
Sep. 30, 2018
Leases [Abstract]        
Operating lease right-of-use assets $ 9,317 $ 9,500 $ 0 $ 0
Operating lease liability $ 16,425 $ 16,900   $ 0
Weighted average remaining lease term 9 years 3 months     10 years 3 months
Weighted average discount rate 13.08%     0.00%

XML 20 R40.htm IDEA: XBRL DOCUMENT v3.19.3
Stock-Based Compensation - Stock-Based Compensation Expense Related to All Stock Based Awards Recognized in Statements of Operations and Comprehensive Income (Loss) (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2019
Sep. 30, 2018
Sep. 30, 2019
Sep. 30, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Stock-based compensation expense $ 2,420 $ 2,731 $ 7,711 $ 8,834
Research and development        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Stock-based compensation expense 1,190 1,211 3,728 4,012
General and administrative        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Stock-based compensation expense $ 1,230 $ 1,520 $ 3,983 $ 4,822
XML 21 R44.htm IDEA: XBRL DOCUMENT v3.19.3
Stock-Based Compensation - Summary of RSU Activity (Details) - Restricted stock units - $ / shares
 9 Months Ended
Aug. 15, 2019
Jul. 06, 2017
Sep. 30, 2019
Number of RSU Shares      
Number of RSU shares, Outstanding beginning balance (in shares)     228,150
Number of RSU shares, Granted (in shares) 400,000 500,000 412,220
Number of RSU shares, Released (in shares)     (202,550)
Number of RSU shares, Forfeited (in shares)     (25,600)
Number of RSU shares, Outstanding ending balance (in shares)     412,220
Weighted Average Grant Date Fair Value      
Weighted average grant date fair value, Outstanding at beginning of year (in dollars per share)     $ 13.87
Weighted average grant date fair value, Granted (in dollars per share)     10.27
Weighted average grant date fair value, Released (in dollars per share)     13.87
Weighted average grant date fair value, Forfeited (in dollars per share)     13.87
Weighted average grant date fair value, Outstanding at ending of year (in dollars per share)     $ 10.27
XML 22 R4.htm IDEA: XBRL DOCUMENT v3.19.3
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (UNAUDITED) - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2019
Sep. 30, 2018
Sep. 30, 2019
Sep. 30, 2018
Operating expenses:        
Research and development $ 13,511 $ 11,031 $ 43,797 $ 28,549
General and administrative 4,742 6,320 15,329 17,464
Total operating expenses 18,253 17,351 59,126 46,013
Loss from operations (18,243) (17,340) (58,062) (35,521)
Investment income 724 703 2,474 2,003
Unrealized gain (loss) on marketable equity securities 334 (732) (2,091) (1,359)
Loss before tax provision (17,185) (17,369) (57,679) (34,877)
Provision for income taxes 0 18 0 298
Net Loss (17,185) (17,387) (57,679) (35,175)
Other comprehensive income:        
Unrealized (loss) gain on investments, available for sale (39) 87 102 166
Comprehensive loss $ (17,224) $ (17,300) $ (57,577) $ (35,009)
Net loss per share applicable to common stockholders - basic and diluted (in dollars per share) $ (0.72) $ (0.74) $ (2.43) $ (1.51)
Weighted-average number of common shares used in net loss per share applicable to common stockholders - basic and diluted (in shares) 23,807 23,421 23,703 23,349
License and Research and Development Revenue        
Revenue:        
License and research and development revenue $ 10 $ 11 $ 1,064 $ 10,492
XML 23 R8.htm IDEA: XBRL DOCUMENT v3.19.3
Nature of Business
 9 Months Ended
Sep. 30, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Nature of Business
Nature of Business

Concert Pharmaceuticals, Inc., or Concert or the Company, was incorporated on April 12, 2006 as a Delaware corporation with operations based in Lexington, Massachusetts. The Company is a clinical stage biopharmaceutical company that applies its extensive knowledge of deuterium chemistry to discover and develop novel small molecule drugs. The Company’s approach starts with previously studied compounds, including approved drugs, that the Company believes can be improved with deuterium substitution to provide better pharmacokinetic or metabolic properties, enhancing clinical safety, tolerability or efficacy. The Company believes this approach may enable drug discovery and clinical development that is more efficient and less expensive than conventional small molecule drug research and development. The Company’s pipeline includes multiple clinical stage candidates and a number of preclinical compounds that it is currently assessing.
The Company had cash and cash equivalents and investments of $121.5 million at September 30, 2019. The Company believes that its cash and cash equivalents and investments at September 30, 2019 will be sufficient to allow the Company to fund its current operating plan for at least the next twelve months. The Company may pursue additional cash resources through public or private financings, by establishing collaborations with or licensing its technology to other companies and through other arrangements.
Since its inception, the Company has generated an accumulated deficit of $174.2 million through September 30, 2019. The Company's operating results may fluctuate significantly from year to year, depending on the timing and magnitude of clinical trial and other development activities under its current development programs. Substantially all the Company's net losses have resulted from costs incurred in connection with its research and development programs and from general and administrative costs associated with its operations. The Company expects to continue to incur significant expenses and increasing operating losses for at least the next several years.

The Company is subject to risks common to companies in the biotechnology industry, including, but not limited to, risks of failure or unsatisfactory results of nonclinical studies and clinical trials, the need to obtain additional financing to fund the future development of its pipeline, the need to obtain marketing approval for its product candidates, the need to successfully commercialize and gain market acceptance of its product candidates, dependence on key personnel, protection of proprietary technology, compliance with government regulations, development by competitors of technological innovations and ability to transition from pilot-scale manufacturing to large-scale production of products.

Unless otherwise indicated, all amounts in the following tables are in thousands except share and per share amounts
XML 24 R17.htm IDEA: XBRL DOCUMENT v3.19.3
Loss Per Share
 9 Months Ended
Sep. 30, 2019
Earnings Per Share [Abstract]  
Loss Per Share
Loss Per Share
Basic net loss per common share is calculated by dividing net loss allocable to common stockholders by the weighted-average common shares outstanding during the period, without consideration of common stock equivalents. For purposes of the diluted net loss per share calculation, common stock equivalents are excluded from the calculation if their effect would be anti-dilutive. As such, basic and diluted net loss per share applicable to common stockholders are the same for periods with a net loss.
The following table illustrates the determination of loss per share for each period presented.
 
Three Months Ended
September 30,
 
Nine Months Ended
September 30,
 
2019
 
2018
 
2019
 
2018
 
(in thousands, except per share amounts)
Numerator:
 
 
 
 
 
 
 
Net loss applicable to common stockholders - basic and diluted
$
(17,185
)
 
$
(17,387
)
 
$
(57,679
)
 
$
(35,175
)
 
 
 
 
 
 
 
 
Denominator:
 
 
 
 
 
 
 
Weighted average shares outstanding - basic and diluted
23,807

 
23,421

 
23,703

 
23,349

 
 
 
 
 
 
 
 
Net loss per share applicable to common stockholders - basic and diluted
$
(0.72
)
 
$
(0.74
)
 
$
(2.43
)
 
$
(1.51
)
 
 
 
 
 
 
 
 
Anti-dilutive potential common stock equivalents excluded from the calculation of net loss per share:
 
 
 
 
 
 
 
Stock options
214

 
515

 
290

 
758

Restricted stock units
410

 
133

 
72

 
214

Warrants
61

 
132

 
72

 
132
XML 25 R13.htm IDEA: XBRL DOCUMENT v3.19.3
Accrued Expenses and Other Liabilities
 9 Months Ended
Sep. 30, 2019
Payables and Accruals [Abstract]  
Accrued Expenses and Other Liabilities
Accrued Expenses and Other Liabilities
Accrued expenses and other liabilities consisted of the following:
 
September 30,
2019
 
December 31,
2018
Accrued professional fees and other
$
502

 
$
672

Employee compensation and benefits
2,245

 
3,067

Research and development expenses
1,687

 
1,476

Deferred lease incentive, current portion
—

 
454

 
$
4,434

 
$
5,669
XML 26 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 27 R38.htm IDEA: XBRL DOCUMENT v3.19.3
Revenue - Cipla (Details) - USD ($)
 3 Months Ended 9 Months Ended
Jan. 16, 2019
Sep. 30, 2019
Sep. 30, 2019
Sep. 30, 2018
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]        
Deferred revenue     $ 0 $ (16,000)
Cipla        
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]        
Deferred revenue $ 1,000,000      
Option to purchase inventory, valuation 300,000      
License and research and development revenue 1,000,000 $ 0 $ 1,000,000  
Cipla | Achievement of Certain Milestones        
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]        
Eligible payments receivable 57,000,000      
Cipla | First Milestone        
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]        
Eligible payments receivable $ 3,000,000.0      
XML 28 R30.htm IDEA: XBRL DOCUMENT v3.19.3
Fair Value Measurements - Financial Assets and Liabilities Recognized at Fair Value (Details) - USD ($)
$ in Thousands
Sep. 30, 2019
Dec. 31, 2018
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value, cash equivalents $ 33,384 $ 17,770
Fair value measurements    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total financial assets at fair value 119,091 152,460
Fair value measurements | Level 1    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total financial assets at fair value 96,488 115,752
Fair value measurements | Level 2    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total financial assets at fair value 22,603 36,708
Fair value measurements | Level 3    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total financial assets at fair value 0 0
Shorter maturity | Fair value measurements | Money market funds    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value, cash equivalents 21,253 7,643
Shorter maturity | Fair value measurements | Money market funds | Level 1    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value, cash equivalents 21,253 7,643
Shorter maturity | Fair value measurements | Money market funds | Level 2    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value, cash equivalents 0 0
Shorter maturity | Fair value measurements | Money market funds | Level 3    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value, cash equivalents 0 0
Shorter maturity | Fair value measurements | U.S. Treasury obligations    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value, cash equivalents   1,748
Shorter maturity | Fair value measurements | U.S. Treasury obligations | Level 1    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value, cash equivalents   1,748
Shorter maturity | Fair value measurements | U.S. Treasury obligations | Level 2    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value, cash equivalents   0
Shorter maturity | Fair value measurements | U.S. Treasury obligations | Level 3    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value, cash equivalents   0
Shorter maturity | Fair value measurements | Government agency securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value, cash equivalents 4,238  
Shorter maturity | Fair value measurements | Government agency securities | Level 1    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value, cash equivalents 4,238  
Shorter maturity | Fair value measurements | Government agency securities | Level 2    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value, cash equivalents 0  
Shorter maturity | Fair value measurements | Government agency securities | Level 3    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value, cash equivalents 0  
Longer maturity | Fair value measurements | U.S. Treasury obligations    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value, investments available-for-sale securities 38,689 34,849
Longer maturity | Fair value measurements | U.S. Treasury obligations | Level 1    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value, investments available-for-sale securities 38,689 34,103
Longer maturity | Fair value measurements | U.S. Treasury obligations | Level 2    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value, investments available-for-sale securities 0 746
Longer maturity | Fair value measurements | U.S. Treasury obligations | Level 3    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value, investments available-for-sale securities 0 0
Longer maturity | Fair value measurements | Government agency securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value, investments available-for-sale securities 49,476 100,695
Longer maturity | Fair value measurements | Government agency securities | Level 1    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value, investments available-for-sale securities 26,873 64,733
Longer maturity | Fair value measurements | Government agency securities | Level 2    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value, investments available-for-sale securities 22,603 35,962
Longer maturity | Fair value measurements | Government agency securities | Level 3    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value, investments available-for-sale securities 0 0
Corporate equity securities | Fair value measurements    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value, marketable equity securities 5,435 7,525
Corporate equity securities | Fair value measurements | Level 1    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value, marketable equity securities 5,435 7,525
Corporate equity securities | Fair value measurements | Level 2    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value, marketable equity securities 0 0
Corporate equity securities | Fair value measurements | Level 3    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value, marketable equity securities $ 0 $ 0
XML 29 R34.htm IDEA: XBRL DOCUMENT v3.19.3
Accrued Expenses and Other Liabilities (Details) - USD ($)
$ in Thousands
Sep. 30, 2019
Dec. 31, 2018
Payables and Accruals [Abstract]    
Accrued professional fees and other $ 502 $ 672
Employee compensation and benefits 2,245 3,067
Research and development expenses 1,687 1,476
Deferred lease incentive, current portion 0 454
Accrued expenses and other liabilities $ 4,434 $ 5,669
XML 30 R9.htm IDEA: XBRL DOCUMENT v3.19.3
Basis of Presentation and Significant Accounting Policies
 9 Months Ended
Sep. 30, 2019
Accounting Policies [Abstract]  
Basis of Presentation and Significant Accounting Policies
Basis of Presentation and Significant Accounting Policies
Basis of Presentation
The accompanying condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments, consisting of normal recurring accruals and revisions of estimates, considered necessary for a fair presentation of the condensed consolidated financial statements have been included. Interim results for the three and nine months ended September 30, 2019 are not necessarily indicative of the results that may be expected for the fiscal year ending December 31, 2019 or any other future period.
The accompanying condensed consolidated financial statements reflect the accounts of Concert and its subsidiaries. All intercompany transactions between the Company and its subsidiaries have been eliminated. Management has determined that the Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the Company’s consolidated financial statements and the accompanying notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018 filed with the Securities and Exchange Commission, or SEC, on February 28, 2019.
Use of Estimates and Summary of Significant Accounting Policies

The preparation of the consolidated financial statements in conformity with U.S. generally accepted accounting principles, or GAAP, requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenue, expenses and the disclosure of contingent assets and liabilities and the Company's ability to continue as a going concern. In preparing the consolidated financial statements, management used estimates in the following areas, among others: revenue recognition; lease accounting; income tax expense; stock-based compensation expense; accrued expenses; and the evaluation of the existence of conditions and events that raise substantial doubt regarding the Company’s ability to continue as a going concern. Actual results could differ from those estimates.
With the exception of the adoption of Accounting Standards Update, or ASU, 2016-02 during the nine months ended September 30, 2019 discussed in Note 11, there have been no material changes to the significant accounting policies previously disclosed in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2018.
Recently Adopted Accounting Pronouncements

In February 2016, the Financial Accounting Standards Board, or FASB, issued ASU 2016-02, Leases, or Topic 842. ASU 2016-02 requires lessees to recognize assets and liabilities on the balance sheet for the rights and obligations created by leases. On January 1, 2019, the Company adopted ASU 2016-02 and all related amendments. For discussion regarding the impact of this accounting pronouncement, refer to Note 11 appearing elsewhere in this Quarterly Report on Form 10-Q.

In June 2018, the FASB issued ASU 2018-07, Improvements to Nonemployee Share-Based Payment Accounting, that expands the scope of Topic 718, Compensation - Stock Compensation, to include share-based payment transactions for acquiring goods and services from nonemployees. ASU 2018-07 provides that an entity should apply the requirements of Topic 718 to nonemployee awards except for certain exemptions specified in the amendment. The Company adopted this new standard effective January 1, 2019, and it did not have a material effect on the consolidated financial statements and related disclosures.

In August 2018, the SEC issued Release No. 33-10532 that amends and clarifies certain financial reporting requirements. The principal change to the Company’s financial reporting is the inclusion of the annual disclosure requirement of changes in stockholders’ equity in Rule 3-04 of Regulation S-X to interim periods. The Company adopted this new rule beginning with its first Quarterly Report on Form 10-Q for the quarter ended March 31, 2019.
Pending Accounting Pronouncements

In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses. The new standard requires entities to measure all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions and reasonable and supportable forecasts. ASU 2016-13 will become effective for the Company for fiscal years beginning after December 15, 2019, with early adoption permitted. The Company is currently evaluating the impact ASU 2016-13 will have on its financial statements and related disclosures.

In August 2018, the FASB issued ASU 2018-15, Intangible-Goodwill and Other Internal-Use Software (Subtopic 350-40): Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement that is a Service Contract. The standard aligns the requirements for capitalizing implementation costs in a cloud computing arrangement service contract with the requirements for capitalizing implementation costs incurred for internal-use software. The new guidance also prescribes the balance sheet, income statement and cash flow classification of the capitalized implementation costs and related amortization expense, and requires additional quantitative and qualitative disclosures. ASU 2018-15 is effective for fiscal years beginning after December 15, 2019 and early adoption is permitted. The Company is currently evaluating the impact ASU 2018-15 will have on its financial statements and related disclosures.
XML 31 R5.htm IDEA: XBRL DOCUMENT v3.19.3
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (UNAUDITED) - USD ($)
$ in Thousands
Total
Common Stock
In Treasury
Additional paid-in capital
Accumulated other comprehensive income
Accumulated deficit
Beginning balance (in shares) at Dec. 31, 2017   23,148,000 8,000      
Beginning balance at Dec. 31, 2017 $ 196,432 $ 23   $ 273,059 $ (407) $ (76,243)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Exercise of stock options (in shares)   145,000 17,000      
Exercise of stock options 658     658    
Release of restricted stock units (in shares)   174,000 53,000      
Release of restricted stock units (1,206)     (1,206)    
Unrealized gain (loss) on short-term investments (75)       (75)  
Stock-based compensation expense 3,299     3,299    
Net loss (4,463)         (4,463)
Ending balance (in shares) at Mar. 31, 2018   23,467,000 78,000      
Ending balance at Mar. 31, 2018 210,397 $ 23   275,810 (482) (64,954)
Beginning balance (in shares) at Dec. 31, 2017   23,148,000 8,000      
Beginning balance at Dec. 31, 2017 196,432 $ 23   273,059 (407) (76,243)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Unrealized gain (loss) on short-term investments 166          
Net loss (35,175)          
Ending balance (in shares) at Sep. 30, 2018   23,509,000        
Ending balance at Sep. 30, 2018 185,752 $ 23 $ 81 281,636 (241) (95,666)
Beginning balance (in shares) at Mar. 31, 2018   23,467,000 78,000      
Beginning balance at Mar. 31, 2018 210,397 $ 23   275,810 (482) (64,954)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Exercise of stock options (in shares)   25,000        
Exercise of stock options 253     253    
Unrealized gain (loss) on short-term investments 154       154  
Stock-based compensation expense 2,804     2,804    
Net loss (13,325)         (13,325)
Ending balance (in shares) at Jun. 30, 2018   23,492,000 78,000      
Ending balance at Jun. 30, 2018 200,283 $ 23   278,867 (328) (78,279)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Exercise of stock options (in shares)   17,000        
Exercise of stock options 38   $ 3 38    
Unrealized gain (loss) on short-term investments 87       87  
Stock-based compensation expense 2,731     2,731    
Net loss (17,387)         (17,387)
Ending balance (in shares) at Sep. 30, 2018   23,509,000        
Ending balance at Sep. 30, 2018 185,752 $ 23 $ 81 281,636 (241) (95,666)
Beginning balance (in shares) at Dec. 31, 2018   23,519,000 81,000      
Beginning balance at Dec. 31, 2018 167,740 $ 23   284,369 (137) (116,515)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Exercise of stock options (in shares)   154,000 47,000      
Exercise of stock options 805     805    
Release of restricted stock units (in shares)   202,000 61,000      
Release of restricted stock units (741)     (741)    
Unrealized gain (loss) on short-term investments 97       97  
Stock-based compensation expense 2,929     2,929    
Exercise of stock warrants (in shares)   71,000        
Exercise of stock warrants 1,000     1,000    
Offering expenses incurred (206)     (206)    
Net loss (21,826)         (21,826)
Ending balance (in shares) at Mar. 31, 2019   23,946,000 189,000      
Ending balance at Mar. 31, 2019 149,798 $ 23   288,156 (40) (138,341)
Beginning balance (in shares) at Dec. 31, 2018   23,519,000 81,000      
Beginning balance at Dec. 31, 2018 $ 167,740 $ 23   284,369 (137) (116,515)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Exercise of stock options (in shares) 202,508          
Unrealized gain (loss) on short-term investments $ 102          
Net loss (57,679)          
Ending balance (in shares) at Sep. 30, 2019   24,031,000 189,000      
Ending balance at Sep. 30, 2019 119,263 $ 23   293,469 (35) (174,194)
Beginning balance (in shares) at Mar. 31, 2019   23,946,000 189,000      
Beginning balance at Mar. 31, 2019 149,798 $ 23   288,156 (40) (138,341)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Exercise of stock options (in shares)   40,000        
Exercise of stock options 165     165    
Unrealized gain (loss) on short-term investments 44       44  
Stock-based compensation expense 2,362     2,362    
Net loss (18,668)         (18,668)
Ending balance (in shares) at Jun. 30, 2019   23,986,000 189,000      
Ending balance at Jun. 30, 2019 133,701 $ 23   290,683 4 (157,009)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Exercise of stock options (in shares)   9,000        
Exercise of stock options 36     36    
Unrealized gain (loss) on short-term investments (39)       (39)  
Stock-based compensation expense 2,420     2,420    
Proceeds from at-the-market offering (in shares)   36,000        
Proceeds from at-the-market offering 330     330    
Net loss (17,185)         (17,185)
Ending balance (in shares) at Sep. 30, 2019   24,031,000 189,000      
Ending balance at Sep. 30, 2019 $ 119,263 $ 23   $ 293,469 $ (35) $ (174,194)
XML 32 R1.htm IDEA: XBRL DOCUMENT v3.19.3
Document and Entity Information - shares
 9 Months Ended
Sep. 30, 2019
Nov. 04, 2019
Document And Entity Information [Abstract]    
Entity Current Reporting Status Yes  
Document Type 10-Q  
Amendment Flag false  
Document Period End Date Sep. 30, 2019  
Document Fiscal Year Focus 2019  
Document Fiscal Period Focus Q3  
Entity Registrant Name CONCERT PHARMACEUTICALS, INC.  
Entity Central Index Key 0001367920  
Current Fiscal Year End Date --12-31  
Entity Filer Category Accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company true  
Entity Ex Transition Period true  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   23,841,155
XML 33 R50.htm IDEA: XBRL DOCUMENT v3.19.3
Open Market Sale Agreement (Details) - USD ($)
 8 Months Ended 9 Months Ended
Nov. 04, 2019
Nov. 04, 2019
Sep. 30, 2019
Mar. 01, 2019
Dec. 31, 2018
Subsidiary, Sale of Stock [Line Items]          
Common stock, par value (in dollars per share)     $ 0.001 $ 0.001 $ 0.001
Sale of stock, authorized amount       $ 50,000,000  
Sale of stock, commission rate       3.00%  
Legal expense maximum       $ 50,000  
Professional fees     $ 300,000    
Subsequent Event          
Subsidiary, Sale of Stock [Line Items]          
Sale of stock, commission rate 3.00% 3.00%      
Number of shares issued in transaction (in shares)   36,167      
Proceeds from issuance of common stock $ 400,000        
XML 34 R16.htm IDEA: XBRL DOCUMENT v3.19.3
Stock-Based Compensation
 9 Months Ended
Sep. 30, 2019
Share-based Payment Arrangement [Abstract]  
Stock-Based Compensation
Stock-Based Compensation
The Company’s equity incentive plans provide for the issuance of a variety of stock-based awards, including incentive stock options, nonstatutory stock options and awards of stock, to directors, officers and employees of the Company, as well as consultants and advisors to the Company. As of September 30, 2019, the Company has granted awards in the form of stock options and restricted stock units, or RSUs. The stock options generally have been granted with an exercise price equal to the fair value of the underlying common stock on the date of grant, a vesting period of three or four years, and an expiration date no later than ten years from the date of grant.
Effective January 1, 2019, an additional 937,503 shares were added to the Company’s 2014 Stock Incentive Plan, or the 2014 Plan, for future issuance pursuant to the terms of the 2014 Plan. As of September 30, 2019, there were 1,192,083 shares of common stock available for future award grants under the 2014 Plan.
Total stock-based compensation expense related to all stock-based options and awards recognized in the condensed consolidated statements of operations and comprehensive loss consisted of:

 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2019
 
2018
 
2019
 
2018
Research and development
$
1,190

 
$
1,211

 
$
3,728

 
$
4,012

General and administrative
1,230

 
1,520

 
3,983

 
4,822

Total stock-based compensation expense
$
2,420

 
$
2,731

 
$
7,711

 
$
8,834



Stock Options

Stock options are valued using the Black-Scholes-Merton option valuation model, and compensation cost is recognized based on such fair value over the period of vesting. The weighted average fair value of options granted in the three and nine months ended September 30, 2019 and 2018 reflect the following weighted-average assumptions:
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2019
 
2018
 
2019
 
2018
Expected volatility
74.37
%
 
77.72
%
 
76.86
%
 
77.19
%
Expected term
6.0 years

 
6.0 years

 
6.0 years

 
6.0 years

Risk-free interest rate
1.59
%
 
2.98
%
 
2.16
%
 
2.65
%
Expected dividend yield
—
%
 
—
%
 
—
%
 
—
%

For the three and nine months ended September 30, 2019 and 2018, expected volatility was estimated using a weighted-average of the Company's historical volatility of its common stock and the historical volatility of the common stock of a group of similar companies that were publicly traded. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available.

The following table provides certain information related to the Company's outstanding stock options:
 
 
Three Months Ended
September 30,
 
Nine Months Ended
September 30,
 
 
2019
 
2018
 
2019
 
2018
 
 
(in thousands, except per share data)
Weighted average fair value of options granted, per option
 
$
6.46

 
$
10.42

 
$
8.95

 
$
17.92

Aggregate grant date fair value of options vested during the period
 
$
2,234

 
$
2,110

 
$
7,070

 
$
5,839

Total cash received from exercises of stock options
 
$
36

 
$
23

 
$
1,006

 
$
934

Total intrinsic value of stock options exercised
 
$
59

 
$
187

 
$
1,167

 
$
2,539

The following is a summary of stock option activity for the nine months ended September 30, 2019:
 
Number of
Option Shares
 
Weighted
Average
Exercise
Price per
Share
 
Weighted
Average
Remaining
Contractual
Term
 
Aggregate
Intrinsic
Value
 
 
 
 
 
(In years)
 
(In thousands)
Outstanding at December 31, 2018
3,557,406

 
$
15.26

 
 
 
 
      Granted
1,032,250

 
$
13.25

 
 
 
 
      Exercised
(202,508
)
 
$
8.33

 
 
 
 
      Forfeited or expired
(184,474
)
 
$
18.44

 
 
 
 
Outstanding at September 30, 2019
4,202,674

 
$
14.96

 
6.99
 
$
390

Exercisable at September 30, 2019
2,429,295

 
$
13.70

 
6.03
 
$
390

Vested and expected to vest at September 30, 2019(1)
4,049,442

 
$
14.90

 
6.93
 
$
390


(1) 
This represents the number of vested stock option shares as of September 30, 2019, plus the number of unvested stock option shares that the Company estimated as of September 30, 2019 would vest, based on the unvested stock option shares at September 30, 2019 and an estimated forfeiture rate of 7%.

As of September 30, 2019, there was $17.4 million of unrecognized compensation cost related to stock options that are expected to vest. The stock option costs are expected to be recognized over a weighted average remaining vesting period of 2.5 years.

Restricted Stock Units

On July 6, 2017, the Company granted 0.5 million RSUs, or the 2017 RSU grant, to executives and employees. The awards granted to non-executive employees were service-based, whereas the awards granted to executives were a blend of service-based and performance-based. Assuming all service and performance conditions were achieved, fifty percent of the RSUs would vest on March 31, 2018, and the remaining fifty percent of the RSUs would vest on March 31, 2019. Certain executive awards were subject to the achievement of defined performance criteria prior to March 31, 2018, including the closing of the asset purchase contemplated by the Vertex Agreement and the institution by the Patent Trial and Appeal Board, or PTAB, of the Post Grant Review, or PGR, petition filed by the Company against Incyte Corporation. In January 2018, the PTAB decided not to institute the PGR petition and, as a result, the corresponding performance-based awards did not vest on March 31, 2018.

The Company used the accelerated attribution method to recognize expense over the required service period based on its estimate of the number of performance-based awards that vested. For any change in the estimate of the number of performance-based awards that were probable of vesting, the Company cumulatively adjusted compensation expense in the period that the change in estimate was made.

On August 15, 2019, or the 2019 RSU grant date, the Company granted 0.4 million RSUs, or the 2019 RSU grant, to certain executives and employees. All awards are service-based and vest ratably over two years. On the first anniversary of the 2019 RSU grant date, thirty-five percent of the RSUs will vest. The remainder of the RSUs will vest on the second anniversary of the 2019 RSU grant date.

RSUs are not included in issued and outstanding common stock until the shares are vested and settled. As of September 30, 2019, all achieved RSUs from the 2017 RSU grant had vested, and no RSUs from the 2019 RSU grant had vested. The fair value of an RSU is measured based on the market price of the underlying common stock as of the date of grant.
The following is a summary of RSU activity, including both service-based and performance-based RSUs for the nine months ended September 30, 2019:

 
Number of
RSU Shares
 
Weighted
Average
Grant Date Fair Value
 
 
 
 
Outstanding at December 31, 2018
228,150

 
$
13.87

      Granted
412,220

 
$
10.27

      Released
(202,550
)
 
$
13.87

      Forfeited
(25,600
)
 
$
13.87

Outstanding at September 30, 2019
412,220

 
$
10.27


As of September 30, 2019, there was $4.0 million of unrecognized compensation cost related to RSUs that are expected to vest. The RSU costs are expected to be recognized over a weighted average remaining vesting period of 1.9 years.
XML 35 R12.htm IDEA: XBRL DOCUMENT v3.19.3
Restricted Cash
 9 Months Ended
Sep. 30, 2019
Cash and Cash Equivalents [Abstract]  
Restricted Cash
Restricted Cash
Restricted cash as of September 30, 2019 and 2018 is held as collateral for stand-by letters of credit issued by the Company to its landlords in connection with the current and previous leases of the Company's Lexington, Massachusetts facilities.

Cash, cash equivalents and restricted cash consisted of the following:

 
September 30,
2019
 
September 30,
2018
Cash and cash equivalents
$
33,384

 
$
39,597

Restricted cash
1,157

 
1,557

Total cash, cash equivalents and restricted cash shown in the statements of cash flows
$
34,541

 
$
41,154
XML 36 R31.htm IDEA: XBRL DOCUMENT v3.19.3
Cash, Cash Equivalents, Investments and Marketable Equity Securities - Cash Equivalents and Short-term and Long-term Investments (Details) - USD ($)
$ in Thousands
 9 Months Ended 12 Months Ended
Sep. 30, 2019
Dec. 31, 2018
Sep. 30, 2018
Cash and Cash Equivalents      
Amortized cost, cash and cash equivalents $ 33,384 $ 17,770 $ 39,597
Fair value, cash and cash equivalent 33,384 17,770  
U.S. Treasury obligations      
Debt Securities      
Amortized cost, investments available for sale 38,683 34,856  
Unrealized gains 14 2  
Unrealized losses (8) (9)  
Fair value, available-for-sale securities 38,689 34,849  
Government agency securities      
Debt Securities      
Amortized cost, investments available for sale 49,443 100,748  
Unrealized gains 34 7  
Unrealized losses (1) (60)  
Fair value, available-for-sale securities 49,476 100,695  
Investments, available for sale      
Debt Securities      
Amortized cost, investments available for sale 88,126 135,604  
Unrealized gains 48 9  
Unrealized losses (9) (69)  
Fair value, available-for-sale securities 88,165 135,544  
Marketable equity securities      
Marketable Securities      
Amortized cost 10,451 10,451  
Unrealized gains 0 0  
Unrealized losses (5,016) (2,926)  
Fair value 5,435 7,525  
Cash      
Cash and Cash Equivalents      
Amortized cost, cash and cash equivalents 7,893 8,379  
Fair value, cash and cash equivalent 7,893 8,379  
Money market funds      
Cash and Cash Equivalents      
Amortized cost, cash and cash equivalents 21,253 7,643  
Fair value, cash and cash equivalent 21,253 7,643  
U.S. Treasury obligations      
Cash and Cash Equivalents      
Amortized cost, cash and cash equivalents 4,238 1,748  
Fair value, cash and cash equivalent $ 4,238 $ 1,748  
Measurement Input, Expected Term | U.S. Treasury obligations      
Debt Securities      
Average maturity 169 days 151 days  
Measurement Input, Expected Term | Government agency securities      
Debt Securities      
Average maturity 88 days 153 days  
Measurement Input, Expected Term | U.S. Treasury obligations      
Cash and Cash Equivalents      
Cash and Cash Equivalents, Term 52 days 31 days  
XML 37 R35.htm IDEA: XBRL DOCUMENT v3.19.3
Revenue - Additional Information (Details)
 1 Months Ended 9 Months Ended
Feb. 28, 2019
USD ($)
Sep. 30, 2019
USD ($)
segment
Dec. 31, 2018
USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Number of segments | segment   1  
Contract asset   $ 0 $ 16,000,000
Contract liability   10,500,000 $ 10,500,000
Celgene      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Contract liability   7,800,000  
Celgene | CTP-730      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Contract liability   1,400,000  
Celgene | One of the other additional license programs      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Contract liability   6,400,000  
GSK      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Contract liability   $ 2,800,000  
Indemnification agreement | Disposed of by sale, not discontinued operations | Assets for synthesis and research and development for treating Cystic Fibrosis      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Amount released $ 16,000,000    
XML 38 R39.htm IDEA: XBRL DOCUMENT v3.19.3
Stock-Based Compensation - Additional Information (Details) - USD ($)
$ in Millions
 9 Months Ended
Aug. 15, 2019
Jan. 01, 2019
Jul. 06, 2017
Sep. 30, 2019
Stock options        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Total unrecognized compensation cost related to unvested options       $ 17.4
Total unrecognized compensation cost, weighted-average recognition period       2 years 6 months 18 days
Restricted stock units        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Vesting period 2 years     1 year 10 months 18 days
Number of RSU shares, granted (in shares) 400,000   500,000 412,220
Award vesting percentage 35.00%      
Total unrecognized compensation cost related to restricted stock units       $ 4.0
Restricted stock units | Tranche one        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Award vesting percentage     50.00%  
Restricted stock units | Tranche two        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Award vesting percentage     50.00%  
2014 Stock Incentive Plan        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Additional shares issued under the plan (in shares)   937,503    
Common stock available for future award grant (in shares)       1,192,083
Minimum        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Vesting period       3 years
Maximum        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Vesting period       4 years
Awards expiration period       10 years
XML 39 R28.htm IDEA: XBRL DOCUMENT v3.19.3
Nature of Business - Additional Information (Details) - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2019
Dec. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]    
Cash and cash equivalents and investments $ 121,500  
Period of sufficiency of cash resources to fund operating plan 12 months  
Accumulated deficit $ 174,194 $ 116,515
XML 40 FilingSummary.xml IDEA: XBRL DOCUMENT 3.19.3 html 218 323 1 false 50 0 false 7 false false R1.htm 0001000 - Document - Document and Entity Information Sheet http://www.concertpharma.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 1001000 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) Sheet http://www.concertpharma.com/role/CondensedConsolidatedBalanceSheetsUnaudited CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) Statements 2 false false R3.htm 1001501 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical) Sheet http://www.concertpharma.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical) Statements 3 false false R4.htm 1002000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (UNAUDITED) Sheet http://www.concertpharma.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (UNAUDITED) Statements 4 false false R5.htm 1002000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS??? EQUITY (UNAUDITED) Sheet http://www.concertpharma.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS??? EQUITY (UNAUDITED) Statements 5 false false R6.htm 1002001 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (UNAUDITED) (Parenthetical) Sheet http://www.concertpharma.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnauditedParenthetical CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (UNAUDITED) (Parenthetical) Statements 6 false false R7.htm 1003000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) Sheet http://www.concertpharma.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) Statements 7 false false R8.htm 2101100 - Disclosure - Nature of Business Sheet http://www.concertpharma.com/role/NatureOfBusiness Nature of Business Notes 8 false false R9.htm 2102100 - Disclosure - Basis of Presentation and Significant Accounting Policies Sheet http://www.concertpharma.com/role/BasisOfPresentationAndSignificantAccountingPolicies Basis of Presentation and Significant Accounting Policies Notes 9 false false R10.htm 2103100 - Disclosure - Fair Value Measurements Sheet http://www.concertpharma.com/role/FairValueMeasurements Fair Value Measurements Notes 10 false false R11.htm 2104100 - Disclosure - Cash, Cash Equivalents, Investments and Marketable Equity Securities Sheet http://www.concertpharma.com/role/CashCashEquivalentsInvestmentsAndMarketableEquitySecurities Cash, Cash Equivalents, Investments and Marketable Equity Securities Notes 11 false false R12.htm 2105100 - Disclosure - Restricted Cash Sheet http://www.concertpharma.com/role/RestrictedCash Restricted Cash Notes 12 false false R13.htm 2106100 - Disclosure - Accrued Expenses and Other Liabilities Sheet http://www.concertpharma.com/role/AccruedExpensesAndOtherLiabilities Accrued Expenses and Other Liabilities Notes 13 false false R14.htm 2107100 - Disclosure - Income Taxes Sheet http://www.concertpharma.com/role/IncomeTaxes Income Taxes Notes 14 false false R15.htm 2108100 - Disclosure - Revenue Sheet http://www.concertpharma.com/role/Revenue Revenue Notes 15 false false R16.htm 2109100 - Disclosure - Stock-Based Compensation Sheet http://www.concertpharma.com/role/StockBasedCompensation Stock-Based Compensation Notes 16 false false R17.htm 2110100 - Disclosure - Loss Per Share Sheet http://www.concertpharma.com/role/LossPerShare Loss Per Share Notes 17 false false R18.htm 2111100 - Disclosure - Lease Sheet http://www.concertpharma.com/role/Lease Lease Notes 18 false false R19.htm 2112100 - Disclosure - Open Market Sale Agreement Sheet http://www.concertpharma.com/role/OpenMarketSaleAgreement Open Market Sale Agreement Notes 19 false false R20.htm 2202201 - Disclosure - Basis of Presentation and Significant Accounting Policies (Policies) Sheet http://www.concertpharma.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies Basis of Presentation and Significant Accounting Policies (Policies) Policies http://www.concertpharma.com/role/BasisOfPresentationAndSignificantAccountingPolicies 20 false false R21.htm 2303301 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.concertpharma.com/role/FairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://www.concertpharma.com/role/FairValueMeasurements 21 false false R22.htm 2304301 - Disclosure - Cash, Cash Equivalents, Investments and Marketable Equity Securities (Tables) Sheet http://www.concertpharma.com/role/CashCashEquivalentsInvestmentsAndMarketableEquitySecuritiesTables Cash, Cash Equivalents, Investments and Marketable Equity Securities (Tables) Tables http://www.concertpharma.com/role/CashCashEquivalentsInvestmentsAndMarketableEquitySecurities 22 false false R23.htm 2305301 - Disclosure - Restricted Cash (Tables) Sheet http://www.concertpharma.com/role/RestrictedCashTables Restricted Cash (Tables) Tables http://www.concertpharma.com/role/RestrictedCash 23 false false R24.htm 2306301 - Disclosure - Accrued Expenses and Other Liabilities (Tables) Sheet http://www.concertpharma.com/role/AccruedExpensesAndOtherLiabilitiesTables Accrued Expenses and Other Liabilities (Tables) Tables http://www.concertpharma.com/role/AccruedExpensesAndOtherLiabilities 24 false false R25.htm 2309301 - Disclosure - Stock-Based Compensation (Tables) Sheet http://www.concertpharma.com/role/StockBasedCompensationTables Stock-Based Compensation (Tables) Tables http://www.concertpharma.com/role/StockBasedCompensation 25 false false R26.htm 2310301 - Disclosure - Loss Per Share (Tables) Sheet http://www.concertpharma.com/role/LossPerShareTables Loss Per Share (Tables) Tables http://www.concertpharma.com/role/LossPerShare 26 false false R27.htm 2311301 - Disclosure - Lease (Tables) Sheet http://www.concertpharma.com/role/LeaseTables Lease (Tables) Tables http://www.concertpharma.com/role/Lease 27 false false R28.htm 2401401 - Disclosure - Nature of Business - Additional Information (Details) Sheet http://www.concertpharma.com/role/NatureOfBusinessAdditionalInformationDetails Nature of Business - Additional Information (Details) Details 28 false false R29.htm 2402402 - Disclosure - Basis of Presentation and Significant Accounting Policies - Additional Information (Details) Sheet http://www.concertpharma.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetails Basis of Presentation and Significant Accounting Policies - Additional Information (Details) Details 29 false false R30.htm 2403402 - Disclosure - Fair Value Measurements - Financial Assets and Liabilities Recognized at Fair Value (Details) Sheet http://www.concertpharma.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesRecognizedAtFairValueDetails Fair Value Measurements - Financial Assets and Liabilities Recognized at Fair Value (Details) Details 30 false false R31.htm 2404402 - Disclosure - Cash, Cash Equivalents, Investments and Marketable Equity Securities - Cash Equivalents and Short-term and Long-term Investments (Details) Sheet http://www.concertpharma.com/role/CashCashEquivalentsInvestmentsAndMarketableEquitySecuritiesCashEquivalentsAndShortTermAndLongTermInvestmentsDetails Cash, Cash Equivalents, Investments and Marketable Equity Securities - Cash Equivalents and Short-term and Long-term Investments (Details) Details 31 false false R32.htm 2404403 - Disclosure - Cash, Cash Equivalents, Investments and Marketable Equity Securities - Additional Information (Details) Sheet http://www.concertpharma.com/role/CashCashEquivalentsInvestmentsAndMarketableEquitySecuritiesAdditionalInformationDetails Cash, Cash Equivalents, Investments and Marketable Equity Securities - Additional Information (Details) Details 32 false false R33.htm 2405402 - Disclosure - Restricted Cash (Details) Sheet http://www.concertpharma.com/role/RestrictedCashDetails Restricted Cash (Details) Details http://www.concertpharma.com/role/RestrictedCashTables 33 false false R34.htm 2406402 - Disclosure - Accrued Expenses and Other Liabilities (Details) Sheet http://www.concertpharma.com/role/AccruedExpensesAndOtherLiabilitiesDetails Accrued Expenses and Other Liabilities (Details) Details http://www.concertpharma.com/role/AccruedExpensesAndOtherLiabilitiesTables 34 false false R35.htm 2408401 - Disclosure - Revenue - Additional Information (Details) Sheet http://www.concertpharma.com/role/RevenueAdditionalInformationDetails Revenue - Additional Information (Details) Details 35 false false R36.htm 2408404 - Disclosure - Revenue - Vertex (Details) Sheet http://www.concertpharma.com/role/RevenueVertexDetails Revenue - Vertex (Details) Details 36 false false R37.htm 2408407 - Disclosure - Revenue - Processa (Details) Sheet http://www.concertpharma.com/role/RevenueProcessaDetails Revenue - Processa (Details) Details 37 false false R38.htm 2408408 - Disclosure - Revenue - Cipla (Details) Sheet http://www.concertpharma.com/role/RevenueCiplaDetails Revenue - Cipla (Details) Details 38 false false R39.htm 2409402 - Disclosure - Stock-Based Compensation - Additional Information (Details) Sheet http://www.concertpharma.com/role/StockBasedCompensationAdditionalInformationDetails Stock-Based Compensation - Additional Information (Details) Details 39 false false R40.htm 2409403 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense Related to All Stock Based Awards Recognized in Statements of Operations and Comprehensive Income (Loss) (Details) Sheet http://www.concertpharma.com/role/StockBasedCompensationStockBasedCompensationExpenseRelatedToAllStockBasedAwardsRecognizedInStatementsOfOperationsAndComprehensiveIncomeLossDetails Stock-Based Compensation - Stock-Based Compensation Expense Related to All Stock Based Awards Recognized in Statements of Operations and Comprehensive Income (Loss) (Details) Details 40 false false R41.htm 2409404 - Disclosure - Stock-Based Compensation - Estimated Weighted-Average Assumptions of Options Granted (Details) Sheet http://www.concertpharma.com/role/StockBasedCompensationEstimatedWeightedAverageAssumptionsOfOptionsGrantedDetails Stock-Based Compensation - Estimated Weighted-Average Assumptions of Options Granted (Details) Details 41 false false R42.htm 2409405 - Disclosure - Stock-Based Compensation - Fair Value of Options (Details) Sheet http://www.concertpharma.com/role/StockBasedCompensationFairValueOfOptionsDetails Stock-Based Compensation - Fair Value of Options (Details) Details 42 false false R43.htm 2409406 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Details) Sheet http://www.concertpharma.com/role/StockBasedCompensationSummaryOfStockOptionActivityDetails Stock-Based Compensation - Summary of Stock Option Activity (Details) Details 43 false false R44.htm 2409407 - Disclosure - Stock-Based Compensation - Summary of RSU Activity (Details) Sheet http://www.concertpharma.com/role/StockBasedCompensationSummaryOfRsuActivityDetails Stock-Based Compensation - Summary of RSU Activity (Details) Details 44 false false R45.htm 2410402 - Disclosure - Loss Per Share - Computation of Basic and Diluted Earnings (Loss) Per Share (Details) Sheet http://www.concertpharma.com/role/LossPerShareComputationOfBasicAndDilutedEarningsLossPerShareDetails Loss Per Share - Computation of Basic and Diluted Earnings (Loss) Per Share (Details) Details 45 false false R46.htm 2411402 - Disclosure - Lease - Additional Information (Details) Sheet http://www.concertpharma.com/role/LeaseAdditionalInformationDetails Lease - Additional Information (Details) Details 46 false false R47.htm 2411403 - Disclosure - Lease - Supplemental Cash Flow Information (Details) Sheet http://www.concertpharma.com/role/LeaseSupplementalCashFlowInformationDetails Lease - Supplemental Cash Flow Information (Details) Details 47 false false R48.htm 2411404 - Disclosure - Lease - Supplemental Balance Sheet Information (Details) Sheet http://www.concertpharma.com/role/LeaseSupplementalBalanceSheetInformationDetails Lease - Supplemental Balance Sheet Information (Details) Details 48 false false R49.htm 2411405 - Disclosure - Lease - Lease Maturities (Details) Sheet http://www.concertpharma.com/role/LeaseLeaseMaturitiesDetails Lease - Lease Maturities (Details) Details 49 false false R50.htm 2412401 - Disclosure - Open Market Sale Agreement (Details) Sheet http://www.concertpharma.com/role/OpenMarketSaleAgreementDetails Open Market Sale Agreement (Details) Details http://www.concertpharma.com/role/OpenMarketSaleAgreement 50 false false R9999.htm Uncategorized Items - cnce-20190930.xml Sheet http://xbrl.sec.gov/role/uncategorizedFacts Uncategorized Items - cnce-20190930.xml Cover 51 false false All Reports Book All Reports cnce-20190930.xml cnce-20190930.xsd cnce-20190930_cal.xml cnce-20190930_def.xml cnce-20190930_lab.xml cnce-20190930_pre.xml http://xbrl.sec.gov/dei/2018-01-31 http://fasb.org/srt/2019-01-31 http://fasb.org/us-gaap/2019-01-31 true true XML 41 R24.htm IDEA: XBRL DOCUMENT v3.19.3
Accrued Expenses and Other Liabilities (Tables)
 9 Months Ended
Sep. 30, 2019
Payables and Accruals [Abstract]  
Accrued Expenses and Other Liabilities
Accrued expenses and other liabilities consisted of the following:
 
September 30,
2019
 
December 31,
2018
Accrued professional fees and other
$
502

 
$
672

Employee compensation and benefits
2,245

 
3,067

Research and development expenses
1,687

 
1,476

Deferred lease incentive, current portion
—

 
454

 
$
4,434

 
$
5,669
XML 42 R20.htm IDEA: XBRL DOCUMENT v3.19.3
Basis of Presentation and Significant Accounting Policies (Policies)
 9 Months Ended
Sep. 30, 2019
Accounting Policies [Abstract]  
Basis of Presentation
Basis of Presentation
The accompanying condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments, consisting of normal recurring accruals and revisions of estimates, considered necessary for a fair presentation of the condensed consolidated financial statements have been included. Interim results for the three and nine months ended September 30, 2019 are not necessarily indicative of the results that may be expected for the fiscal year ending December 31, 2019 or any other future period.
The accompanying condensed consolidated financial statements reflect the accounts of Concert and its subsidiaries. All intercompany transactions between the Company and its subsidiaries have been eliminated. Management has determined that the Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the Company’s consolidated financial statements and the accompanying notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018 filed with the Securities and Exchange Commission, or SEC, on February 28, 2019.
Use of Estimates and Summary of Significant Accounting Policies
Use of Estimates and Summary of Significant Accounting Policies

The preparation of the consolidated financial statements in conformity with U.S. generally accepted accounting principles, or GAAP, requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenue, expenses and the disclosure of contingent assets and liabilities and the Company's ability to continue as a going concern. In preparing the consolidated financial statements, management used estimates in the following areas, among others: revenue recognition; lease accounting; income tax expense; stock-based compensation expense; accrued expenses; and the evaluation of the existence of conditions and events that raise substantial doubt regarding the Company’s ability to continue as a going concern. Actual results could differ from those estimates.
With the exception of the adoption of Accounting Standards Update, or ASU, 2016-02 during the nine months ended September 30, 2019 discussed in Note 11, there have been no material changes to the significant accounting policies previously disclosed in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2018.
Recently Adopted Accounting Pronouncements and Pending Accounting Pronouncements
Recently Adopted Accounting Pronouncements

In February 2016, the Financial Accounting Standards Board, or FASB, issued ASU 2016-02, Leases, or Topic 842. ASU 2016-02 requires lessees to recognize assets and liabilities on the balance sheet for the rights and obligations created by leases. On January 1, 2019, the Company adopted ASU 2016-02 and all related amendments. For discussion regarding the impact of this accounting pronouncement, refer to Note 11 appearing elsewhere in this Quarterly Report on Form 10-Q.

In June 2018, the FASB issued ASU 2018-07, Improvements to Nonemployee Share-Based Payment Accounting, that expands the scope of Topic 718, Compensation - Stock Compensation, to include share-based payment transactions for acquiring goods and services from nonemployees. ASU 2018-07 provides that an entity should apply the requirements of Topic 718 to nonemployee awards except for certain exemptions specified in the amendment. The Company adopted this new standard effective January 1, 2019, and it did not have a material effect on the consolidated financial statements and related disclosures.

In August 2018, the SEC issued Release No. 33-10532 that amends and clarifies certain financial reporting requirements. The principal change to the Company’s financial reporting is the inclusion of the annual disclosure requirement of changes in stockholders’ equity in Rule 3-04 of Regulation S-X to interim periods. The Company adopted this new rule beginning with its first Quarterly Report on Form 10-Q for the quarter ended March 31, 2019.
Pending Accounting Pronouncements

In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses. The new standard requires entities to measure all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions and reasonable and supportable forecasts. ASU 2016-13 will become effective for the Company for fiscal years beginning after December 15, 2019, with early adoption permitted. The Company is currently evaluating the impact ASU 2016-13 will have on its financial statements and related disclosures.

In August 2018, the FASB issued ASU 2018-15, Intangible-Goodwill and Other Internal-Use Software (Subtopic 350-40): Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement that is a Service Contract. The standard aligns the requirements for capitalizing implementation costs in a cloud computing arrangement service contract with the requirements for capitalizing implementation costs incurred for internal-use software. The new guidance also prescribes the balance sheet, income statement and cash flow classification of the capitalized implementation costs and related amortization expense, and requires additional quantitative and qualitative disclosures. ASU 2018-15 is effective for fiscal years beginning after December 15, 2019 and early adoption is permitted. The Company is currently evaluating the impact ASU 2018-15 will have on its financial statements and related disclosures.
XML 43 R41.htm IDEA: XBRL DOCUMENT v3.19.3
Stock-Based Compensation - Estimated Weighted-Average Assumptions of Options Granted (Details)
 3 Months Ended 9 Months Ended
Sep. 30, 2019
Sep. 30, 2018
Sep. 30, 2019
Sep. 30, 2018
Share-based Payment Arrangement [Abstract]        
Expected volatility 74.37% 77.72% 76.86% 77.19%
Expected term 6 years 6 years 6 years 6 years
Risk-free interest rate 1.59% 2.98% 2.16% 2.65%
Expected dividend yield 0.00% 0.00% 0.00% 0.00%
XML 44 R45.htm IDEA: XBRL DOCUMENT v3.19.3
Loss Per Share - Computation of Basic and Diluted Earnings (Loss) Per Share (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2019
Jun. 30, 2019
Mar. 31, 2019
Sep. 30, 2018
Jun. 30, 2018
Mar. 31, 2018
Sep. 30, 2019
Sep. 30, 2018
Numerator:                
Net loss applicable to common stockholders - basic and diluted $ (17,185) $ (18,668) $ (21,826) $ (17,387) $ (13,325) $ (4,463) $ (57,679) $ (35,175)
Denominator:                
Weighted-average number of common shares used in net loss per share applicable to common stockholders - basic and diluted (in shares) 23,807     23,421     23,703 23,349
Net loss per share applicable to common stockholders - basic and diluted (in dollars per share) $ (0.72)     $ (0.74)     $ (2.43) $ (1.51)
Stock options                
Anti-dilutive potential common stock equivalents excluded from the calculation of net income (loss) per share:                
Anti-dilutive stock options, restricted stock units, and warrants (in shares) 214     515     290 758
Restricted stock units                
Anti-dilutive potential common stock equivalents excluded from the calculation of net income (loss) per share:                
Anti-dilutive stock options, restricted stock units, and warrants (in shares) 410     133     72 214
Warrants                
Anti-dilutive potential common stock equivalents excluded from the calculation of net income (loss) per share:                
Anti-dilutive stock options, restricted stock units, and warrants (in shares) 61     132     72 132
XML 45 R49.htm IDEA: XBRL DOCUMENT v3.19.3
Lease - Lease Maturities (Details) - USD ($)
$ in Thousands
Sep. 30, 2019
Jan. 01, 2019
Sep. 30, 2018
Leases [Abstract]      
2019 $ 696    
2020 2,406    
2021 2,969    
2022 3,058    
2023 3,150    
Thereafter 17,223    
Total lease payments 29,502    
Less imputed interest (13,077)    
Total $ 16,425 $ 16,900 $ 0
XML 46 R7.htm IDEA: XBRL DOCUMENT v3.19.3
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2019
Sep. 30, 2018
Operating activities    
Net loss $ (57,679) $ (35,175)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 1,256 875
Stock-based compensation expense 7,711 8,834
Accretion of premiums and discounts on investments (899) (234)
Amortization of deferred lease incentive 0 (589)
Non-cash license consideration (Note 8) 0 (10,452)
Other noncash items 0 (46)
Unrealized loss on marketable equity securities 2,090 1,359
Loss on disposal of asset 4 52
Non-cash lease expense (Note 11) 161  
Changes in operating assets and liabilities:    
Accounts receivable 4 155
Interest receivable 265 115
Prepaid expenses and other current assets (1,091) (4)
Contract asset 16,000 0
Other assets (16) 26
Accounts payable 207 457
Accrued expenses and other liabilities (827) (100)
Income taxes receivable (36) (77)
Income taxes payable (390) 372
Deferred rent 0 2,033
Deferred revenue 0 (16)
Operating lease liability (Note 11) (445)  
Net cash used in operating activities (33,685) (32,415)
Investing activities    
Purchases of property and equipment (520) (2,405)
Purchases of investments (93,326) (46,120)
Maturities of investments 141,706 93,144
Net cash provided by investing activities 47,860 44,619
Financing activities    
Proceeds from exercises of stock options 1,006 934
Proceeds from exercise of warrants 1,000 0
Repurchase of common stock pursuant to share surrender (741) (1,206)
Proceeds from at-the-market offering, net of issuance costs 174 0
Net cash provided by (used in) financing activities 1,439 (272)
Net increase in cash and cash equivalents and restricted cash 15,614 11,932
Cash, cash equivalents and restricted cash at beginning of period 18,927 29,222
Cash, cash equivalents and restricted cash at end of period 34,541 41,154
Supplemental cash flow information:    
Cash paid for income taxes 453 50
Purchases of property and equipment unpaid at period end 0 99
Public offering costs unpaid at period end 50 0
Cash paid included in measurement of lease liabilities 2,082 0
Tenant improvements paid by landlord $ 0 $ 4,996
XML 47 R3.htm IDEA: XBRL DOCUMENT v3.19.3
CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical) - $ / shares
Sep. 30, 2019
Dec. 31, 2018
Statement of Financial Position [Abstract]    
Preferred stock, par value (in dollars per share) $ 0.001 $ 0.001
Preferred stock, shares authorized (in shares) 5,000,000 5,000,000
Preferred stock, shares issued (in shares) 0 0
Preferred stock, shares outstanding (in shares) 0 0
Common stock, par value (in dollars per share) $ 0.001 $ 0.001
Common stock, shares authorized (in shares) 100,000,000 100,000,000
Common stock, shares issued (in shares) 24,030,711 23,518,690
Common stock, shares outstanding (in shares) 23,841,155 23,437,587
XML 48 R33.htm IDEA: XBRL DOCUMENT v3.19.3
Restricted Cash (Details) - USD ($)
$ in Thousands
Sep. 30, 2019
Dec. 31, 2018
Sep. 30, 2018
Dec. 31, 2017
Cash and Cash Equivalents [Abstract]        
Cash and cash equivalents $ 33,384 $ 17,770 $ 39,597  
Restricted cash 1,157 1,157 1,557  
Total cash, cash equivalents and restricted cash shown in the statements of cash flows $ 34,541 $ 18,927 $ 41,154 $ 29,222
XML 49 R37.htm IDEA: XBRL DOCUMENT v3.19.3
Revenue - Processa (Details) - Processa - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Mar. 21, 2018
Mar. 19, 2018
Sep. 30, 2019
Sep. 30, 2018
Mar. 31, 2018
Sep. 30, 2019
Sep. 30, 2018
Revenue Recognition, Milestone Method [Line Items]              
Equity received from sale (in shares) 2,090,301 2,090,301          
Allocable arrangement consideration $ 10,500   $ 2 $ 10,500 $ 10,500 $ 24 $ 10,500
XML 50 R9999.htm IDEA: XBRL DOCUMENT v3.19.3
Label Element Value
Accounting Standards Update 2014-09 [Member]  
Cumulative Effect of New Accounting Principle in Period of Adoption us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption $ 15,752,000
Accounting Standards Update 2014-09 [Member] | Retained Earnings [Member]  
Cumulative Effect of New Accounting Principle in Period of Adoption us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption $ 15,752,000
XML 51 R14.htm IDEA: XBRL DOCUMENT v3.19.3
Income Taxes
 9 Months Ended
Sep. 30, 2019
Income Tax Disclosure [Abstract]  
Income Taxes
Income Taxes

Deferred tax assets and deferred tax liabilities are recognized based on temporary differences between the financial reporting and tax basis of assets and liabilities using statutory rates. A valuation allowance is recorded against deferred tax assets if it is more likely than not that some or all of the deferred tax assets will not be realized.

The Company’s ability to use its operating loss carryforwards and tax credits to offset future taxable income is subject to restrictions under Sections 382 and 383 of the United States Internal Revenue Code, or the Internal Revenue Code. Net operating loss and tax credit carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant stockholders over a three-year period in excess of 50 percent, as defined under Sections 382 and 383 of the Internal Revenue Code. Such changes would limit the Company’s use of its operating loss carryforwards and tax credits. In such a situation, the Company may be required to pay income taxes, even though significant operating loss carryforwards and tax credits exist.

The Company records a provision or benefit for income taxes on ordinary pre-tax income or loss based on its estimated effective tax rate for the year. As of September 30, 2019, the Company forecasts an ordinary pre-tax loss for the year ended December 31, 2019 and, since it maintains a full valuation allowance on its deferred tax assets, the Company did not record an income tax benefit for the three or nine months ended September 30, 2019.
XML 52 R10.htm IDEA: XBRL DOCUMENT v3.19.3
Fair Value Measurements
 9 Months Ended
Sep. 30, 2019
Fair Value Disclosures [Abstract]  
Fair Value Measurements
Fair Value Measurements

The Company has certain financial assets and liabilities that are recorded at fair value which have been classified as Level 1, 2 or 3 within the fair value hierarchy as described in the accounting standards for fair value measurements:

•
Level 1—quoted prices for identical instruments in active markets;
•
Level 2—quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, and model-derived valuations in which all significant inputs and significant value drivers are observable in active markets; and
•
Level 3—valuations derived from valuation techniques in which one or more significant value drivers are unobservable.

The tables below present information about the Company’s financial assets and liabilities that are measured and carried at fair value as of September 30, 2019 and December 31, 2018 (in thousands) and indicate the level within the fair value hierarchy where each measurement is classified.
 
Level 1
 
Level 2
 
Level 3
 
Total
September 30, 2019
 
 
 
Cash equivalents:
 
 
 
Money market funds
$
21,253

 
$
—

 
$
—

 
$
21,253

U.S. Treasury obligations
4,238

 
—

 
—

 
4,238

Investments, available for sale:
 
 

U.S. Treasury obligations
38,689

 
—

 
—

 
38,689

Government agency securities
26,873

 
22,603

 
—

 
49,476

Marketable equity securities:
 
 
 
 
 
 
 
Corporate equity securities (Note 8)
5,435

 
—

 
—

 
5,435

Total
$
96,488

 
$
22,603

 
$
—

 
$
119,091



 
Level 1
 
Level 2
 
Level 3
 
Total
December 31, 2018
 
 
 
Cash equivalents:
 
 
 
Money market funds
$
7,643

 
$
—

 
$
—

 
$
7,643

U.S. Treasury obligations
1,748

 
—

 
—

 
1,748

Investments, available for sale:
 
 
 
U.S. Treasury obligations
34,103

 
746

 
—

 
34,849

Government agency securities
64,733

 
35,962

 
—

 
100,695

Marketable equity securities:
 
 
 
 
 
 
 
Corporate equity securities (Note 8)
7,525

 
—

 
—

 
7,525

Total
$
115,752

 
$
36,708

 
$
—

 
$
152,460
XML 53 R18.htm IDEA: XBRL DOCUMENT v3.19.3
Lease
 9 Months Ended
Sep. 30, 2019
Leases [Abstract]  
Lease
Lease

The FASB issued ASU 2016-02, or the leasing standard or ASC 842, in February 2016. ASU 2016-02 requires lessees to recognize assets and liabilities on the balance sheet for the rights and obligations created by all leases with terms of more than 12 months. ASU 2016-02 also requires certain qualitative and quantitative disclosures designed to give financial statement users information on the amount, timing and uncertainty of cash flows arising from leases.
The Company adopted ASU 2016-02 effective January 1, 2019. The Company has elected to employ the transitionary relief recently offered by the FASB under ASU 2018-11, and implement the new standard without the restatement of comparative periods’ financial information. ASU 2018-11 also provides for recognizing the effects of applying ASU 2016-02 as a cumulative-effect adjustment to retained earnings as of January 1, 2019; however, no such adjustment was required as of January 1, 2019.
The Company has elected to employ the package of practical expedients offered under ASC 842, which allow the Company to not reassess the following:
•
the presence of a lease in any expired or existing contracts;
•
the lease classification for any expired or existing leases; and
•
the initial direct costs for any existing leases.

The Company currently leases 55,522 square feet of office and laboratory space, or the Lease, located at 65 Hayden Avenue, Lexington, Massachusetts, or the Premises, which was classified as an operating lease under ASC 840. The Lease is also classified as an operating lease under ASC 842 in accordance with the Company’s election of the practical expedient under ASC 842. Pursuant to the package of practical expedients, the Company will also not reassess initial direct costs for the Premises. Additionally, the Company has made the policy election to adopt the practical expedient to not separate lease components from nonlease components for the right-to-use asset class of office and laboratory space. This policy election results in the Company accounting for the lease component, the use of the Premises and the non-lease components, which include the use of the parking garage, building elevators and HVAC, as a single lease component.
The Company occupied the Premises in the third quarter of 2018; however, the Company gained access to the space on January 1, 2018 in order to start making certain tenant improvements. Accordingly, for accounting purposes the lease commencement date was determined to be January 1, 2018 under the prior guidance of ASC 840, and therefore the Company had begun recognizing lease expense as of that date. The Lease term extends ten years following January 1, 2019. The Company is entitled to two five-year options to extend the Lease; however, these options were not included in the calculation of the Lease asset or liability. The Company has elected to employ the provision under ASC 842 to use hindsight with respect to determining the lease term (i.e., consideration of the actual outcome of lease renewals, termination options and purchase options) and in assessing any impairment of right-of-use assets for existing leases. The Company notes no events such as renewals or termination options have occurred with respect to the Lease for the Premises. Therefore, the hindsight practical expedient under ASC 842 has no impact on the accounting term as previously determined under ASC 840. As of September 30, 2019, the remaining lease term for the Premises is 9 years and 3 months.
The Lease provides for annual base rent of approximately $2.8 million in the first year following the Base Rent Commencement Date of January 1, 2019, which increases on a yearly basis by 3.0% (subject to an abatement of base rent of approximately $0.5 million at the beginning of the second year of the Lease term if the Company is not in default under the Lease). There are no variable payments, exercise purchase options, penalties, fees or residual value guarantees under the Lease. The Company is also obligated to pay the Landlord for certain costs, taxes and operating expenses related to the Premises, subject to certain exclusions; however, the Company has concluded that these payments are not in-substance fixed payments and therefore are not included in the calculation of the related lease liability and asset under ASC 842.
The Company recorded the liability associated with the Lease for the Premises at the present value of the lease payments not yet paid, discounted using the discount rate for the Lease established at the commencement date. As the Lease does not provide an implicit rate, the Company had to estimate the incremental borrowing rate, or IBR, as of the commencement date. The IBR is defined under ASC 842 as the rate of interest that the Company would have to pay to borrow on a collateralized basis over a similar term for an amount equal to the lease payments in a similar economic environment.
The IBR for the Lease was determined by establishing a credit rating of the Company using the Rank Order Model. Based on the established credit rating, the Company determined a borrowing rate using the Recovery Rate method, adjusted for the risk-free rate, which resulted in an IBR of approximately 13%. The Company used this IBR of 13% to discount the remaining lease payments over the remaining lease term and recorded a lease liability of $16.9 million on January 1, 2019. This lease liability will be amortized over the remaining lease term in an amount equal to the difference between the cash rent paid and the monthly interest calculated on the remaining lease liability. As of September 30, 2019, the Company had a current lease liability of $0.2 million and a non-current lease liability of $16.2 million recorded in its condensed consolidated balance sheets.
The Company received an improvement allowance from the Landlord of approximately $5.0 million for certain permitted costs related to the design of Company improvements to the Premises, consisting of normal tenant improvements. The Company is deemed to be the owner of these tenant improvements during the lease term.
These $5.0 million of improvements are included in the Company’s property, plant and equipment balances in its condensed consolidated balance sheets as of September 30, 2019 and are depreciated over the shorter of their useful life or the related lease term.
On January 1, 2019, the Company recorded a right-of-use asset in the amount $9.5 million, which represents the lease liability of $16.9 million, adjusted for previously accrued rent of $2.9 million and previously recorded unamortized lease incentives (the improvement allowance) in the amount of $4.5 million. The right-of-use asset will be amortized over the remaining lease term in an amount equal to the difference between the calculated straight-line expense of the total lease payments less the monthly interest calculated on the remaining lease liability. As of September 30, 2019, the Company had a long-term lease asset of $9.3 million recorded in its condensed consolidated balance sheets.
The Company will recognize lease expense, calculated as the remaining cost of the lease allocated over the remaining lease term, on a straight-line basis. Lease expense will be presented as part of continuing operations in the condensed consolidated statement of operations and comprehensive loss. For the nine months ended September 30, 2019, the Company recognized $1.8 million in lease expense.
For the nine months ended September 30, 2019, the Company paid $2.1 million in rent relating to the Lease. As a payment arising from an operating lease, the $2.1 million will be classified within operating activities in the Condensed Consolidated Statements of Cash Flows.
Supplemental cash flow information:
For the nine months ended September 30,
(in thousands)
2019
Cash paid for amounts included in the measurement of lease liabilities
Operating cash flows from operating leases
$
2,082


Supplemental balance sheet information:
For the nine months ended September 30,
(in thousands)
2019
2018
 
 
 
Operating lease right-of-use assets
$
9,317

$
—

Operating lease liability
16,425

—

 
 
 
Weighted average remaining lease term
9.25

10.25

Weighted average discount rate
13.08
%
—
%

Maturities of lease liabilities:
For the twelve months ended December 31,
 
(in thousands)
 
 
2019
$
696

*
2020
2,406

 
2021
2,969

 
2022
3,058

 
2023
3,150

 
Thereafter
17,223

 
Total lease payments
29,502

 
Less imputed interest
(13,077
)
*
Total
$
16,425

 
* Excludes the nine months ended September 30, 2019
 
 
XML 54 R26.htm IDEA: XBRL DOCUMENT v3.19.3
Loss Per Share (Tables)
 9 Months Ended
Sep. 30, 2019
Earnings Per Share [Abstract]  
Computation of Basic and Diluted Earnings (Loss) Per Share
The following table illustrates the determination of loss per share for each period presented.
 
Three Months Ended
September 30,
 
Nine Months Ended
September 30,
 
2019
 
2018
 
2019
 
2018
 
(in thousands, except per share amounts)
Numerator:
 
 
 
 
 
 
 
Net loss applicable to common stockholders - basic and diluted
$
(17,185
)
 
$
(17,387
)
 
$
(57,679
)
 
$
(35,175
)
 
 
 
 
 
 
 
 
Denominator:
 
 
 
 
 
 
 
Weighted average shares outstanding - basic and diluted
23,807

 
23,421

 
23,703

 
23,349

 
 
 
 
 
 
 
 
Net loss per share applicable to common stockholders - basic and diluted
$
(0.72
)
 
$
(0.74
)
 
$
(2.43
)
 
$
(1.51
)
 
 
 
 
 
 
 
 
Anti-dilutive potential common stock equivalents excluded from the calculation of net loss per share:
 
 
 
 
 
 
 
Stock options
214

 
515

 
290

 
758

Restricted stock units
410

 
133

 
72

 
214

Warrants
61

 
132

 
72

 
132
XML 55 R22.htm IDEA: XBRL DOCUMENT v3.19.3
Cash, Cash Equivalents, Investments and Marketable Equity Securities (Tables)
 9 Months Ended
Sep. 30, 2019
Cash and Cash Equivalents [Abstract]  
Cash Equivalents and Short-term and Long-term Investments
Cash, cash equivalents, available for sale investments, and marketable equity securities included the following at September 30, 2019 and December 31, 2018:
 
 
Average maturity
 
Amortized cost
 
Unrealized gains
 
Unrealized losses
 
Fair value
September 30, 2019
 
 
 
 
 
 
 
 
 
 
Cash
 
 
 
$
7,893

 
$
—

 
$
—

 
$
7,893

Money market funds
 
 
 
21,253

 
—

 
—

 
21,253

U.S. Treasury obligations
 
52 days
 
4,238

 
—

 
—

 
4,238

Cash and cash equivalents
 
 
 
$
33,384

 
$
—

 
$
—

 
$
33,384

 
 
 
 
 
 
 
 
 
 
 
U.S. Treasury obligations
 
169 days
 
38,683

 
14

 
(8
)
 
38,689

Government agency securities
 
88 days
 
49,443

 
34

 
(1
)
 
49,476

Investments, available for sale
 
 
 
$
88,126

 
$
48

 
$
(9
)
 
$
88,165

 
 
 
 
 
 
 
 
 
 
 
September 30, 2019
 
 
 
Acquisition value
 
Unrealized gains
 
Unrealized losses
 
Fair value
Marketable equity securities (Note 8)
 
 
 
$
10,451

 
$
—

 
$
(5,016
)
 
$
5,435


 
 
Average maturity
 
Amortized cost
 
Unrealized gains
 
Unrealized losses
 
Fair value
December 31, 2018
 
 
 
 
 
 
 
 
 
 
Cash
 
 
 
$
8,379

 
$
—

 
$
—

 
$
8,379

Money market funds
 
 
 
7,643

 
—

 
—

 
7,643

U.S. Treasury obligations
 
31 days
 
1,748

 
—

 
—

 
1,748

Cash and cash equivalents
 
 
 
$
17,770

 
$
—

 
$
—

 
$
17,770

 
 
 
 
 
 
 
 
 
 
 
U.S. Treasury obligations
 
151 days
 
$
34,856

 
$
2

 
$
(9
)
 
$
34,849

Government agency securities
 
153 days
 
100,748

 
7

 
(60
)
 
100,695

Investments, available for sale
 
 
 
$
135,604

 
$
9

 
$
(69
)
 
$
135,544

 
 
 
 
 
 
 
 
 
 
 
December 31, 2018
 
 
 
Acquisition value
 
Unrealized gains
 
Unrealized losses
 
Fair value
Marketable equity securities (Note 8)
 
 
 
$
10,451

 
$
—

 
$
(2,926
)
 
$
7,525
EXCEL 56 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 58 R43.htm IDEA: XBRL DOCUMENT v3.19.3
Stock-Based Compensation - Summary of Stock Option Activity (Details) - USD ($)
$ / shares in Units, $ in Thousands
 9 Months Ended
Sep. 30, 2019
Number of Option Shares  
Number of options, Outstanding beginning balance (in shares) 3,557,406
Number of options, Granted (in shares) 1,032,250
Number of options, Exercised (in shares) (202,508)
Number of options, Forfeited or expired (in shares) (184,474)
Number of options, Outstanding ending balance (in shares) 4,202,674
Number of options, Exercisable (in shares) 2,429,295
Number of options, Vested and expected to vest (in shares) 4,049,442
Weighted Average Exercise Price per Share  
Weighted average exercise price per share, Outstanding at beginning of year (in dollars per share) $ 15.26
Weighted average exercise price per share, Granted (in dollars per share) 13.25
Weighted average exercise price per share, Exercised (in dollars per share) 8.33
Weighted average exercise price per share, Forfeited or expired (in dollars per share) 18.44
Weighted average exercise price per share, Outstanding ending balance (in dollars per share) 14.96
Weighted average exercise price per share, Exercisable (in dollars per share) 13.70
Weighted average exercise price per share, Vested and expected to vest (in dollars per share) $ 14.90
Weighted Average Remaining Contractual Term (In years)  
Weighted average remaining contractual term, Outstanding 6 years 11 months 27 days
Weighted average remaining contractual term, Exercisable 6 years 11 days
Weighted average remaining contractual term, Vested and expected to vest 6 years 11 months 5 days
Aggregate Intrinsic Value  
Aggregate intrinsic value, Outstanding $ 390
Aggregate intrinsic value, Exercisable 390
Aggregate intrinsic value, Vested and expected to vest $ 390
Stock options  
Aggregate Intrinsic Value  
Estimated forfeiture rate 7.00%
XML 59 R47.htm IDEA: XBRL DOCUMENT v3.19.3
Lease - Supplemental Cash Flow Information (Details)
$ in Thousands
 9 Months Ended
Sep. 30, 2019
USD ($)
Leases [Abstract]  
Operating cash flows from operating leases $ 2,082
XML 60 R27.htm IDEA: XBRL DOCUMENT v3.19.3
Lease (Tables)
 9 Months Ended
Sep. 30, 2019
Leases [Abstract]  
Lease, Cost
Supplemental cash flow information:
For the nine months ended September 30,
(in thousands)
2019
Cash paid for amounts included in the measurement of lease liabilities
Operating cash flows from operating leases
$
2,082
Assets and Liabilities, Lessee
Supplemental balance sheet information:
For the nine months ended September 30,
(in thousands)
2019
2018
 
 
 
Operating lease right-of-use assets
$
9,317

$
—

Operating lease liability
16,425

—

 
 
 
Weighted average remaining lease term
9.25

10.25

Weighted average discount rate
13.08
%
—
%
Lessee, Operating Lease, Liability, Maturity
Maturities of lease liabilities:
For the twelve months ended December 31,
 
(in thousands)
 
 
2019
$
696

*
2020
2,406

 
2021
2,969

 
2022
3,058

 
2023
3,150

 
Thereafter
17,223

 
Total lease payments
29,502

 
Less imputed interest
(13,077
)
*
Total
$
16,425

 
* Excludes the nine months ended September 30, 2019
 
 
XML 61 R23.htm IDEA: XBRL DOCUMENT v3.19.3
Restricted Cash (Tables)
 9 Months Ended
Sep. 30, 2019
Cash and Cash Equivalents [Abstract]  
Restrictions on Cash and Cash Equivalents
Cash, cash equivalents and restricted cash consisted of the following:

 
September 30,
2019
 
September 30,
2018
Cash and cash equivalents
$
33,384

 
$
39,597

Restricted cash
1,157

 
1,557

Total cash, cash equivalents and restricted cash shown in the statements of cash flows
$
34,541

 
$
41,154
XML 62 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 63 R42.htm IDEA: XBRL DOCUMENT v3.19.3
Stock-Based Compensation - Fair Value of Options (Details) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2019
Sep. 30, 2018
Sep. 30, 2019
Sep. 30, 2018
Share-based Payment Arrangement [Abstract]        
Weighted average grant date fair value of options granted, per option (in dollars per share) $ 6.46 $ 10.42 $ 8.95 $ 17.92
Aggregate grant date fair value of options vested during the period $ 2,234 $ 2,110 $ 7,070 $ 5,839
Total cash received from exercises of stock options 36 23 1,006 934
Total intrinsic value of stock options exercised $ 59 $ 187 $ 1,167 $ 2,539
XML 64 R46.htm IDEA: XBRL DOCUMENT v3.19.3
Lease - Additional Information (Details)
$ in Thousands
 9 Months Ended
Sep. 30, 2019
USD ($)
ft²
extension
Jan. 01, 2019
USD ($)
Dec. 31, 2018
USD ($)
Sep. 30, 2018
USD ($)
New Accounting Pronouncements or Change in Accounting Principle [Line Items]        
Area of leased office and laboratory space | ft² 55,522      
Term of contract 10 years      
Number of extensions | extension 2      
Length of extension 5 years      
Weighted average remaining lease term 9 years 3 months     10 years 3 months
Annual base rent amount $ 2,800      
Annual rent increase, percent 3.00%      
Abatement of base rent amount $ 500      
Discount rate 13.00%      
Operating lease liability $ 16,425 $ 16,900   $ 0
Lease liability, current portion 235   $ 0  
Lease liability, net of current portion 16,190   0  
Tenant improvement allowance 5,000      
Operating lease right-of-use assets 9,317 9,500 $ 0 $ 0
Operating lease, expense 1,800      
Operating lease, payments $ 2,082      
Accounting Standards Update 2016-02        
New Accounting Pronouncements or Change in Accounting Principle [Line Items]        
Reduction to accrued rent   2,900    
Reduction to incentive to lessee   $ 4,500    
XML 65 R6.htm IDEA: XBRL DOCUMENT v3.19.3
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (UNAUDITED) (Parenthetical)
$ in Thousands
 3 Months Ended
Sep. 30, 2018
USD ($)
Statement of Stockholders' Equity [Abstract]  
Unrealized gain on short-term investments, tax $ 47
XML 66 R2.htm IDEA: XBRL DOCUMENT v3.19.3
CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) - USD ($)
Sep. 30, 2019
Dec. 31, 2018
Current assets:    
Cash and cash equivalents $ 33,384,000 $ 17,770,000
Investments, available for sale 88,165,000 135,544,000
Marketable equity securities 5,435,000 7,525,000
Interest receivable 291,000 556,000
Accounts receivable 11,000 15,000
Contract asset (Note 8) 0 16,000,000
Prepaid expenses and other current assets 3,830,000 2,739,000
Total current assets 131,116,000 180,149,000
Property and equipment, net 7,993,000 8,919,000
Restricted cash 1,157,000 1,157,000
Other assets 16,000 0
Income taxes receivable 2,358,000 2,322,000
Operating lease right-of-use assets, long-term (Note 11) 9,317,000 0
Total assets 151,957,000 192,547,000
Current liabilities:    
Accounts payable 1,302,000 1,277,000
Accrued expenses and other liabilities 4,434,000 5,669,000
Income taxes payable 0 390,000
Deferred revenue, current portion 7,783,000 1,413,000
Lease liability, current portion (Note 11) 235,000 0
Total current liabilities 13,754,000 8,749,000
Deferred revenue, net of current portion 2,750,000 9,120,000
Deferred lease incentive, net of current portion   4,088,000
Deferred rent, net of current portion   2,850,000
Lease liability, net of current portion (Note 11) 16,190,000 0
Total liabilities 32,694,000 24,807,000
Commitments (Note 11)
Stockholders’ equity:    
Preferred stock, $0.001 par value per share; 5,000,000 shares authorized; no shares issued and outstanding in 2019 and 2018, respectively 0 0
Common stock, $0.001 par value per share; 100,000,000 shares authorized; 24,030,711 and 23,518,690 shares issued and 23,841,155 and 23,437,587 outstanding in 2019 and 2018, respectively 23,000 23,000
Additional paid-in capital 293,469,000 284,369,000
Accumulated other comprehensive loss (35,000) (137,000)
Accumulated deficit (174,194,000) (116,515,000)
Total stockholders’ equity 119,263,000 167,740,000
Total liabilities and stockholders’ equity $ 151,957,000 $ 192,547,000
XML 67 R32.htm IDEA: XBRL DOCUMENT v3.19.3
Cash, Cash Equivalents, Investments and Marketable Equity Securities - Additional Information (Details) - USD ($)
 9 Months Ended 12 Months Ended
Sep. 30, 2019
Dec. 31, 2018
Cash and Cash Equivalents [Abstract]    
Debt securities, realized gain $ 0 $ 0
Debt securities, realized loss 0 0
Equity securities, realized gain 0 0
Equity securities, realized loss 0 0
Other than temporary impairment losses, investments $ 0 $ 0
XML 68 R36.htm IDEA: XBRL DOCUMENT v3.19.3
Revenue - Vertex (Details) - Disposed of by sale, not discontinued operations - Assets for synthesis and research and development for treating Cystic Fibrosis - USD ($)
 1 Months Ended
Feb. 28, 2019
Mar. 03, 2017
Revenue Recognition, Milestone Method [Line Items]    
Cash consideration   $ 160,000,000
Indemnification agreement    
Revenue Recognition, Milestone Method [Line Items]    
Amount released $ 16,000,000  
Contingent consideration asset, After achievement of milestone events    
Revenue Recognition, Milestone Method [Line Items]    
Contingent consideration receivable   $ 90,000,000
XML 69 R19.htm IDEA: XBRL DOCUMENT v3.19.3
Open Market Sale Agreement
 9 Months Ended
Sep. 30, 2019
Equity [Abstract]  
Open Market Sale Agreement
Open Market Sale Agreement

On March 1, 2019, the Company entered into an Open Market Sale Agreement, or the ATM Agreement, with Jefferies LLC, or Jefferies, with respect to an at-the-market offering program under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock, par value $0.001 per share, having an aggregate offering price of up to $50 million, referred to as Placement Shares, through Jefferies as its sales agent. The Company will pay Jefferies a commission equal to 3.0% of the gross sales proceeds of any Placement Shares sold through Jefferies under the ATM Agreement, and also has provided Jefferies with customary indemnification and contribution rights. In addition, the Company has agreed to reimburse certain legal expenses and fees by Jefferies in connection with the offering up to a maximum of $50,000, in addition to certain ongoing disbursements of Jefferies' counsel. As of November 4, 2019, the Company has sold 36,167 shares of its common stock in accordance with the ATM Agreement for net proceeds of $0.4 million, after payment of cash commissions of 3.0 percent of the gross proceeds to its sales agent. Additionally, the Company incurred approximately $0.3 million related to legal, accounting and other fees in connection with the ATM Agreement as of September 30, 2019.
XML 70 R15.htm IDEA: XBRL DOCUMENT v3.19.3
Revenue
 9 Months Ended
Sep. 30, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Revenue
Revenue

The Company's revenue is generated through collaborative licensing agreements, patent assignments, and sales of intellectual property. The Company generates its revenue through one segment and the revenue recognized under each of the Company's arrangements during the current and prior period is described below.

On January 1, 2018, the Company adopted ASU 2014-19, Revenue from Contracts with Customers, or ASC 606. The Company adopted ASC 606 using the modified retrospective approach. For detailed information regarding the adoption of ASC 606, the impact on its consolidated financial statements and its collaboration arrangements, see Note 2 and Note 12 to the accompanying consolidated financial statements appearing in the Company's Annual Report on Form 10-K filed with the SEC on February 28, 2019.
Contract Assets
The Company did not have a contract asset as of September 30, 2019 as compared to $16.0 million as of December 31, 2018. The decrease in the contract asset balance is the result of the receipt of the $16.0 million that had initially been held in escrow for indemnification purposes related to the asset purchase by Vertex Pharmaceuticals, Inc., or Vertex, and was released to the Company in February 2019.
Contract Liabilities
As of September 30, 2019 and December 31, 2018, the Company had $10.5 million in contract liabilities related to unsatisfied performance obligations as well as variable consideration paid in advance but currently constrained from recognition.
The contract liabilities consist of the following deferred revenue:
 
•
$7.8 million related to the Company's collaboration with Celgene Corporation, or Celgene, $1.4 million of which is attributable to the CTP-730 program and is currently expected to be recognized as revenue in the next twelve months as the Company satisfies its remaining research and development activities pursuant to mutually agreed upon development plans, and $6.4 million of which is attributable to two additional license programs that the Company will not recognize as revenue unless Celgene exercises its rights with respect to those programs, or in the second quarter of 2020 at such time that Celgene's rights lapse; and
•
$2.8 million related to a payment received from GlaxoSmithKline, or GSK, that the Company will not recognize as revenue until all repayment obligations lapse.
Revenue Arrangements
Vertex

On March 3, 2017, the Company and Vertex entered into an Asset Purchase Agreement, or the Vertex Agreement, pursuant to which, subject to the satisfaction or waiver of the conditions therein, the Company sold and assigned to Vertex, CTP-656, a deuterated analog of ivacaftor, now known as VX-561, and other cystic fibrosis assets of the Company. On July 25, 2017, or the Vertex Closing Date, the transaction contemplated by the Vertex Agreement closed and Vertex paid the Company $160 million in cash consideration. In addition, Vertex has agreed to pay the Company an aggregate of up to $90 million upon the achievement of certain milestone events. In February 2019, the $16.0 million initially held in escrow was released to the Company.

As of December 31, 2018, the Vertex indemnification variable consideration represented a contract asset to be released from escrow 18 months following the Vertex Closing Date and was classified as a current asset in the accompanying consolidated balance sheet. In February 2019, the $16.0 million initially held in escrow was released to the Company. Additionally, the variable consideration related to the regulatory milestone payments are fully constrained due to the uncertainty associated with the achievement of the respective milestones. Accordingly, no contract asset was recorded as of September 30, 2019.

Processa

On October 4, 2017, the Company entered into a License and Option Agreement, or the Option, with Promet Therapeutics, LLC, or Promet, pursuant to which the Company granted Promet an option to obtain an exclusive license to CTP-499, a deuterated analog of 1-(S)-5-hydroxyhexyl-3,7-dimethylxanthine, or HDX, an active metabolite of pentoxifylline, provided certain conditions were met. On October 5, 2017, Promet closed an asset purchase agreement with Heatwurx, Inc., a public company, creating Processa Pharmaceuticals, Inc., or Processa.

On March 21, 2018, the Company entered into an Amendment to the Option, or the Amendment, and a Securities Purchase Agreement, both with Promet and Processa. Pursuant to the Amendment, the Company granted Promet, who then assigned to Processa, an exclusive, worldwide, royalty-bearing license to develop, manufacture and commercialize CTP-499, now known as PCS-499. Upon transfer of the license and as consideration for the license, the Company received 2,090,301 shares of common stock of Processa.

The Company is also eligible to receive royalties on worldwide net sales.

The Amendment contained one performance obligation: an exclusive, worldwide, royalty-bearing license to develop, commercialize and sublicense CTP-499. The Company determined that the transaction price was $10.5 million, which was based on the fair value of the non-cash consideration received on March 19, 2018, which consisted of 2,090,301 shares of publicly traded common stock of Processa. The transaction price of $10.5 million was allocated to the single performance obligation. The performance obligation was considered satisfied at contract inception as the exclusive license transferred control to the customer at this point in time. Accordingly, revenue of $10.5 million was recognized during the first quarter of 2018.

Subsequent changes to the fair value of the underlying securities are recognized as unrealized gains or losses on marketable equity securities within the condensed consolidated statement of operations and comprehensive loss.
The Amendment contains consideration that is variable based on royalties upon the customer's commercial success with the licensed product. The consideration related to royalty payments is considered variable consideration that is fully constrained in accordance with the royalty recognition constraint. The variable consideration related to royalties will be recognized in the period the products are sold by Processa and the Company has a present right to payment.

For the three and nine months ended September 30, 2019, the Company recognized $2 thousand and $24 thousand in revenue, respectively, related to intellectual property cost reimbursements. For the three months and nine months ended September 30, 2018, the Company recognized $10.5 million in revenue related to the transfer of the license.

Cipla

The Company entered into a License Agreement, or the Cipla Agreement, on January 16, 2019, or the Cipla Closing Date, with Cipla Technologies LLC, or Cipla, pursuant to which the Company granted Cipla an exclusive, worldwide, royalty-bearing license to develop, manufacture and commercialize CTP-354, a novel GABAA receptor subtype-selective modulator. As consideration for the license, the Company received an upfront payment of $1.0 million.
The Cipla Agreement also provides Cipla the option to purchase the Company’s existing inventory of CTP-354 held as of the Effective Date, valued in aggregate at $0.3 million. Additionally, upon the achievement of certain milestone events, Cipla has agreed to pay the Company an aggregate of up to $57.0 million. The first milestone payment the Company may be entitled to receive is $3.0 million when the first IND for the first CTP-354 product goes into effect.
Furthermore, the Company is eligible to receive royalties on worldwide net sales of future product sales at defined percentages ranging from the mid-single to high-single digits.
The Cipla Agreement contained one performance obligation: an exclusive, worldwide, royalty-bearing license to develop, manufacture, commercialize and sublicense CTP-354, referred to as the Transfer of License Performance Obligation. The Company concluded the option to purchase existing inventory did not provide Cipla a material right, and as such, was treated as a separate contract. The transaction price was determined to be $1.0 million based on the upfront consideration received as of the Cipla Closing Date.
As of the Cipla Closing Date, the Transfer of License Performance Obligation was satisfied as the control of CTP-354 transferred to Cipla, the customer. As a result, the full transaction price was recognized as revenue on the Cipla Closing Date. The sale of existing inventory is recognized as goods are transferred to the customer.
The arrangement with Cipla contains consideration that is variable based on the customer’s achievement of certain development and regulatory milestones in addition to royalties upon the customer’s commercial success with the licensed product. The next milestone payment the Company may be entitled to receive of $3.0 million related to the first IND for the first CTP-354 product going into effect is considered variable consideration that is fully constrained due to the uncertainty associated with the achievement of the development milestone. The consideration related to royalties is also variable consideration that is fully constrained in accordance with the royalty recognition constraint. The variable consideration related to royalties will be recognized in the period the products are sold by Cipla and the Company has a present right to payment.
The Company did not recognize revenue for the three months ended September 30, 2019. The Company recognized $1.0 million in revenue associated with the sale of existing inventory and the Transfer of License Performance Obligation for the nine months ended September 30, 2019.
XML 71 R11.htm IDEA: XBRL DOCUMENT v3.19.3
Cash, Cash Equivalents, Investments and Marketable Equity Securities
 9 Months Ended
Sep. 30, 2019
Cash and Cash Equivalents [Abstract]  
Cash, Cash Equivalents, Investments and Marketable Equity Securities
Cash, Cash Equivalents, Investments and Marketable Equity Securities
Cash equivalents include all highly liquid investments maturing within 90 days from the date of purchase. Investments consist of securities with original maturities greater than 90 days when purchased. The Company classifies these investments as available-for-sale and records them at fair value in the accompanying consolidated balance sheets. In accordance with ASU 2016-01, unrealized gains or losses from equity securities are included in net income. Unrealized gains or losses from other investments, including debt securities, are included in accumulated other comprehensive income (loss). Premiums or discounts from par value are amortized to investment income over the life of the underlying investment.
Cash, cash equivalents, available for sale investments, and marketable equity securities included the following at September 30, 2019 and December 31, 2018:
 
 
Average maturity
 
Amortized cost
 
Unrealized gains
 
Unrealized losses
 
Fair value
September 30, 2019
 
 
 
 
 
 
 
 
 
 
Cash
 
 
 
$
7,893

 
$
—

 
$
—

 
$
7,893

Money market funds
 
 
 
21,253

 
—

 
—

 
21,253

U.S. Treasury obligations
 
52 days
 
4,238

 
—

 
—

 
4,238

Cash and cash equivalents
 
 
 
$
33,384

 
$
—

 
$
—

 
$
33,384

 
 
 
 
 
 
 
 
 
 
 
U.S. Treasury obligations
 
169 days
 
38,683

 
14

 
(8
)
 
38,689

Government agency securities
 
88 days
 
49,443

 
34

 
(1
)
 
49,476

Investments, available for sale
 
 
 
$
88,126

 
$
48

 
$
(9
)
 
$
88,165

 
 
 
 
 
 
 
 
 
 
 
September 30, 2019
 
 
 
Acquisition value
 
Unrealized gains
 
Unrealized losses
 
Fair value
Marketable equity securities (Note 8)
 
 
 
$
10,451

 
$
—

 
$
(5,016
)
 
$
5,435


 
 
Average maturity
 
Amortized cost
 
Unrealized gains
 
Unrealized losses
 
Fair value
December 31, 2018
 
 
 
 
 
 
 
 
 
 
Cash
 
 
 
$
8,379

 
$
—

 
$
—

 
$
8,379

Money market funds
 
 
 
7,643

 
—

 
—

 
7,643

U.S. Treasury obligations
 
31 days
 
1,748

 
—

 
—

 
1,748

Cash and cash equivalents
 
 
 
$
17,770

 
$
—

 
$
—

 
$
17,770

 
 
 
 
 
 
 
 
 
 
 
U.S. Treasury obligations
 
151 days
 
$
34,856

 
$
2

 
$
(9
)
 
$
34,849

Government agency securities
 
153 days
 
100,748

 
7

 
(60
)
 
100,695

Investments, available for sale
 
 
 
$
135,604

 
$
9

 
$
(69
)
 
$
135,544

 
 
 
 
 
 
 
 
 
 
 
December 31, 2018
 
 
 
Acquisition value
 
Unrealized gains
 
Unrealized losses
 
Fair value
Marketable equity securities (Note 8)
 
 
 
$
10,451

 
$
—

 
$
(2,926
)
 
$
7,525


Although available to be sold to meet operating needs or otherwise (and therefore classified as current assets), securities are generally held through maturity. The cost of securities sold is determined based on the specific identification method for purposes of recording realized gains and losses. During 2019 and 2018, there were no realized gains or losses on sales of investments, and no investments were adjusted other than for temporary declines in fair value.